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AďstraĐt  
The alpha-2-macroglobulin superfamily consists of large multi-domain proteins that are 
activated by protease cleavage. One arm of this family consists of protease inhibitors that 
undergo a large conformational change upon protease cleavage, simultaneously 
physically trapping the cleaving protease and covalently linking to it via a thioester bond. 
However, there is little mechanistic understanding of how protease cleavage activates the 
conformational changes that lead to protease inactivation. These protease inhibitors are 
found in tetrameric, dimeric and monomer forms within eukaryotic blood/lymph fluid. 
 
The recently described Escherichia coli alpha-2-macroglobulin (ECAM) is a periplasmic, 
inner membrane anchored protease inhibitor. The gene encoding ECAM, yfhM, is found 
within an operon alongside pbpC, which encodes penicillin binding protein 1C. These two 
proteins have been proposed to function in defence and repair against host proteases 
with ECAM acting to inhibit proteases that have breached the outer membrane and 
Pbp1C repairing damage to the peptide linkages within the peptidoglycan layer. 
 
This thesis describes the structural and biophysical characterisation of ECAM and an 
investigation into the role of Pbp1C in ECAM function. In order to gain insight into the 
mechanism through which protease cleavage activates ECAM we used a combination of  
X-ray crystallography, small angle X-ray scattering and analytical ultracentrifugation to 
characterise the conformational changes that occur on protease cleavage. The X-ray 
structure of protease cleaved ECAM revealed a putative mechanism of activation and 
conformational change essential for protease inhibition. In this competitive mechanism, 
protease cleavage of the bait-region domain results in the untethering of an intrinsically 
disordered region of this domain which disrupts native inter-domain interactions that 
maintain ECAM in the inactivated form. Owing to the similarity in structure and domain 
architecture of ECAM aŶd huŵaŶ α-2-macroglobulin, this protease-activation mechanism 
is likely to operate across the diverse members of this group. Further to this, it was shown 
that ECAM is processed in vivo, existing largely as truncated forms in growing E. coli cells. 
Interestingly, Pbp1C plays a key role in ECAM processing, with cell lacking pbpC showing 
an accumulation of full-length and dimeric forms of ECAM.   
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1.1 Alpha ŵaĐƌogloďuliŶ supeƌfaŵilǇ 
The alpha macroglobulin superfamily is composed of globular proteins from a wide range 
of species with varied function.  There are two main functional subtypes described to 
date with the first involved in inhibition of proteases through the formation of a complex 
between the alpha macroglobulin and protease. The second is involved in defence against 
pathogens, with the alpha macroglobulin covalently binding to the pathogen resulting in 
lysis or clearance. Alpha macroglobulins that have a protease inhibitory role include the 
eukaryotic proteins alpha-2-macroglobulin (α2M), pregnancy zone protein (PZP), CD109, 
CPAMD8, A2ML1 and the more recently characterised bacterial αϮM ;BA2M) that is found 
in a wide range of Gram-negative bacteria1–6.  The second type of alpha macroglobulin 
play an important role in the eukaryotic innate immune system including complement 
proteins C3, C4 and C5 as well as TEP1 which has been described as having an important 
role in arthropod innate immunity7–10.  The two branches of the alpha macroglobulin 
family have common evolutionary origins and although functionally distinct have similar 
mechanisms of activation, via protease cleavage11,12. All alpha macroglobulins have a high 
molecular weight of ~180 kDa and some form homomultimers, with monomers consisting 
of a conserved order of domains albeit with some structural variation between species 
and subtype2,13. 
Comparisons between eukaryotic and BA2M have highlighted the strong similarity in the 
domains present as well as particular motifs that are required to maintain the function of 
these proteins (Figure 1-1)14. The structural differences seen between the proteins 
highlight the change iŶ fuŶĐtioŶ ďetǁeeŶ oƌgaŶisŵ, αϮM haǀiŶg ŵaŶy loŶg loops that aƌe 
important for forming the tetramer structure and the extra MG domains seen in BA2M 
are important for anchoring the protein to the inner membrane13,14. One feature that is 
conserved in most alpha macroglobulins is the thioester bond within the thioester 
domain (TED) which is important for covalently binding to the proteins corresponding 
taƌget, ďe it a pathogeŶ foƌ ĐoŵpleŵeŶt αϮMs aŶd TEPϭ oƌ the ĐleaǀiŶg pƌotease foƌ αϮM 
and BA2M10,13,14. WithiŶ uŶaĐtiǀated αϮMs the thioesteƌ is pƌotected from hydrolysis by 
solvent by a hydrophobic pocket between the TED and the C-terminal macroglobulin 
domain (CTMG) 14. The residues involved in the hydrophobic pocket protecting this 
Chapter 1 
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thioester from solvent hydrolysis have been shown to differ between eukaryotic or 
archaea and BA2Ms14. In the TEP1 structure there are three tyrosines and a methionine in 
the CTMG orientated towards the thioester10,14,15. These residues although conserved in 
all eukaryotic and archaea αϮMs, however are not conserved within BA2M14. Instead in 
BA2Ms conserved residues that are involved in formation of the hydrophobic pocket are 
located in the TED itself14.   
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Figure 1-1 CoŵparisoŶ of doŵaiŶ ĐoŵpositioŶ aŶd struĐtures of ŵeŵďers of the α-macroglobulin 
superfamily.   
;aͿ DoŵaiŶ aligŶŵeŶt of ďaĐteƌial α-2-ŵaĐƌogloďuliŶ, thioesteƌ pƌoteiŶ ϭ, α-2-macroglobulin and 
ĐoŵpleŵeŶt pƌoteiŶs Cϯ, Cϰ aŶd Cϱ. ;ďͿ Cƌystal stƌuĐtuƌes of Ŷatiǀe ďaĐteƌial αϮM, Ŷatiǀe TEPϭ and 
ŵethylaŵiŶe aĐtiǀated α-2-ŵaĐƌogloďuliŶ aligŶed usiŶg ŵaĐƌogloďuliŶ doŵaiŶ ϴ ;ďaĐteƌial αϮMͿ aŶd 
ŵaĐƌogloďuliŶ doŵaiŶ ϲ ;TEPϭ aŶd αϮMͿ. Note the siŵilaƌity in orientation of domains between bacterial 
αϮM aŶd TEPϭ aŶd diffeƌeŶĐe seeŶ iŶ aĐtiǀated αϮM. ANA, anaphylotoxin domain; BRD, bait region domain; 
CTMG, C-terminal macroglobulin domain; CUB, complement protein subcomponent domain; 
MG, macroglobulin domain; RBD, receptor binding domain; TED, thioester domain. 
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1.1.1 EukaƌǇotiĐ ŵaĐƌogloďuliŶs 
αϮM is a large soluble protein found in high concentration within human blood that 
functions as a broad spectrum protease inhibitor1,16,17. This protein was first purified from 
blood in 1946 and was named alpha-2 due to the fraction of blood plasma in which it was 
found and macroglobulin due to its high molecular weight18. α2M is produced mainly in 
the liver with blood plasma concentrations of as much as 2 mg ml-1 1,18,19.This 720 kDa 
molecular weight protein complex is a tetramer made of subunits of 180 kDa, each 
comprised of 1451 amino acid residues16,17. This tetramer has been described as a 
͞diŵer of diŵeƌs͟ with two monomers being connected by disulphide bonds and the 
secondary dimerisation interface forming via the interaction of bait regions 
(Figure 1-2 a)16,20. Each of these tetramers have been found to inhibit proteases at a 1:1 
or 1:2 ratio with variability found between protease types that are inhibited16,21. The 
inhibition of proteases encompasses the four main classes of protease including serine, 
cysteine, aspartyl aŶd ŵetallopƌoteases ǀia a ͞VeŶus flytƌap͟ ŵeĐhaŶisŵ13,16,17. This 
mechanism occurs where the α2M is cleaǀed ǁithiŶ its ͚ďait ƌegioŶ͛ and this results in a 
large conformational rearrangement22. This rearrangement brings the normally buried β-
cysteinyl-γ-glutamyl thioester into contact with the cleaving protease forming a covalent 
bond between the deaminated glutamine and surface lysines of the protease13,22. Once 
the protease has been entrapped within α2M it is no longer able to cleave large 
substrates due to steric hindrance of the active site. However, the protease active site 
remains intact and able to interact with smaller substrates and inhibitors1,16. Without 
cleavage of the bait region, conformational activation of α2M can be caused by chemical 
cleavage of the thioester bond with methylamine to form a γ-glutamyl methylamide. 
Treatment with small nucleophiles, such as methylamine, removes αϮMs ability to inhibit 
proteases17,23,24.  
Two forms of αϮM have been defined in reference to the speed at which they move 
during blue native electrophoresis with native αϮM moving slow and αϮM activated with 
protease or small nucleophile moving fast20. Native and both chemically activated and 
protease-aĐtiǀated αϮM haǀe ďeeŶ Đoŵpaƌed usiŶg eleĐtƌoŶ ŵiĐƌosĐopy ;EMͿ aŶd it has 
Chapter 1 
6 
 
been found that there is a distinct difference in shape between the native and activated 
foƌŵs, hoǁeǀeƌ, ďoth types of aĐtiǀated αϮM aƌe iŶdistiŶguishaďle ;Figuƌe ϭ-2 b, c) 25.  
 
 
 
 
Figure 1-2 Alpha-2-macroglobulin structures.  
(a) The crystal structure of tetrameric αϮM with subunits shown in red, blue, green and orange (PDB:4ACQ, 
Marrero et al 201213). The domain shown in cyan is the C-terminal macroglobulin domain only present as 
part of the orange subunit. Electron microscope image of native (b) and trypsin activated (c) forms of αϮM. 
Notice the similarity between the trypsin activated electron microscope image and the methylamine 
activated crystal structure. Electron microscopy images from Tapon-bretaudiere et al25.  
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Although there is no native crystal structure foƌ αϮM puďlished to date, the structure of 
methylamine activated αϮM has been determined to 4.3 Å resolution (Figure 1-2 a) 13. 
Upon conformational activation the C-terminal macroglobulin domain (CTMG), also 
known as the receptor binding domain, becomes exposed at the surface of the tetramer. 
This CTMG domain has been shown to bind specific cell-surface receptors that result in 
endocytosis of the activated complex and degradation by lysosomes. This process results 
in clearance of activated αϮM from the blood within minutes of activation19,26. 
αϮM has the ability to inhibit all four main classes of protease (serine, carboxyl, thiol, and 
metalloproteases) and has been shown to inhibit natively produced proteases such as 
chymase, a chymotrypsin-like protease produced by mast cells27. αϮM can also inhibit 
proteases produced by bacteria and as such has been suggested in having a protective 
role against infection from pathogens28. The ability of α2M to bind various cytokines such 
as fibroblast growth factor, platelet-derived growth factor, nerve growth factor, 
interleukin-ϭβ, aŶd iŶteƌleukiŶ-6 also indicates that it has an important role in the 
regulation of signalling29–33. With the ability to inhibit cytokines such as interleukin-6 it 
has further been suggested as having a role within chronic ĐoŶditioŶs suĐh as CƌohŶ͛s 
disease33. 
Various homologous protease and cytokine inhibiting alpha macroglobulins have been 
identified, some with specific targets. Pregnancy zone protein has been named as such 
due to the increased levels of expression seen during pregnancy2.  The levels of PZP 
increase from normal levels of 0.01-0.03 mg ml-1 to 1 mg ml-1 during the third trimester of 
pregnancy.  With high sequence identity between αϮM and PZP of 72% it is thought PZP 
has a similar protease inhibitory role even though PZP exists as a dimer. PZP has been 
suggested as having a major role in controlling the activity of proteases that are released 
during cellular turnover that would be elevated during pregnancy.  Alpha-2-macroglobulin 
like protein 1 (A2ML1) has strong similarity to αϮM and is expressed mainly in the 
epidermis5.  A2ML1 lacks the cysteines involved in the disulphide bridges in α2M, 
involved in multimer formation, and is monomeric. Due to its expression in the epidermis 
A2ML1 is thought to play an important role in the shedding of the outer skin. 
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1.1.2 Alpha ŵaĐƌogloďuliŶ doŵaiŶ ĐoŵpositioŶ 
The overall N-terminal to C-terminal domain architecture of αϮMs consists of a series of 
seven macroglobulin (MG) ďeta saŶdǁiĐh doŵaiŶs that foƌŵ a ͚key ƌiŶg͛ shape ǁith a ďait 
region spanning the centre13,14,34.  The macroglobulin domains are followed by a CUB 
;͚ĐoŵpleŵeŶt Cϭƌ/Cϭs, Uegf, Bŵpϭ͛ oƌ ͚ĐoŵpleŵeŶt pƌoteiŶ suďĐoŵpoŶeŶt doŵaiŶ͛) 
arm that connects the TED to the ďeta ͚key ƌiŶg͛ ǁith a fiŶal C-terminal MG ͚ƌeĐeptoƌ 
ďiŶdiŶg doŵaiŶ͛ ;‘BDͿ26,35,36. The CUB doŵaiŶ that liŶks the TED to the ŵaiŶ ͚key ƌiŶg͛ is a 
sandwich of two beta sheets, half of which is before the TED and half is after leading to 
the final RBD13.  The TED is mainly α-helical and contains a conserved cysteine-glutamine 
thioester present in most types of αϮM. This thioester forms a bond between the 
Ɛ-cysteinyl-γ-glutamyl of the CXXQ motif23,37.  When the glutamic acid from the thioester 
comes into contact with lysine they form a covalent bond, linking the protease to the 
αϮM13.  The final macroglobulin domain in human αϮM is involved in clearance of the 
protease cleaved activated form from the blood and as such is called the receptor binding 
domain26. The bait region of α2M is cleavable by a wide range of proteases suggesting a 
role in general housekeeping and regulation of proteases22,38,39. However, some 
alpha macroglobulins do not carry a promiscuous bait region having a specified role in 
clearance of targeted proteases, cytokines or enzymes2,5. 
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1.1.3 CoŵpleŵeŶt alpha ŵaĐƌogloďuliŶs 
The complement system involves a large network of proteins that results in the 
opsonisation or lysis of pathogens as well as mediating inflammation and eventual 
clearance of opsonised pathogens by phagocytosis40–43. The complement system obtained 
its name in the 1890s when it was found that a heat-labile protein found in the serum 
͚ĐoŵpleŵeŶted͛ the killiŶg of ďaĐteƌia ďy heat-stable antibodies42. There are three 
complement proteins C3, C4 and C5 that are members of the alpha macroglobulin 
superfamily and each plays a major role in the complement system of human innate 
immunity. As part of the complement cascade these proteins are cleaved by various 
convertases and proteases (Figure 1-3). This results in a conformational change and 
activation of each protein forming C3b, C4b and C5b as well as releasing their respective 
C3a, C4a and C5a anaphylatoxins44,45. This complement cascade can start through the 
binding of antibodies, mannose-binding lectins (MBL) or complement C3b to the surface 
of pathogens leading to three distinct pathways for complement cascade activation 
(Figure 1-3). 
 
The alternative pathway is initiated when C3b opsonin binds to carbohydrates, lipids or 
proteins on the surface of pathogens. Upon C3b binding to a pathogen complement 
factor B binds to form C3bB that can be cleaved by complement factor D resulting in C3 
convertase34. C3 is always being hydrolysed to form C3b without requiring any other 
enzymes to cleave C3 to C3a anaphylatoxin and C3b. The constant generation of C3b 
allows the alternative pathway to begin without either of the other pathways being 
initiated. 
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Figure 1-3 Complement activation pathways and the involvement of alpha macroglobulin proteins. 
Complement C3 has multiple roles, it is important in activating the alternative pathway, in turning C3 
convertase to C5 convertase and in the downstream opsonisation of pathogens. Complement protein C4 
has a role in the classical and lectin pathway, upon cleavage it can bind C2a to become C3 convertase, 
which is able to cleave C3 and combine with C3 to become C5 convertase. Cleavage of C5 to C5b results in 
the generation of the membrane attack complex. The activation of C3, C4 and C5 results in the release of 
the anaphylatoxins C3a, C4a and C5a respectively leading to inflammation. Alpha macroglobulin proteins 
are highlighted in yellow and pink indicating inactive and activated forms respectively. The activated form 
of C4, C4b, becomes part of the C3 convertase complex resulting from the classical and lectin pathways. 
Adapted from Ricklin, Lambris; 2007 and Vidya Sarma, Ward;201230,46. 
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The mannose-binding lectin pathway is triggered by MBLs or ficolin binding to 
carbohydrates on the surface of pathogens47–52. MBLs and ficolin are normally bound to 
MBL-associated serine proteases in circulation and upon binding to the surface of a 
pathogen these become activated and cleave C4 into C4a anaphylatoxin and C4b45,53. The 
MBL-associated serine proteases are also able to cleave C2 and the resulting complex of 
C4b and C2a become the C3 convertase C4bC2a54. 
 
The classical pathway is activated with antibodies binding to antigens on the surface of 
pathogens. Complement C1q then binds the Fc (fragment , crystallisable) tail region of the 
bound immunoglobulin G or immunoglobulin M, with the subsequent binding of C1r and 
C1s proteins the new heteromultimeric protein becomes the C1 complex55. The C1s 
subunit of the C1 complex is then able to cleave both C4, into C4a anaphylatoxin and C4b, 
and cleave C2 resulting in the C3 convertase C4bC2a.  
All three pathways converge in generating C3 convertase which has the ability to cleave 
C3 into C3a anaphylatoxin and C3b opsonin (Figure 1-4). C3 convertase can also complex 
with C3b to become C5 convertase. C5 convertase is able to cleave both C3 into C3a 
anaphylatoxin and C3b opsonin as well as C5 into C5a anaphylatoxin and C5b56. When 
considering the generation of C3b opsonin being one of the end points of the 
complement cascade and also the start of the alternative pathway there can be 
considered an amplification loop that leads to the generation C3b.  
All three anaphylatoxins C3a, C4a and C5a have multiple similar effects on inflammatory 
response56,57. A major role is their ability to activate chemotaxis in neutrophils and 
monocytes that bring these phagocytes closer to the complement activated cells to 
enhance clearance58–61. These anaphylatoxins are also able to cause the release of 
histamine for activating neutrophils and causing vasodilation as well as well as causing 
cytokine release58. 
With the activation of C5 to C5b begins the generation of the membrane attack complex 
where complement proteins C6, C7, C8 form a complex with multiple copies of 
complement C962,63. The membrane attack complex subsequently lyses the attacked 
pathogen by inserting itself into the cells membrane and forming a pore. 
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Complement proteins C3, C4 and C5 share a similar domain composition although C5 
does not contain a thioester 8(Figure 1-1). 
 
 
 
Figure 1-4 Crystal structure of C3, C3a anaphylatoxin, and C3b opsonin.  
(a) A representation of the domains found in all complement alpha macroglobulins C3/4/5, C3/4/5a and 
C3/4/5b. (b) Crystal structure of C3 (PDB:2A73) before activation with domains coloured as shown in (a).   
(c) The anaphylatoxin C3a (PDB:2A73), with arrows indicating its location in C3, causes inflammation and 
chemotaxis to the site of complement activation. The movement of domains is shown in (d) upon cleavage 
of C3 to C3a and C3b (PDB:2I07)44,64. Note the release of the TED so that it moves to orientate towards the 
pathogen surface for opsonisation. ANA, anaphylatoxin domain; CUB, complement protein subcomponent 
domain; MG, macroglobulin domain; TED, thioester domain.  
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Although there are striking structural similarities seen between α2M and the complement 
proteins there are a number of features unique to complement proteins. All complement 
alpha macroglobulins have an anaphylatoxin domain in place of their bait region which is 
cleaved off of the remainder of the protein upon activation (Figure 1-4).  Complement 
proteins also have a C345C domain which is important for binding of the proteases that 
are involved in cleaving off the anaphylatoxin domain. Another major difference between 
ĐoŵpleŵeŶt pƌoteiŶs aŶd αϮM is the ĐoŶfoƌŵatioŶal ĐhaŶge seeŶ upoŶ aĐtiǀatioŶ34,44,64. 
For αϮM, upoŶ Đleaǀage aŶd activation, domains move to encapsulate the cleaving 
protease. In contrast in complement proteins, conformational reorientation of domains 
occurs bringing the thioester domain towards the surface of the pathogen to covalently 
bind to surface targets for opsonisation (Figure 1-4). 
LiŶks haǀe ďeeŶ ŵade ďetǁeeŶ the eǀolutioŶaƌy oƌigiŶs of αϮM aŶd ĐoŵpleŵeŶt 
proteins11,65. It is thought that αϮM pƌedates the eǀolutioŶ of ĐoŵpleŵeŶt pƌoteiŶs aŶd 
that the gradual evolution of the complement proteins predates the evolution of 
antibodies11. Theƌe has ďeeŶ soŵe suggestioŶ that ďaĐteƌial αϮM has ďeeŶ hoƌizoŶtally 
acquired from eukaryotic hosts as an adaptive mechanism of defence to foreign 
proteases66. 
 
1.1.4 TEPϭ 
Thioester-containing protein 1 (TEP1) is a protein found in the malarial vector Anopheles 
gambiae, that similar to complement plays a role in innate immunity against 
pathogens10,15. It has been shown to mediate the binding and killing of the malarial 
parasite Plasmodium berghei in conjunction with another heteroprotein, LRIM1-APL1C 
complex upon TEP1 cleavage and activation15. The LRIM1-APL1C complex is thought to 
stabilise the activated complex protecting the thioester to allow it to react with the 
pathogen. The domain architecture of TEP1 is very similar to otheƌ eukaƌyotiĐ αϮM ǁith 
close similarity also being noted between unactivated TEP1 and uŶaĐtiǀated “aαϮM10. 
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1.1.5 BaĐteƌial Alpha-Ϯ-ŵaĐƌogloďuliŶs 
αϮMs have most recently been found in Gram-negative bacteria6,67.  Where eukaryotic 
αϮM aƌe soluďle aŶd aƌe usually fouŶd iŶ ŵultiŵeƌ foƌŵs, BA2M͛s aƌe membrane 
anchored lipoproteins with evidence suggesting they are monomeric14,67,68.  
Escherichia coli αϮM (ECAM) is the third biggest protein produced by Escherichia coli K-12 
(BW25113) at 181 kDa, only surpassed only by a putative surface adhesin Yeej and 
ferredoxin reductase69–71. ECAM is bound to the inner membrane located within the 
periplasm with an N-terminal anchor.  The gene encoding ECAM, yfhM is found alongside 
the gene pbpC that encodes a penicillin binding protein. These two proteins have been 
suggested as having a linked function in defence and repair in which proteases that have 
breached the outer membrane are inhibited by ECAM, with PbpC repairing the damage 
caused to the peptide component of peptidoglycan6 (Figure 1-5).   
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Figure 1-5 Proposed defence and repair mechanism of bacterial α-2-macroglobulin and Pbp1C.  
Host antibodies, complement or antimicrobial peptides breach the outer membrane allowing host 
proteases and lysozyme entry to attack peptidoglycan elements. Host proteases are entrapped by bacterial 
α-2-macroglobulin and Ivy lysozyme inhibitors disable lysozyme allowing Pbp1C to repair the peptidoglycan. 
Figure elements not represented to scale and adapted from Budd et al 20046. 
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Within the E. coli genome, as well as yfhM, there is a second ECAM encoding gene6. The 
second copy, yfaS is found in and operon with four other genes, yfaA, yfaT, yfaQ and 
yfaP. The genes within this operon, however, have had little investigation into their 
function. YfaS has only 15% amino-acid sequence identity with YfhM and does not 
contain a thioester and so would not be expected to covalently bind to proteases6. The 
yfhM and yfaS genes are conserved among a wide range of Gram-negative bacteria, 
although often with only one copy within a genome. A copy of at least one α2M encoding 
gene has been found within alpha, beta, gamma, delta and epsilon proteobacteria with 
copies being found within various other phyla of bacteria6. An αϮM encoding gene has 
been found within the genome of archaea however these appear to have closer similarity 
to the eukaƌyotiĐ foƌŵ of αϮM ƌatheƌ thaŶ ďaĐteƌial αϮMs14.  
The Pseudomonas aeruginosa genome has only one BA2M encoding gene, magD, which is 
within an operon  that also contains the genes magA, magB, magC, magE, and magF68. 
The proteins from this Mag operon have been suggested as having a role in bacterial 
pathogenicity due to their coregulation at the post-transcriptional level with other 
virulence factors72. magA mRNA has been shown to be a direct target of the RNA-binding 
protein RsmA that has been shown to bind and downregulate the expression of various 
genes important for synthesis of P. aeruginosa biofilms73,74. Two notable operons that are 
downregulated by RsmA are psl and pel that are involved in exopolysaccharide72,74–76. 
MagD has been suggested as not having direct interaction with the inner-membrane, but 
is bound via interaction with MagB68. This complex is also thought to involve MagA and 
MagF, as they can be identified along with MagB via immunoprecipitation for MagD 
followed by proteomic analysis68. The ability of MagD to interact with human neutrophil 
elastase suggests a similar function to YfhM as a protease inhibitor68. 
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Figure 1-6 Structural models of ECAM from SAXS and EM.  
Small angle X-ray scattering Ab initio models generated using GASBOR of (a) native untreated ECAM, (b) 
methylamine-treated (c) chymotrypsin-treated and (d) elastase-treated ECAM. (e) Isosurface 
representations of the 3D reconstruction obtained for the methylamine treated form of ECAM with red 
arrows highlighting regions of potentially greatest flexibility. Figure produced from figures shown in Neves 
et al 201277. 
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Structural characterisation of ECAM was first attempted by small angle X-ray scattering 
(SAXS) and electron microscopy (EM) where native ECAM was compared with ECAM 
activated with methylamine, or the proteases elastase and chymotrypsin 68,77(Figure 1-6. 
a, b, c, d respectively). These forms were compared due to expected similarity between 
ďaĐteƌial αϮM aŶd huŵaŶ αϮM iŶ ĐoŶfoƌŵatioŶal aĐtiǀatioŶ ǀia sŵall ŵoleĐule aŶd 
proteases. Within this work it was found that the envelopes generated after reaction with 
methylamine and chymotrypsin and elastase showed distinct differences (Figure 1-6). 
Fuƌtheƌ ǁoƌk ǁas peƌfoƌŵed usiŶg the P. aeƌugiŶosa MagD αϮM that appeaƌed to shoǁ 
very similar envelope shape68. Although both of these SAXS studies using ECAM and 
MagD found that there was a difference between native BA2M and methylamine reacted 
BA2M the recently published crystal structure of Salmonella enterica spp. Typhimurium 
αϮM ;“aA2M) (Figure 1-7) showed that there was no conformational change on 
methylamine treatment14.  
 
The high resolution model of SaA2M displays distiŶĐt siŵilaƌity to α2M14. Although 
SaA2M was described as being monomeric it was noted that a crystallographic dimer was 
present. All of the doŵaiŶs seeŶ ǁithiŶ huŵaŶ αϮM aƌe pƌeseŶt in SaA2M, however, 
there are an additional two N-terminal domains that anchor it to the inner membrane14. 
These two domains also form part of the dimer interaction seen within the crystal with 
contacts also found between these domains and the bait region. EM performed on 
methylamine activated ECAM alongside the earlier SAXS work showed a loop region and a 
flexible region, with similarities between the flexible region in this EM model and the C-
terminus of complement 77(Figure 1-6 e). 
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Figure 1-7 Domain organisation and crystal structure of unactivated SalŵoŶella αϮM. 
(a) The domain composition including macroglobulin domains (MG) (highlighted C-terminal macroglobulin 
domain), bait region domain (BRD), CUB domain and the thioester domain (TED) that contains the CLEQ 
thioester. The crystal structure of Salmonella αϮM shown (PDB:4U48 from Wong, Dessen14) in (b) has been 
coloured according to the domain arrangement seen in (a).  
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1.1.6 Thioesteƌs iŶ Gƌaŵ positiǀe ďaĐteƌia 
Not only have thioesters been identified in alpha macroglobulins but also in Gram-
positive bacterial pilus adhesins (Figure 1-8 a)78. These exist as long macromolecular 
filaments called pili that are important for bacterial virulence  (Figure 1-8 b) 78. These 
have been shown to allow bacteria to colonise host organisms and have been suggested 
as being viable for development of vaccines 79–81. The thioester found in gram positive 
pilin adhesins has been suggested as functioning in a similar fashion as complement 
proteins in reacting with surface amines 82. 
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Figure 1-8 The structure of Streptococcus pyogenes and its location in the pilus adhesin  
(a) Shown is a ribbon representation of the middle, top, and bottom domain coloured red, blue, and green, 
respectively; the termini are also labelled. Residues composing the thioester bond (Cys-426 and Gln-575) 
are shown with their carbon atoms in magenta. Residues composing the intramolecular isopeptide bonds 
(Lys-297 and Asp-595 in the middle domain, Lys-610 and Asn-715 in the bottom domain) are shown with 
their carbon atoms in yellow. Regions connecting the domains are shown in grey. The missing Spy0125-NTR 
(not expressed in the construct) would be positioned to the right of the middle domain. (b) A structural 
model of an intact pilus is shown. Spy0125 is coloured as above except the thioester and isopeptide 
residues are shown in red and grey. Two molecules of Spy0128 are shown (representing the polymerized 
pilus, cyan and pink with intramolecular isopeptide bonds coloured as above). Spy0130 is presented as 
a grey molecular surface. The location of the intermolecular isopeptide bonds are shown as solid lines. 
Yellow and blue ovals represent cell wall and cell wall precursors, respectively.  Figure reproduced from 
Jonathan A. Pointon et al. J. Biol. Chem. 201078. 
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1.1.7 Thioesteƌ ƌeaĐtioŶ 
Alpha macroglobulin proteins require activation by proteolysis and domain movement, 
which exposes the thioester bond, whereas pilins do not require activation (Figure 1-9) 
14,37,82,83. Alpha macroglobulins and pilins have a preference for amino groups however in 
C4b and C3, a His/Asp substitution near the thioester bond changes the substrate 
specificity and allows reaction with hydroxyl groups 14,37,82,83.  
 
 
Figure 1-9 Thioester reaction with surface amines 
Shown is a simplified scheme for the reactions of the thioester bonds in the thioester domain (TED, green) 
of alpha macroglobulin proteins (including ĐoŵpleŵeŶt, αϮM aŶd BAϮMͿ aŶd piliŶ adhesiŶs ǁith suƌfaĐe 
amines (dark red). Figure modified from Linke-Winnebeck et al 201482. 
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1.2 PeŶiĐilliŶ ďiŶdiŶg pƌoteiŶs 
Penicillin binding proteins (PBPs) are enzymes that catalyse the expansion of the murein 
sacculus by addition of a heterodimer glycan subunit with a pentapeptide side chain that 
is cleaved from lipid II84–88. The name penicillin binding protein comes from their ability to 
covalently bind to penicillin as well as other β-lactam antibiotics89. The interaction of β-
lactams and PBPs is due to the similarity in structure between β-lactam antibiotics and 
the D-alanine-D-alanine termini of the pentapeptide sidechain found on peptidoglycan90–
92. DuƌiŶg this iŶteƌaĐtioŶ the β-lactam amide bond is cleaved forming a covalent bond 
with the serine residue in the PBP active site. PBPs have various functions in the synthesis 
and regulation of peptidoglycan structure. There are three main classes of PBP, Class A, B, 
and C. Class A PBPs are bifunctional transglycosylase/transpeptidases (TGase/TPase) 
murein synthases84,87. Their TPase is the target of β-lactam antibiotics and functions in 
crosslinking pentapeptide sidechains between glycan chains84,87. Class B PBPs are 
monofunctional TPases without the TGase activity found in Class A PBPs. Class C PBPs 
have several subclasses consisting of carboxypeptidases (CPases) and endopeptidases 
(EPases) that are involved in the regulation of peptidoglycan turnover84,87. 
 
1.2.1 MuƌeiŶ sǇŶthesis 
Synthesis of murein subunits occurs within the cytoplasm of Gram-negative bacteria 
through the action of a number of enzymes. Biosynthesis begins with the conversion of 
uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) from fructose-6-phosphate by 
the sequential action of glucosamine-6-phosphate synthase (GlmS), phosphoglucosamine 
mutase (GlmM) and glucosamine-1-phosphate acetyltransferase and 
N-acetylglucosamine-1-phosphate uridyltransferase (the final two processes performed 
by the GlmU bifunctional enzyme)92–97. The next main step involves the conversion of 
UDP-GlcNAc to uridine diphosphate N-acetylmuramic acid (UDP-MurNAc) by the enzymes 
MurA and MurB98,99. The addition of the pentapeptide sidechain is then catalysed 
sequentially by MurC, MurD, MurE and MurF100–103. The anchoring of UDP-MurNAc-
pentapeptide to an inner-membrane monophosphorylated undecaprenol is catalysed by 
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MraY to form lipid I101. The final step of addition of a GlcNAc to the lipid I to form a lipid II 
for transport to the periplasm is performed by MurG104,105.  Transport of lipid II from the 
cytoplasm across the inner membrane was long considered to be performed by either 
FtsW or RodA however recently it was discovered that a flippase enzyme MurJ is 
responsible for lipid II transport106. Once transported across the inner membrane lipid II 
has undecaprenyl-diphosphate cleaved off and the new subunit is polymerised into the 
murein sacculus by murein synthases (Figure 1-10). 
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Figure 1-10 Murein sacculus synthesis. 
Peptidoglycan subunits (Lipid II) are synthesised in the cytoplasm and transported to the periplasm by 
flippase MurJ and glycosyl chains are extended by transglycosylases (TGase). DD-transpeptidases (DD-
TPase) further crosslink peptide sidechains to form the lattice of the peptidoglycan murein sacculus. 
Uncrosslinked peptides are cleaved by DD-, LD- and DL-carboxypeptidases (CPases), and crosslinks are 
cleaved by DD- and LD-endopeptidases (EPases). Peptides are removed from the glycan chain by amidases, 
and exo- endo-specific lytic transglycosylases (LTs) cleave the glycan chain to form 1, 6-anhydro-N-
acetylmuramic acid (anhMurNAc) residues that are characteristic of the ends of glycan chains. The 
anchoring of the peptidoglycan sacculus to the outer-membrane is catalysed by LD-TPases forming 
crosslinks to outer-membrane lipoprotein (Lpp) as well as the catalysis of integration of unusual D-amino 
acids to the peptidoglycan. The number of known enzymes identified in Escherichia coli are shown in 
brackets although not all enzymes involved are known or characterised yet. GlcNAc, N-acetylglucosamine; 
meso-Dap, meso-diaminopimelic acid; MurNAc, N-acetylmuramic acid. Figure recreated and modified from 
Typas et al 2012107. 
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1.2.2 MuƌeiŶ sǇŶthases 
There are several types of enzyme that work together to synthesise the peptidoglycan 
network within the periplasm, including bifunctional TG/TPases, monofunctional TPases, 
and monofunctional TGases84,108. There are two types of TPase enzyme within murein 
synthesis, DD-TPases and LD-TPases. DD-TPases form crosslinks between the meso-
diaminopimelic acid of one sidechain and D-alanine of another109,110. LD-TPases form 
crosslinks between the meso-diaminopimelic acids of two side chains111. 
 
Class A Penicillin binding proteins are large, ~80 kDa, inner membrane bound periplasmic 
proteins involved in the synthesis of the murein sacculus112–114. These have both a TGase 
domain for crosslinking new subunits into the peptidoglycan and TPase domain for 
crosslinking peptides between chains. Three members have been identified within 
Escherichia coli, Pbp1A, Pbp1B and Pbp1C with a double knockout of Pbp1A and Pbp1B 
being lethal. 
 
Penicillin binding protein 1A (Pbp1A) is encoded by the gene ponA (mrcA) whose single 
deletion results in minimum effect on cell growth or morphology115. This protein has been 
shown to be a major target foƌ β-lactam antibiotics as strains lacking Pbp1B are more 
toleƌaŶt to β-lactams. An outer membrane activating protein LpoA, which interacts 
directly with Pbp1A, is required to activate Pbp1A function110. Pbp1A also functions 
alongside Class B PBPs to form a complex anchored to cytoskeletal elements within the 
cells cytoplasm through Mre and Rod proteins116,117. These proteins have a role in 
dispersed elongation of the cell as well as preseptation elongation near the central point 
where septation occurs118. Pbp1A has a small cytoplasmic region and spans the inner-
membrane with a TGase domain at the inner-membrane interface showing the five 
conserved motifs seen in TGase domains (Figure 1-11). The C-terminal domain has DD-
TPase function for crosslinking peptides within the peptidoglycan (Figure 1-10)112,119. 
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Figure 1-11 Penicillin binding proteins and their domain structure 
(a) Orientation and domain composition of proteins involved in peptidoglycan synthesis. (b) Classes of 
penicillin binding protein and domains found in each type. Adapted from Vollmer, Bertsche 2008108. 
 
  
Chapter 1 
28 
 
Penicillin binding protein 1B (Pbp1B) has thƌee isofoƌŵs ;α, β, aŶd γͿ ǁhich have varying 
lengths of the N-terminal cytoplasmic region (Figure 1-11)114,120–122. Similar to Pbp1A an 
outer membrane activating protein, LpoB, is required for activation of Pbp1B enzyme 
function and a complex is formed with Pbp3 as well as Fts proteins, linking to the 
cytoplasmic cytoskeleton110. Pbp1B has both TGase and DD-TPase function (Figure 1-10). 
 
Penicillin binding protein 1C (Pbp1C) has been shown to have TGase function and has the 
ability to bind moenomycin as do Pbp1A and Pbp1B123. Moenomycin has structural 
similarity to peptidoglycan subunits and is shown to bind and inhibit TGases123. Pbp1Cs 
TPase function is only inferred from the sequence identity to Pbp1A and Pbp1B 
(Figure 1-11) 123. Upon knockout of pbpC, the gene encoding Pbp1C, no notable change in 
growth or morphology is found and the presence of this gene is not able to compensate 
for the double knockout of mrcA and mrcB (encoding Pbp1A, Pbp1B, respectively) 123. 
PďpϭC has ďeeŶ shoǁŶ to haǀe lesseƌ affiŶity to β-lactams than other PBPs with notable 
binding to the β-lactam antibiotics oxecephalosporin latamoxef and a Bolton/Hunter 
derivative of ampicillin123. It is also said that as there is varied specificity to β-lactams and 
the lack of compensation of TPase function lost by the other Class A PBPs, that Pbp1C is 
no longer a functioning TPase enzyme123. Pbp1C has been suggested to function as part of 
a complex as it can interact with Pbp1B, PBP2, PBP3 and MltA123. Although LpoA and LpoB 
have been identified as essential for function of Pbp1A and Pbp1B respectively no 
equivalent has been identified for Pbp1C to date. 
 
Class B penicillin binding proteins have 2 major domains with the N-terminal domain 
having some similarity to the TGase domain seen within Class A PBPs however without 
any direct TGase function84,107,124. This N-terminal domain functions in the formation of 
peptidoglycan synthesis complexes with other PBPs and cytoskeletal elements. The 
second domain has DD-TPase function. 
 
Pbp2 is an enzyme with DD-TPase activity essential for cell elongation in E. coli and for the 
characteristic rod shape seen (Figure 1-10, 1-11)117,118. The gene encoding Pbp2, pbpA, is 
found within an operon alongside the gene rodA, which encodes RodA, a protein that 
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spans the inner-membrane and is also essential for extension of the cylindrical wall of the 
E. coli rod117,118. When cells are grown ǁith ŵeĐilliŶaŵ, a PďpϮ speĐifiĐ β-lactam 
antibiotic, they form spheres instead of rods and are not able to form colonies117,118. The 
exposure of bacteria to mecillinam to generate resistant mutants results in strains that 
can tolerate deletion of the gene encoding Pbp2117,118. As this specific inhibition shows 
that Pbp2 is essential for cell elongation it has also been suggested as having an essential 
function in regulation of septation117,118. When Pbp2 is tagged with green fluorescent 
protein it appears within the lateral cylindrical wall as well as at the site of cell division 
disappearing just before the cells divide117,118. Cells that have been exposed to mecillinam 
are only able to divide for several generations before lysing which can be extended for 
further generations by overexpression of FtsZ which is involved in the division machinery 
of the cell117,118. As a reduction of Pbp2 would result in spherical cells it is thought that 
upon inhibition of its function the demand for FtsZ is greater117,118.  
 
The monofunctional DD-TPase Pbp3 was once thought to have bifunctional TGase/TPase 
activity however the TGase like domain only has some of the conserved binding motifs 
found in TGase enzymes (Figure 1-11)113,125,126. Pbp3 is encoded by the gene ftsI and is 
temperature sensitive, not functioning when grown at high temperatures. In the presence 
of the antibiotic aztreonam which has very high affinity for Pbp3, as well as at high 
temperatures that restrict enzyme function, cells grow in long filaments and are unable to 
divide127. It is accepted that Pbp3 is an essential TPase involved in cell division that forms 
a complex with several proteins for peptidoglycan enlargement and cell division. 
 
Monofunctional TGases although not penicillin binding proteins have a major role in the 
synthesis of the murein sacculus114. These enzymes catalyse the addition of lipid II 
peptidoglycan subunits to the generating peptidoglycan chain. Once the subunit has been 
added to the chain the diphosphorylated undecaprenol has a phosphate removed and the  
monophosphorylated undecaprenol returns to the cytoplasm for further transport of 
subunits. Monofunctional TGase enzymes like MtgA from E. coli are bound to the inner 
membrane and have five conserved motifs that are found within other enzymes with 
TGase function (Figure 1-11)114. Although the mtgA gene can be knocked out, this is 
Chapter 1 
30 
 
associated with reduced virulence within pathogenic bacterial strains and abnormal 
growth under laboratory conditions114. 
 
1.2.3 MuƌeiŶ hǇdƌolases 
Murein hydrolases encompass all enzymes that cleave covalent bonds within the murein 
sacculus including muramidases that cleave between sugar subunits, peptidases that 
cleave between amino acid residues and amidases that cleave between sugar and peptide 
crosslinks128–132. 
Muramidase enzymes cleave between sugar subunits with lysozyme cleaving the  
β 1,4-bond between MurNAc and GlcNAc subunits in glycan chains and lytic 
transglycosylases (LTases) cleaving the glycosidic bond between them forming a 
concominant 1,6-anhydro bond on the MurNAc residue128,129,133,134. In E. coli five 
outermembrane lipoproteins (MltA, MltB, MltC, MltD, and EmtA) LTases have been 
identified in addition to one soluble LTase (Slt70)135–138. Endo-LTases such as EmtA cleave 
sugars within the chain whereas exo-LTases (Slt70, MltA and MltB) cleave the 
disaccharide subunits from the 1,6-anhydroMurNAc glycan end of the chain (Figure 1-10).  
There are various types of peptidases associated with murein hydrolysis. 
Carboxypeptidases (CPases) cleave amino acids from peptide side chains. Endopeptidases 
(EPases) hydrolyse the bridge formed between peptide chains by TPases139,140. DD-CPases 
cleave between the D-alanine-D-alanine end residues of a pentapeptide sidechain and LD-
CPases cleave between the meso-diaminopimelic acid and D-alanine (Figure 1-10). An 
important protein for recycling of peptidoglycan is LdcA which is an LD-CPase found 
within the cytoplasm. DD-EPases cleave the bridge formed between the meso-
diaminopimelic acid and D-alanine of two side chains and LD-EPases cleave the bridge 
formed between two meso-diaminopimelic acids of two side chains (Figure 1-10). MepA 
is a protein 30 kDa in size that is found in the periplasm and has been shown to have both 
DD-EPase activity and LD-EPase activity141. 
Class C penicillin binding proteins are peptidases with one main enzymatic domain that 
include both DD-CPases and DD-EPases. Pbp4 and Pbp7 are both located in the periplasm 
and have been shown to be membrane associated with DD-EPase activity; however Pbp4 
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has also been shown to have some DD-CPase activity (Figure 1-11)142–144. Pbp5, Pbp6, and 
Pbp6B have been shown to have DD-CPase activity and although they do not have a 
membrane anchor, are thought to be associated with the inner-membrane 
(Figure 1-11)131,145. These DD-CPases play an important role in cell shape with 
abnormalities seen upon combination of deletions between these and other enzymes 
involved in peptidoglycan synthesis and hydrolysis127. 
The third type of murein hydrolases, amidases, cleave the bond between glycan strand 
and peptide side chain (Figure 1-10). N-acetylmuramyl-L-alanine amidases AmiA, AmiB 
and AmiC all have an important role in cell separation during cell division130,146. The fourth 
amidase identified, AmiD, is expressed in the cytoplasm and is involved in recycling of 
peptidoglycan subunits147.  
 
 
1.2.4 MuƌeiŶ stƌuĐtuƌe  
The murein sacculus is a large hetero-polymer structure found within the periplasm of 
Gram-Ŷegatiǀe ďaĐteƌia that ŵaiŶtaiŶs the ďaĐteƌia͛s shape aŶd is esseŶtial to pƌeǀeŶt 
ƌuptuƌe ďy the ďaĐteƌia͛s iŶteƌŶal tuƌgoƌ148. This is made up of subunits consisting of a 
disaccharide of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) with a 
pentapeptide sidechain extending from the MurNAc sugar 111,149(Figure 1-12). This 
pentapeptide usually consists of a chain of L-alanine, D-glutamate, meso-diaminopimelic 
acid, followed by two D-alanine (Figure 1-12) with the D-glutamate residue linked via its 
y-carboxyl group to the L-centre of meso-diaminopimelic acid150,151. These subunits are 
synthesised within the cytoplasm and cross the cytoplasmic membrane to the periplasm 
in the form of lipid II and the peptidoglycan subunits are cross-linked into the existing 
peptidoglycan by penicillin binding proteins107. The GlcNAc end of the subunit is cross-
linked to the existing MurNAc chain by TGases and the peptide chains are then 
cross-linked by TPases, shortened by CPases or removed by amidases. The two ends of 
the glycan strands are either GlcNAc or 1,6-anhydroMurNAc, which is a modified MurNAc 
with a C-1, C-6 ether-linkage111. 
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Figure 1-12 Schematic of the primary structure of peptidoglycan pentapeptide subunit. 
Circles represent the amino acids labelled that are attached to MurNAc. GlcNAc, N-acetylglucosamine; 
meso-DAP, meso-diaminopimelic acid; MurNAc, N-acetylmuramic acid.  
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Several models have been suggested of how this network of glycan chains with peptide 
crosslinks forms the peptidoglycan network.  Initial work gave evidence for glycan chains 
following a perpendicular angle to the direction of the rod shape with peptide links 
forming parallel to the rod shape 148(Figure 1-13. a). The NMR structure for a dimer of the 
peptidoglycan subunit has been modelled with suggestion that the glycan chain is 
orientated to form chains between membranes forming a hexagon of peptide crosslinks 
ǁhiĐh alloǁs foƌ the ϭϮϬ⁰ aŶgle of ƌotatioŶ ŵeasuƌed ďetǁeeŶ peptide ĐƌossliŶks 
152(Figure 1-13. b, c). This fits well with the model of the outermembrane protein TolC 
that fits within this hexagonal network to span both the outermembrane and the 
peptidoglycan layer (Figure 1-13. d). At the same time as this work electron 
cryotomography was performed on the purified sacculus of gram-negative bacteria added 
evidence away towards a disordered circumferential layered model of peptidoglycan. The 
disordered circumferential layered model has glycan strands arranged perpendicular to 
lengthwise rod shape of the bacterium 153. This perpendicular model of glycan strands to 
the rod shape of bacterium was further confirmed using atomic force microscopy (AFM) 
of whole cells of Lactococcus lactis 154. The use of AFM and super resolution fluorescence 
microscopy on purified sacculus later suggested that the synthesis of new peptidoglycan 
is limited to areas with pores in the peptidoglycan allowing new growth 155,156. 
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Figure 1-13 Electron micrograph of murein sacculus of E. coli and the three dimensional structure of 
peptidoglycan. 
(a) Black dots within the electron micrograph show 6 nm gold particles bound to anti-murein antibody 
bound to the sacculus. Model on right shows an area approximately 30 x 30 nm. (b) Sphere representation 
of the three dimensional model of N-acetylglucosamine (GlcNAc), N-acetylmuramic acid (MurNAc) chain in 
teal and peptide sidechains in pink. With each peptidoglycan subunit there is a 120 rotation along the 
GlcNAc-MurNAc disaccharide axis between peptide crosslinks. (c) Top down view of model of sacculus. (d) 
“teƌeo ǀieǁ of peptidoglyĐaŶ ǁith TolC β-barrel domain in a hexagonal pore of the peptidoglycan, the 
pƌotƌudiŶg β-barrel would be bound in the outer membrane. Image in (a) was reproduced from Vollmer, 
Bertsche 2008108. Structural model of murein used in (b), (c) and (d) provided on request by Shahriar 
Monbashery152. 
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1.3 Aiŵs of the pƌojeĐt 
The overall aims of this project were to develop functional and structural understanding 
into ECAM and Pbp1C. These two proteins that are encoded together within an operon, 
have been described as functioning alongside each other, with ECAM inhibiting proteases 
and Pbp1C repairing peptidoglycan however we further set out to determine if there was 
any direct interaction between these proteins. At the outset of this work there had been 
limited biophysical characterisation of either ECAM or Pbp1C with only some minor 
analytical ultracentrifugation performed on ECAM. At the outset of this work a crystal 
structure of methylamine activated human αϮM had been published at 4.3 Å resolution. 
However, there had been Ŷo Ŷatiǀe αϮM stƌuĐtuƌe puďlished oƌ aŶ αϮM stƌuĐtuƌe that 
had been activated through protease cleavage. Further it was hoped that through the use 
of knockouts and western blotting the behaviour of these proteins in vivo could be better 
understood. 
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2 Materials aŶd Methods 
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2.1 ReageŶts  
All chemicals and reagents used within this work were purchased from Melford, Sigma 
Aldrich or Thermo-Fisher Scientific unless stated otherwise. 
 
2.2 BaĐteƌial stƌaiŶs, plasŵids aŶd gƌoǁth ŵedia 
Bacterial strains and plasmids used in this work are shown in Table 2-1 and Tables 2-2, 2-3 
respectively. Bacteria were grown in Lysogeny broth (LB;10 g NaCl, 10 g tryptone, 5 g 
yeast extract per litre in dH2O adjusted to pH 7.5) at 37°C. Bacteria were grown on agar 
plates and stored short term at 4°C and stored long term in 50% glycerol at -80°C.  
 
Table 2-1 E. coli strains and knockouts 
E. coli strain Noted characteristics Source 
DHϱα F- ΦϴϬlaĐ)ΔMϭϱ ,Δ;laĐ)YA-argF), U169, recA1, endA1, 
hsdR17(rk-, mk+), phoA, supE44, thi-ϭ, gyrAϵϲ, relAϭ λ- Invitrogen 
BL21(DE3) 
fhuAϮ [loŶ], oŵpT gal ;λ DEϯͿ [dĐŵ], ∆hsdS,λ DEϯ = λ 
sBaŵHIo, ∆EĐoRI-B int::(lacI::PlacUV5::T7 gene1) i21, 
∆ŶiŶϱ 
New England 
Biolabs 
T7 Express Crystal 
Competent E. coli  
fhuA2 lacZ::T7 gene1 [lon] ompT gal sulA11 R(mcr-
73::miniTn10--TetS)2 [dcm] R(zgb-210::Tn10--TetS) 
eŶdAϭ ŵetBϭ Δ;ŵĐrC-mrr)114::IS10 
New England 
Biolabs 
K-12 (BW25113) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, rph-1, 
Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
K-12 mutants     
ΔyfhM               
yfhM766(del)::kan 
(JW2504-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔyfhMϳϲϲ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔpďpC               
pbpC765(del)::kan 
(JW2503-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔpďpCϳϲϱ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
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ΔytfN                  
ytfN770(del)::kan 
(JW4180-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, rph-1, 
Δ;rhaD-rhaBͿϱϲϴ, ΔytfNϳϳϬ::kaŶ, hsdRϱϭϰ 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔytfM                  
ytfM769(del)::kan 
(JW4179-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, rph-1, 
Δ;rhaD-rhaBͿϱϲϴ, ΔytfMϳϲϵ::kaŶ, hsdRϱϭϰ 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔyfaA                  
yfaA784(del)::kan 
(JW2224-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔyfaAϳϴϰ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔytaP                  
yfaP779(del)::kan 
(JW2219-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔyfaPϳϳϵ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔytaQ                  
yfaQ780(del)::kan 
(JW2220-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔyfaQϳϴϬ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔytaS                   
yfaS781(del)::kan 
(JW2221-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔyfaSϳϴϭ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔytaT                   
yfaT783(del)::kan 
(JW2223-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔyfaTϳϴϯ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔŵrĐA                  
mrcA731(del)::kan 
(JW3359-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔŵrĐAϳϯϭ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔŵrĐB                  
mrcB765(del)::kan 
(JW0145-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔŵrĐBϳϲϱ::kaŶ, 
ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, rph-ϭ, Δ;rhaD-rhaB)568, 
hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔpďpG                  
pbpG760(del)::kan 
(JW5355-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔpďpGϳϲϬ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔaŵpC                  
ampC777(del)::kan 
(JW4111-2) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, rph-1, 
Δ;rhaD-rhaBͿϱϲϴ, ΔaŵpCϳϳϳ::kaŶ, hsdRϱϭϰ 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔdaĐA                  
dacA771(del)::kan 
(JW0627-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-3), 
ΔdaĐAϳϳϭ::kaŶ, λ-, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
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ΔdaĐB                  
dacB789(del)::kan 
(JW3149-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔdaĐBϳϴϵ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔdaĐC                  
dacC739(del)::kan 
(JW0823-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔdaĐCϳϯϵ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔopgH                  
opgH720(del)::kan 
(JW1037-2) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, 
ΔopgHϳϮϬ::kaŶ, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
ΔprĐ                                         
prc-755(del)::kan 
(JW1819-1) 
F-, Δ;araD-araBͿϱϲϳ, ΔlaĐ)ϰϳϴϳ;::rrŶB-ϯͿ, λ-, ΔprĐ-
755::kan, rph-ϭ, Δ;rhaD-rhaB)568, hsdR514 
Coli Genetic Stock 
Center, Yale (Keio 
collection) 
 
Table 2-2 Protein expression vectors 
Plasmid Noted Characteristics Source 
pET21-a(+) Ampicillinr, cloning/expression vector, promoter; T7 Invitrogen 
pET28-a(+) Kanamycinr, cloning/expression vector, promoter; T7 Invitrogen 
pBAD18-kan Kanamycinr, cloning/expression vector, arabinose induced 
Coli Genetic Stock 
Center, Yale  
pKM54 
pET21-a(+) with yfhM bases 48-4962 (ECAM residues 17-
1653) inserted into NdeI/XhoI sites, N-terminal His6 tag 
Dr Khedidja 
Mosbahi 
pCF1 (ECAM) 
pET21-a(+) with yfhM bases 55-4959 (ECAM residues 19-
1653) inserted into NdeI/XhoI sites, C-terminal His6 tag, 6 
mutations noted 
This study 
pCF2 (ECAM) 
pET21-a(+) with yfhM bases 55-4959 (ECAM residues 19-
1653) inserted into NdeI/XhoI sites, C-terminal His6 tag, 5 
mutations noted 
This study 
pCF3 (ECAM) 
pET21-a(+) with yfhM bases 55-4959 (ECAM residues 19-
1653) inserted into NdeI/XhoI sites, C-terminal His6 tag, 4 
mutations noted  
This study 
pCF4 (Pbp1C) 
pET28-a(+) with pbpC bases 1-2313 (Pbp1C residues 1-770) 
inserted into XhoI/KpnI sites, N-terminal His6 tag 
This study 
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pCF5 (ECAM) 
pET21-a(+) with yfhM bases 55-4959 (ECAM residues 19-
1653) inserted into NdeI/XhoI sites, 2 mutations noted with 
deletion resulting in no C-terminal His6 tag 
This study 
 
 
Table 2-3 Complementation vectors 
Plasmid Noted Characteristics Source 
ppbpCc 
pBAD18-kan with pbpC bases 1-2313 (Pbp1C residues 1-
770) inserted into EcoRI/KpnI sites 
This study 
ppbpCo 
pBAD18-kan with pbpC bases 1-2310 (Pbp1C residues 1-
770) inserted into EcoRI/KpnI sites, N-terminal stop codon 
excluded 
This study 
 
 
 
2.3 PƌepaƌatioŶ of ĐheŵiĐallǇ ĐoŵpeteŶt Đells  
Magnesium chloride buffer (MCB; 0.1 M MgCl2) and calcium chloride buffer (CCB; 0.05 M 
CaCl2; 15% glycerol added post-autoclave) were autoclaved and chilled in iced water. 
Strains of E. coli cells (50 ml) were grown to approximately 0.6 OD600 nm in LB and pelleted 
at 4°C by centrifugation at 4000 g for 15 minutes. Cell pellets were washed and 
centrifuged twice using ice-chilled MCB before being resuspended in 2 ml CCB. Chemically 
competent cells were aliquoted in 200 µl fractions, frozen in liquid nitrogen and stored at 
-80°C. 
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2.4 MoleĐulaƌ ďiologǇ 
All restriction, DNA polymerase, and T4 DNA ligase enzymes were purchased from New 
England Biolabs (NEB). 
 
2.4.1 PolǇŵeƌase ĐhaiŶ ƌeaĐtioŶ ;PCRͿ 
PCR was used to amplify the targeted gene using the reaction protocol shown in Table 2-4 
using components in Table 2-5 with PCR products electrophoresed on agarose gel. 
Table 2-4 Amplification PCR reaction 
Temperature (°C) Step Time (s) 
95 Initial denaturing 30 
95 Denaturing 45 
52-60 Annealing 45 
72 Extension 60/kb 
~ 
Go to Denaturing step 
for 30 cycles 
~ 
72 Final Extension 600 
10 Hold ~ 
 
Table 2-5 Amplification PCR reaction components 
Component Stock Concentration 
Volume 
(µl) 
Phusion DNA 
polymerase 
2 units/µl 1 
Reaction buffer 5x 10 
Reverse primer 1 nM 5 
Forward primer 1 nM 5 
Template Variable 1-5 
dNTPs 5 mM 1 
dH2O 100% 23-27 
Total   50 
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Mutagenesis primers MutP1-P4 (Table 2-8) were used to perform PCR mutagenesis to 
correct four mutations in the ECAM clone pCF3 (Table 2-2). The four mutations were to 
base numbers 655, 1817, 4760 and 4782 resulting in t-c, a-g, g-a, t-c base changes 
respectively. The first three mutations resulted in amino acid changes of S-P, Q-R, S-N, 
respectively with the final mutation being silent. PCR mutagenesis was performed 
following the mutagenesis PCR reaction protocol shown in Table 2-6 using components in 
Table 2-7 with PCR products electrophoresed on agarose gel. 
 
Table 2-6 Mutagenesis PCR reaction 
Temperature (°C) Step Time (s) 
95 Initial denaturing 30 
95 Denaturing 30 
55 Annealing 60 
68 Extension 60/kb 
~ 
Go to Denaturing step 
for 18 cycles 
~ 
72 Final extension 600 
10 Hold ~ 
 
Table 2-7 Mutagenesis PCR reaction components 
Component Stock Concentration 
Volume 
(µl) 
Phusion DNA 
polymerase 
2 units/µl 1 
Reaction buffer 5x 10 
Reverse primer 1 nM 5 
Forward primer 1 nM 5 
Template 2.5 nM 1 
dNTPs 5 mM 1 
dH2O 100% 27 
Total   50 
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2.4.2 OligoŶuĐleotide pƌiŵeƌs aŶd seƋueŶĐiŶg 
Primers used within this work were synthesised by Eurofins Operon 157. Sequencing was 
performed by Source BioScience 158. 
Table 2-8 yfhM (ECAM) primers 
Primer 
Restriction 
enzyme site 
Sequence 5' to 3' (restriction 
site bold) 
Purpose 
YfhMNdeIF NdeI 
TAGTAGTACATATGGACAACA
ACGATAACGCGCCAAC 
yfhM (ECAM) -54 bases 
for signal sequence, 
cloning forward  
cfyfhMns XhoI 
TTTGACGTCTCGAGCGGTCTGA
CAATCAGCAGATC 
yfhM (ECAM) -3 base 
stop codon, cloning 
reverse 
YtfMCFseq1 n/a 
ACGAAAAAACTATAACTACCCG
CG 
yfhM (ECAM) 
sequencing primer 1, 
forward 
YtfMCFseq2 n/a CCCAGCAAGGAATTGAAGTCTC 
yfhM (ECAM) 
sequencing primer 2, 
forward 
YtfMCFseq3 n/a CGAAGATTTTATGCCAGAGCGC 
yfhM (ECAM) 
sequencing primer 3, 
forward 
YtfMCFseq4 n/a 
CCGCTTTTGACATCGTTTATAG
C 
yfhM (ECAM) 
sequencing primer 4, 
forward 
YtfMCFseq5 n/a CCGGTCGATAAAACCTGGAATC 
yfhM (ECAM) 
sequencing primer 5, 
forward 
YtfMCFseq6 n/a CAGGGCGAAGGCTCGGTTA 
yfhM (ECAM) 
sequencing primer 6, 
forward 
YtfMCFseq7 n/a CCGGCGGATGGATTGCAAAAC 
yfhM (ECAM) 
sequencing primer 7, 
forward 
YtfMCFseq8 n/a CGCTGGTGTTGGCCCGTC 
yfhM (ECAM) 
sequencing primer 8, 
forward 
MutP1aF n/a 
CAAAGTCTGGAAAACGGCGCG
GCCCAG 
ECAM mutation repair 
mutagenesis forward 1 
MutP1bR n/a 
CTGGGCCGCGCCGTTTTCCAGA
CTTTG 
ECAM mutation repair 
mutagenesis reverse 1 
MutP2aF n/a 
GCCCAGCAAGGAATTGAAGTC
TCTTTATTAAATGAGAAAGGG 
ECAM mutation repair 
mutagenesis forward 2 
MutP2bR n/a 
CCCTTTCTCATTTAATAAAGAG
ACTTCAATTCCTTGCTGGGC 
ECAM mutation repair 
mutagenesis reverse 2 
MutP3aF n/a 
GTAGTGTTCGTTTCTGGGCTGG
CTATAGC 
ECAM mutation repair 
mutagenesis forward 3 
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MutP3bR n/a 
GCTATAGCCAGCCCAGAAACG
AACACTAC 
ECAM mutation repair 
mutagenesis reverse 3 
MutP4aF n/a 
GATGGAGAAATTCAGGCCACC
ATTAGCGGG 
ECAM mutation repair 
mutagenesis forward 4 
MutP4bR n/a 
CCCGCTAATGGTGGCCTGAATT
TCTCCATC 
ECAM mutation repair 
mutagenesis reverse 4 
Table 2-9 pbpC (Pbp1C) primers 
Primer 
Restriction 
enzyme site 
Sequence 5' to 3' (restriction 
site bold) 
Purpose 
CFPbpCNde1-105F NdeI 
GCAACCATATGCTGCATGAAGT
CAATCCCGC 
pbpC (Pbp1C) -105 base, 
cloning forward 
CFPbpCNde1-135F NdeI 
GCAACCATATGGTGGCGCAGG
ATGGTACG 
pbpC (Pbp1C) -135 base, 
cloning forward 
CFPbpCNde1-165F NdeI 
GCAACCATATGTTCGCCGATGC
TGACGGC 
pbpC (Pbp1C) -165 base, 
cloning forward 
CFPbpCXho1R XhoI 
TACTACTCGAGCTATTGCATGA
CAAATTTCACTGTC 
pbpC (Pbp1C) cloning 
reverse 
cfpbpCssXho1F XhoI 
TAGTAGCTCGAGATGCCTCGCT
TGTTAACCAAACG 
pbpC (Pbp1C) cloning 
forward 
cfpbpCssKpn1R KpnI 
CATACTGGTACCCTATTGCATG
ACAAATTTCACTGTCG 
pbpC (Pbp1C) cloning 
reverse 
pbpCEcoR1F EcoRI 
GCTGCTGAATTCATGCCTCGCT
TGTTAACCAAACG 
pbpC (Pbp1C) cloning 
forward, 
complementation vector 
pbpCKpn1RA KpnI 
GCTGCTGGTACCCTATTGCATG
ACAAATTTCACTGTCGCG 
pbpC (Pbp1C) cloning 
reverse, 
complementation vector 
closed 
pbpCKpn1RB KpnI 
GCTGCTGGTACCTTGCATGACA
AATTTCACTGTCGCGA 
pbpC (Pbp1C) -3 base 
stop codon, cloning 
reverse, 
complementation vector 
open for including myc 
tag 
 
 
 
2.4.3 DNA ƌestƌiĐtioŶ eŶzǇŵe digest 
Purified DNA (10-20 µg) was added to 20 units of appropriate restriction enzymes and 
1 µl of 10x Cutsmart buffer (NEB, UK) and made to a final volume of 15 µl. Restriction 
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digests were incubated at 37°C for 3-4 hours and separated by agarose gel 
electrophoresis. 
 
 
2.4.4 Agaƌose gel eleĐtƌophoƌesis 
Agarose was melted by microwave at 0.8% (w/v) agarose in TBE buffer (0.17 M Tris, 0.2 M 
borate, 5 mM EDTA, pH 8). The melted agarose was cooled to approximately 50°C and 
GelRed (Cambridge Bioscience, UK) was added (1:10000) and poured into the 
electrophoresis apparatus. The set gel was submerged in TBE buffer and samples mixed 
with 5x DNA loading dye (Bioline, UK) were loaded onto the gel alongside a 1 kb+ DNA 
ladder (Invitrogen) as a base pair size reference. The gel was run for 40-60 minutes at 
60 V and visualised using a UVIpro Gold transilluminator (UVItec, UK).  
 
2.4.5 Agaƌose gel DNA eǆtƌaĐtioŶ 
Extraction of DNA from agarose was performed using a Qiagen gel extraction kit (Qiagen, 
UK) following the manufacturers protocol. DNA was eluted using elution buffer (10 mM 
Tris, pH 8.0) and stored at -20°C. 
 
2.4.6 DNA ligatioŶ 
A ligation reaction containing 3:1 ratio of digested PCR insert to digested plasmid 
alongside 5 Units of T4 DNA ligase and 1X T4 DNA ligase buffer with a total final volume of 
15 µl. DNA ligation reaction was incubated overnight at room temperature with 5 µl being 
used foƌ tƌaŶsfoƌŵatioŶ iŶto ĐheŵiĐally ĐoŵpeteŶt DHϱα Đells. 
 
2.5 TƌaŶsfoƌŵatioŶ of ĐheŵiĐallǇ ĐoŵpeteŶt E. Đoli Đells 
Chemically competent E. coli cells (50-100 µl) were thawed on ice with 50-100 ng of 
plasmid. DNA ligation transformations consisted of 5 µl of ligation reaction added to 50-
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100 µl of chemically competent cells. Cells were incubated on ice for 30 minutes before 
being heat shocked at 42°C for 45 seconds. 500 µl of LB was added and cells were allowed 
to recover at 37°C for 60 minutes and were then plated out onto LB agar plates 
containing appropriate antibiotics and grown overnight at 37°C. 
2.6 PƌoteiŶ oǀeƌeǆpƌessioŶ aŶd puƌifiĐatioŶ 
2.6.1 CloŶiŶg eǆpƌessioŶ aŶd puƌifiĐatioŶ of ECAM 
The gene for ECAM, yfhM from E. coli K-12, was amplified by PCR using primers 
YfhMNdeIF and cfyfhMns, and cloned into pET21a vector using NdeI and XhoI restriction 
sites. The first 22 residues from the N-terminus of the gene, containing the signal 
sequence identified using SignalP, were excluded from the construct. The stop codon was 
also excluded, resulting in a protein containing residues 23-1631 and a C-terminal 6xHis-
tag (LEHHHHHH). The first plasmid generated pCF1, was sequenced using primers 
YtfMCFseq1-8 and found to have 6 base mutations resulting in 6 amino acid changes. The 
second plasmid cloned, pCF2, was found to have 5 mutations and the third plasmid, pCF3 
contained 4 mutations. ECAM plasmid pCF3 was mutated using MutP1a/b-4a/b however 
only the MutP1a/b primers were successful and resulted in plasmid pCF5 which contained 
two mutations and a deletion resulting in no 6xHis-tag. As the three amino acid residue 
changes identified in pCF3 (detailed on page 39) were not expected to cause change in 
protein function it was decided to use pCF3 for all future expression of ECAM. ECAM was 
expressed in E. coli BL21 (DE3) grown in LB to 0.6 OD600nm and induced using 1 mM D-
isopropyl-β-thiogalactopyranoside (IPTG) with cells grown for a further 6 hours. The cell 
pellet was collected by centrifugation at 4,400 g for 15 minutes and cells were re-
suspended in binding buffer (20 mM Tris, 10 mM imidazole, 500 mM sodium chloride, pH 
7.5) and lysed by sonication with 2 mg ml-1 lysozyme in the presence of protease 
inhibitors (Complete Mini, Roche). Cell debris was removed by centrifugation at 46,000 g 
foƌ ϯϬ ŵiŶutes at ϰ°C. Cell supeƌŶataŶt ǁas theŶ loaded oŶto a HisTƌap™ HP ĐoluŵŶ ;GE 
Healthcare) and bound protein was eluted with elution buffer (20 mM Tris, 500 mM 
imidazole, 500 mM NaCl, pH 7.5) using a linear gradient increasing from 10 mM to 500 
mM. Fractions containing ECAM were pooled and dialysed overnight at 4°C into 50 mM 
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Tris, 200 mM NaCl, pH 7.5 and run on a Superdex S200 gel-filtration column (GE 
Healthcare). Central fractions from the peak were combined and concentrated using a 
100 kDa molecular weight cut off centrifugal concentrator. 
 
ECAM was later nickel affinity purified in the presence of TCEP using a binding buffer and 
elution buffer supplemented with 5 mM TCEP (tris(2-carboxyethyl)phosphine) that was 
dialysed out prior to SEC. 
 
ECAM was expressed for crystallography in T7 Express Crystal Competent E. coli 
(methionine auxotrophic strain, New England Biosciences), using an inducible T7 
promoter and 1 mM IPTG as the inducer. Bacteria expressing selenomethionine-labelled 
ECAM were grown using M9 minimal media (35 mM Na2HPO4, 22 mM KH2PO4, 8.5 mM 
NaCl, 18.7 mM NH4Cl, 2 mM MgSO4, 0.2 mM CaCl2, 0.2% D-glucose (anhydrous)) 
supplemented with 50 mg L-1 selenomethionine and 20 mg L-1 of each of nine essential 
amino acids (excluding methionine). Cells were grown at 37°C to an OD600 of 0.6 and 
protein production was induced by addition of 1 mM IPTG and cells were grown for a 
further 6 hours.  
 
2.6.2 CloŶiŶg eǆpƌessioŶ aŶd puƌifiĐatioŶ of PďpϭC 
Full length Pbp1C was initially expressed using plasmid pKM54 that uses ampicillin as a 
seleĐtioŶ aŶtiďiotiĐ. PeŶiĐilliŶ ďiŶdiŶg pƌoteiŶs aƌe iŶaĐtiǀated ďy β-lactam antibiotics such 
as ampicillin and so pbpC was re-cloned into pET28a as this plasmid uses kanamycin as a 
selection antibiotic. Primers cfpbpCssXho1F and cfpbpCssKpn1R were used to amplify full 
length pbpC and was transformed into pET28a generating plasmid pCF4. Pbp1C was 
expressed in E. coli BL21 (DE3) grown in LB to 0.6 OD600nm and induced using 1 mM IPTG 
with cells grown for a further 6 hours. The cell pellet was collected by centrifugation at 
4,400 g for 15 minutes and cells were re-suspended in binding buffer (20 mM Tris, 10 mM 
imidazole, 500 mM sodium chloride, pH 7.5) and lysed by sonication with 1 mg ml-1 
lysozyme in the presence of protease inhibitors (Complete Mini, Roche). Cell debris was 
removed by centrifugation at 46,000 g for 30 minutes at 4°C. As Pbp1C expression 
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resulted in inclusion bodies without any soluble protein a protocol was followed to 
solubilise, refold and purify. 
 
2.6.2.1 Solubilising Pbp1C 
The inclusion body pellet containing Pbp1C was first suspended in 40 ml of wash buffer 1 
(50 mM Tris, 200 mM NaCl, pH 7.5 with 0.1% lauryldimethylamine N-oxide (LDAO)) before 
being centrifuged at 4400 g to form a pellet. The pellet was washed twice using wash 
buffer 1 and once with wash buffer 2 (50 mM Tris, 200 mM NaCl, pH 7.5).  For every 750 
mg of washed wet pellet, 100 ml of Solubilisation Buffer (50 mM Tris, 200 mM NaCl, pH 
7.5, 5% Sarkosyl) was added and resuspended until the pellet was soluble and no pellet 
could form through centrifugation. 
 
2.6.2.2 Refolding and purification of Pbp1C 
Solubilised Pbp1C was refolded by dialysing overnight at 4°C into Refolding Buffer (0.4% 
LDAO, 0.1 M L-arginine, 50 mM Tris, 200 mM NaCl, pH 7.5) and subsequently dialysed 
into SEC buffer (200 mM NaCl, 50 mM Tris, 0.1% LDAO, pH 7.5) for purification by size 
exclusion chromatography. Size Exclusion Chromatography (SEC) was performed on an 
ÄKTA purifier.  Pbp1C samples to be purified were loaded onto S200 SEC Superdex 
column with Pbp1C SEC buffer (200 mM NaCl, 50 mM Tris, 0.1% LDAO, pH 7.5).  
 
2.6.3 PƌoteiŶ ĐoŶĐeŶtƌatioŶ 
ECAM and Pbp1C were concentrated using Vivaspin 20 (Sartorius) concentrator tube (100 
kDa molecular weight cut off) by centrifugation at 4400 g. 
 
2.7 PƌoteiŶ ĐoŶĐeŶtƌatioŶ deteƌŵiŶatioŶ 
The ExPASy online program ProtParam was used to calculate the molar extinction 
coefficient of proteins 159,160. Protein samples then had their absorbance measured at 280 
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nm wavelength over a path length of 1 cm, and these values were applied to the formula 
below to calculate protein concentration. 
 
    � = Protein concentration � = ��  � = Absorbance of sample measured at 280 nm wavelength 
over a path length of 1 cm � = Molar extinction coefficient 
 
2.8 SDS-PAGE 
Bacterial pellets or protein samples were mixed with Laemmli buffer (200 mM Tris, pH 
6.8, 8% (v/v) SDS, 0.4% (v/v) bromophenol blue, 40% (v/v) glycerol, 4.7% (v/v) 
β-mercaptoethanol) at a 4:1 ratio, heated at 95°C for 5-10 minutes and centrifuged (500 
g) for approximately 1 minute and loaded onto the gel alongside a broad range molecular 
weight marker (2-212 kDa (NEB, UK) or 3-260 kDa (Novex prestained marker, Thermo 
Fisher Scientific)). SDS-PAGE was performed using tris-glycine running buffer (0.02 M Tris, 
0.25 M glycine, 5% (w/v) SDS) at 30 mA until the buffer front reached the bottom of the 
gel (approximately 45-60 minutes). 
For samples to be analysed by mass spectrometry analysis of protease cleaved ECAM, 
crystals were washed in reservoir solution before being dissolved in deionised water and 
heated to 95°C in Laemmli buffer for 5 minutes. These were then were run on NuPAGE® 
Novex® 4-12% Bis-Tris gel (Invitrogen) and visible bands were cut for proteomic analysis. 
 
2.9 WesteƌŶ ďlottiŶg  
For immunoblotting samples, bacterial pellets that had been run by SDS-PAGE were 
transferred onto nitrocellulose membranes using an ECL semi-dry transfer unit at 7 mA 
overnight. Transferred membranes were blocked using blocking buffer (20 mM Tris, 200 
mM NaCl, 0.01% (v/v) Tween 20, 5% (w/v) skimmed milk (Marvel, UK) on a shaker for an 
hour at room temperature. Blocking buffer was poured off and rabbit anti-ECAM primary 
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antibody was diluted 1 in 3000 with Wash buffer (20 mM Tris, 200 mM NaCl, pH 7.2, 
0.01% Tween 20) and added to the nitrocellulose and placed on a shaker for 1 hour. The 
nitrocellulose membrane was then washed 3 times for 20 minutes while on shaker using 
wash buffer. Goat anti-rabbit secondary antibody coupled with horseradish peroxidase 
(HRP) was then diluted 1 in 20,000 and incubated with the nitrocellulose membrane for 
30 minutes on a shaker at room temperature. The nitrocellulose membrane was then 
washed three times 20 minutes while on shaker at room temperature. The Western blot 
was developed using enzyme-linked chemiluminescence Western BrightTM Sirius 
chemiluminescent substrate (Advansta, USA) on film. 
 
2.10 Mass speĐtƌoŵetƌǇ 
Peptide fragments from trypsinated excised bands were separated by liquid 
chromatography and subsequently had their mass to charge ratio measured by Orbitrap 
XL Mass spectrometry. These peptide fragments were then compared to a database of in 
silico digested proteins identifying proteins and fragments within excised bands. Samples 
were digested by trypsin and analysed by LC-MSMS (Orbitrap XL), performed at the 
Fingerprints Proteomics Facility at the University of Dundee 161. 
 
2.11 CiƌĐulaƌ diĐhƌoisŵ ;CDͿ speĐtƌosĐopǇ  
Far-UV CD was carried out on Pbp1C (6 ʅMͿ in 0.1 M sodium phosphate pH 7.5 with 0.1% 
(v/v) LDAO using a Jasco J-810 spectropolarimeter. Spectra were collected in 0.02 cm path 
length quartz cuvettes. Data were analysed with the CONTIN procedure that is available 
from the Dichroweb server 162,163. 
 
2.12 ReaĐtioŶ of ECAM ǁith pƌoteases 
Purified ECAM was reacted at a 1:1 molar ratio with porcine elastase (MP Biomedicals) in 
50 mM Tris, 200 mM NaCl, pH 7.5 on ice for 5 minutes before being loaded onto a 
Superdex S200 gel-filtration column (GE Healthcare). The two major peaks from gel 
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filtration were concentrated to 16 mg ml-1 separately using a 100 kDa molecular weight 
cut off centrifugal concentrators and used in crystallization trials. 
Purified ECAM was reacted at a 1:1 molar ratio with chymotrypsin (Sigma-Aldrich) in 50 
mM Tris, 200 mM NaCl, pH 7.5 on ice for 5 minutes before being loaded onto a Superdex 
S200 gel-filtration column (GE Healthcare). The major peak from gel filtration was 
concentrated to 4.0 mg ml-1 using a 100 kDa molecular weight cut off centrifugal 
concentrator for AUC and SAXS experiments. 
 
2.13 ReaĐtioŶ of ECAM ǁith ŵethǇlaŵiŶe 
Purified ECAM was reacted with a final concentration of 5 mM methylamine (Sigma-
Aldrich) in 50 mM Tris, 200 mM NaCl, pH 7.5 on ice for 5 minutes before being loaded 
onto a Superdex S200 gel-filtration column (GE Healthcare). The peak from gel filtration 
was concentrated to 4.6 mg ml-1 using a 100 kDa molecular weight cut off centrifugal 
concentrator for AUC and SAXS experiments. 
 
 
2.14  AŶalǇtiĐal ultƌaĐeŶtƌifugatioŶ ;AUCͿ 
Sedimentation velocity (SV) experiments were carried out in a Beckman Coulter Optima 
XL-I analytical ultracentrifuge using an An-50 Ti eight-hole rotor. ECAM concentrations 
ranged from 0.078 mg ml-1 to 5.0 mg ml-1 ECAM (purified with TCEP) concentrations 
ranged from 0.2 mg ml-1 to 6.0 mg ml-1 ECAM (with TCEP) concentrations ranged from 
0.09 mg ml-1 to 5.4 mg ml-1 ECAM reacted with methylamine concentrations ranged from 
0.073 mg ml-1 to 4.6 mg ml-1 and ECAM reacted with chymotrypsin concentrations ranged 
from 0.06 mg ml-1 to 4.0 mg ml-1. Samples were loaded into 12 mm path-length charcoal-
filled epon double-seĐtoƌ ĐeŶtƌepieĐes ;ϯϲϬ ʅl peƌ saŵpleͿ aŶd the highest ĐoŶĐeŶtƌatioŶ 
sample was loaded into a 3 mm path-length centrepiece ;ϵϬ ʅlͿ aŶd spuŶ at 49,000 rpm 
for ~9 h at 4°C. The outer sector of centrepieces had equivalent volume of buffer that the 
protein samples were dialysed against previously. Scans were collected every 7 minutes 
using both interference and absorbance optics (280 nm; a radial range of 5.8 - 7.2 cm, and 
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radial step-size of 0.005 cm were used). SEDNTERP164 was used to calculate the partial 
specific volume (from the amino acid sequence of ECAM), the buffer density and viscosity 
at 20°C and 4°C (Table 2-10). 
 
 
Table 2-10 ECAM partial specific volumes, buffer densities and viscosities calculated using SEDNTERP for 
the analysis of SV data 
Buffer 
Partial specific volume 
(ml/g) 
Buffer density 
(g/ml) 
Buffer viscosity 
(P) 
50 mM Tris, 200 mM 
NaCl, pH 7.5 
0.728 (4°C) 1.010 (4°C) 0.0162 (4°C) 
0.735 (20°C) 1.008 (20°C) 0.0104 (20°C) 
50 mM Tris, 200 mM 
NaCl, 5 mM TCEP, pH 7.5 
0.728 (4°C) 1.010 (4°C) 0. 0162 (4°C) 
0.735 (20°C) 1.008 (20°C) 0.0104(20°C) 
 
 
Data were analysed using SEDFIT to obtain the apparent sedimentation coefficients of 
ECAM using the continuous c(s) distribution model 165. The apparent sedimentation 
coefficients were then used to calculate the concentration-independent �020,�  by plotting 
sample versus apparent �20,� and extrapolating the graph to infinite dilution. Ultrascan 
SOMO was used to compute theoretical sedimentation coefficients from high-resolution 
X-ray structures 166.    
 
2.15  PƌoteiŶ ĐƌǇstallisatioŶ aŶd data ĐolleĐtioŶ 
Several hundred crystallization conditions were tested including JCSG-plus, MIDA“™ aŶd 
Morpheus® screens (Molecular Dimensions) for both concentrated peaks from reaction of 
ECAM with porcine elastase. A Cartesian Honeybee 8 + 1 (Harvard Bioscience) robot was 
used with 96 well plates dropping 0.5 µl of reservoir solution with 0.5 µl of protein 
sample. Subsequent scaled up crystal growth was performed using 2.5 µl of reservoir 
solution with 2.5 µl of protein sample. The initial crystal was grown in conditions 
containing 0.1 M potassium chloride, 0.1 M HEPES, 25% SOKALAN® CP 7, pH 7.0 and upon 
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optimisation the pH was adjusted to 7.5 for larger crystal growth. Crystals were grown 
using equal volumes of porcine elastase cleaved ECAM and reservoir solution using sitting 
drop vapour diffusion with crystals appearing after 2 days at 16°C for the second fraction 
and after 2 weeks for the first fraction. Cryoprotection was optimised with a 3:2 ratio of 
xylitol saturated reservoir solution to reservoir solution. Crystals were briefly soaked and 
flash cooled in liquid nitrogen for data collection. The best diffraction obtained was 3.8 Å, 
aŶd ŵoleĐulaƌ ƌeplaĐeŵeŶt ǁith ŵethylaŵiŶe aĐtiǀated αϮM ;PDB:ϰACQͿ ǁas 
unsuccessful most likely as sequence identity with the human homologue was low (12%) 
and due to the difference in domain orientation between structural models 13. Further 
expression was performed using a methionine auxotrophic strain of E. coli BL21 (T7 
Express Crystal Competent E. coli, New England Biolabs) and purification and 
crystallization screens were repeated using selenomethionine labelled protein. As 
repeating the previous protocol with selenomethionine protein was unsuccessful, in situ 
proteolytic cleavage screening was performed using porcine elastase. Successful 
crystallization was achieved using a 1:100 ratio of porcine elastase to selenomethionine 
labelled ECAM. Crystallization was successful in the same condition as used previously 
with the crystal having a similar appearance and the same space group as previous 
unlabelled crystals. These crystals diffracted to 3.65 Å and phases were obtained using 
single-wavelength anomalous diffraction (SAD).  
 
Data were collected for ECAM crystals at the I02, I03 and I24 beamlines at Diamond Light 
Source (Didcot, United Kingdom) at 100 K at the selenium K-edge ;ʄ = Ϭ.ϵϳϵϯϵ ÅͿ usiŶg a 
Pilatus 6M detector.  A high redundancy SAD data set was processed and scaled using XDS 
and AIMLESS from the CCP4 suite of programs 167–170. Selenium sites were located using 
Shelx C/D with the best substructure solution consisting of 19 sites although the full 
length ECAM structure was predicted to have 23 selenomethionines 171. These selenium 
sites were input with the SAD dataset to Autosol within the Phenix package to perform 
phasing and electron density modification 172. Density modification in Autosol was 
sufficient to break phase ambiguity, due to the high solvent content of the crystal 
(69%)172. This yielded interpretable, low resolution, maps in which density corresponding 
to secondary structure elements and larger amino acid sidechains were visible. Initially, 
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the α-helical TED ǁas ďuilt iŶ COOT usiŶg idealised α-helical sections 173. The loops 
between these sections were connected where density was visible. The 6 
selenomethionine sites in this domain provided the start sites for the building of amino 
acid side chains in the whole TED, although due to the relatively low resolution, initially 
only larger side chains and those where continuous sequence could be determined were 
built. In addition to the building of the TED, a Ŷuŵďeƌ of αϮM deƌiǀed poly-alanine MG 
domains were rigid body fitted into their corresponding density and manually real-space 
refined in COOT 173. As with the TED, where possible, side chains were fitted using the 
positions of selenomethionine Se atoms as start sites. This initial building yielded a partial 
model which was then used, in conjunction with the selenomethionine substructure to 
rephase experimental data using MR-SAD phasing in Phaser EP169. This process led to 
phase improvement and the appearance of new features in the map, which were 
modelled and the process was repeated iteratively. Partway through the building process 
the atomic coordinates for SaA2M (which shares 82% sequence identity with ECAM)  
were published and the domains from this model provided validation for MG domain 
placement and sidechain modelling in our experimentally phased map (PDB: 4U48 14). The 
SaA2M model also provided a template for building the more difficult sections of the 
model. At this point restrained TLS refinement using REFMAC5 was found to stably 
improve both Rwork and Rfree.  Such refinement was performed and the model improved 
and was finished manually in COOT 173,174. Electron density for the thioester bond 
indicated that the deaminated glutamine has no covalent bond with the cysteine. Before 
submission of the final model, quality of the structure was assessed using the Molprobity 
webserver 175. The atomic coordinates and structure factors were deposited in the 
Protein Data Bank (PDB: 4RTD).  
 
2.16  Sŵall aŶgle X-ƌaǇ sĐatteƌiŶg ;SAXSͿ 
SAXS was carried out on the X33 beamline at the Deutsches Elektronen Synchrotron 
(DESY, Hamburg, Germany).  Data were collected on samples of ECAM and ECAM reacted 
with chymotrypsin at concentrations in the range of 0.4-6 mg ml-1.  Scattering curves for 
buffer were acquired before and after each sample and an average of the buffer 
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scattering was subtracted from the sample scattering.  The data obtained for each sample 
were analysed using PRIMUS, merging scattering data for low concentration samples at 
low angles with high angle data for high concentration samples176. The distance 
distribution function, p(r), was obtained by indirect Fourier transform of the scattering 
intensity using GNOM 176.  A Guinier plot (ln I(s) vs s2) was used to determine the 
molecular weight and radius of gyration, Rg, of ECAM. Ab initio models of the protein in 
solution were built using DAMMIF177–179.  DAMMIF models were averaged using 
DAMAVER  and filtered using DAMFILT177,179. CRYSOL was used to compute theoretical 
scattering curves from high-resolution X-ray structures 180.
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3 OǀereǆpressioŶ, purifiĐatioŶ aŶd ĐharaĐterisatioŶ of 
ECAM 
 
 
 
 
 
Small angle X-ray scattering data was collected by Inokentijs Josts. 
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3.1 IŶtƌoduĐtioŶ 
It has been suggested that ECAM and PbpC function as a defence and repair mechanism 
against host proteases, with ECAM functioning as a protease inhibitor and PbpC repairing 
proteolytic damage to the peptidoglycan layer6. Among the various eukaryotic αϮMs, 
some have been shown to form tetramers with others forming dimers and monomers 
16,17,21. In contrast, ECAM is monomeric prior to protease activation, although once 
cleaved exists as a mixture of monomer, dimers and trimers in solution, with the 
formation of these multimeric forms being concentration dependent67. In addition 
reaction of ECAM with methylamine does not cause a change in conformation as seen for 
αϮM67.  The high resolution X-ray crystal structures of native and methylamine-activated 
SaA2M show that methylamines only effect on SaA2M is localised to the thioester region 
of the TED14. This high resolution model of SaA2M was suggested as being a monomer 
however a crystallographic dimer was also present within its crystal lattice14. In order to 
begin structurally characterising ECAM sedimentation velocity (SV) experiments were 
performed to determine the oligomeric state of the protein in solution. SAXS was further 
used to characterise ECAM in solution. 
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3.2 Results 
3.2.1 EǆpƌessioŶ aŶd puƌifiĐatioŶ of ECAM 
The gene encoding ECAM, yfhM, was cloned minus the region encoding the signal 
sequence and including a C-terminal 6-histidine tag. The gene amplified by PCR was 
cloned into pET21a using NdeI and XhoI. This plasmid was transformed into BL21(DE3) 
Escherichia coli cells for inducible expression. Cells were grown at 37°C to an OD600 of 0.6 
and 0.1 mM IPTG was added to induce ECAM expression. Cells were grown for a further 
four hours, lysed, and purified by Ni2+-affinity chromatography (Figure 3-1 a).  Fractions 
containing purified ECAM were pooled and dialysed against 50 mM Tris-HCl, 200 mM 
NaCl, pH 7.5 and further purified on a Superdex S200 gel-filtration column (Figure 3-1 b, 
c). ECAM eluted as two peaks, with the first eluting at 147 ml and the second at 169 ml 
with the second peak approximately 8 times larger (Figure 3-1 c). The presence of two 
peaks on SEC was the first indication of potential oligomerisation in solution. When both 
peaks were compared by SDS-PAGE at the same concentration they have an identical 
composition with major bands at 260 kDa and 160 kDa (Figure 3-1 c). This suggests that 
there is a monomer and a dimer with a dimer being visible after SDS PAGE due to an 
interaction that survives heating and denaturation. Fractions from the main peak (169 ml) 
were collected and pooled for further experiments (Figure 3-1 c).  
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Figure 3-1 Purification of ECAM by Ni
2+
--affinity chromatography and size exclusion chromatography (SEC) 
with SDS PAGE. 
(a) An elution buffer (blue) gradient eluting ECAM (red) from a Ni2+-affinity column. (b) Highlighted fractions 
corresponding to the Ni2+-affinity elution fractions seen in (a). (c) Size exclusion chromatography of Ni2+-
affinity purified ECAM with inset image of main pooled fraction of purified protein around 169 ml volume. 
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Published purification protocols for ECAM in general include reducing agents such as DTT 
in buffers during cell lysis and Ni2+-affinity purification67,77. To determine the effect of the 
inclusion of a reducing agent on the purification of ECAM, cells expressing ECAM were 
lysed in buffer containing 5 mM TCEP and purified by Ni2+-affinity chromatography (Figure 
3-1 a, 3-2 a). ECAM was then dialysed to remove TCEP and imidazole before further 
purification by SEC where ECAM eluted as a single peak with an elution volume of 152 ml 
(Figure 3-2 b). This is considerably earlier than the major peak from SEC of ECAM  purified 
in the absence of TCEP (169 ml) but is closer to the elution volume of the presumed 
dimeric species (147 ml) (Figure 3-2 b). The apparent difference in the oligomeric state of 
ECAM under different conditions was further investigated by SV. 
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Figure 3-2 Purification of ECAM in the presence of TCEP by Ni
2+
-affinity chromatography and size 
exclusion chromatography (SEC) with SDS PAGE. 
(a) An elution buffer (blue) gradient eluting ECAM (red) in the presence of 5 mM TCEP from a Ni2+-affinity 
column. (b) SEC of ECAM that had been Ni2+-affinity purified in the presence of 5 mM TCEP (blue) compared 
to ECAM without TCEP (red). 
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3.2.2 ECAM is iŶ a ŵoŶoŵeƌ-diŵeƌ eƋuiliďƌiuŵ iŶ solutioŶ 
Sedimentation velocity (SV) enables the oligomeric state of proteins to be determined as 
well as providing information on protein conformation. ECAM purified using the 
purification protocol in the absence of any reducing agent was analysed by SV. The 
absorbance traces are indicative of the presence of two species, due to two shoulders 
emerging during sedimentation(Figure 3-3). 
 
Figure 3-3 Raw absorbance of ECAM during sedimentation velocity experiment. 
The absorbance boundary representing the protein at a radial position within the cell moves further out in 
radial position during sedimentation. The two shoulders present within the purple line indicate multiple 
species within the solution.  
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Integrating the particle distribution profiles revealed two distinct populations which were 
observed at every ECAM concentration and a third species at the highest protein 
concentrations (Figure 3-4 a). Determination of the sedimentation coefficient at infinite 
dilution, at twenty degrees in water (�020,�) for species 1 and species 2 gave values of 
7.49 S and 11.20 S respectively (Figure 3-4 b). A third species was noted at the highest 
concentrations with an �20,�  of approximately 15 S. The presence of multiple species in 
solution confirmed the multiple species previously seen by SEC and SDS-PAGE (Figure 3-1 
c, 3-2 b).  
 
 
 
 
Figure 3-4 AUC analysis of ECAM showing a monomer-dimer mixed population. 
 (a) continuous c(s) distribution for a range of ECAM concentrations shows three species, possibly monomer 
dimer and trimer, for which the ratio of % multimer to % monomer increases at higher concentrations. (b) 
Extrapolation of values to obtain the infinite dilution sedimentation coefficient �020,� for ECAM.  
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When ECAM purified in the presence of TCEP was analysed by SV two species were again 
present in a similar ratio to those observed for ECAM purified in the absence of TCEP 
(Figure 3-5 a, 3-6). �020,� values for species 1 and species 2 of ECAM purified in the 
presence of TCEP are 7.53 S and 10.94 S respectively with no third species observed 
(Figure 3-5 b).   
 
 
 
 
Figure 3-5 AUC analysis of ECAM purified with TCEP showing a monomer-dimer mixed population. 
 (a) continuous c(s) distribution for a range of ECAM concentrations shows a two species with a gradual 
decrease in S for species 2 as concentration increases. (b) Extrapolation of values to obtain the infinite 
dilution sedimentation coefficient �020,� for ECAM. 
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As the concentration of ECAM increased there was an increase in the ratio of species 2 to 
species 1 with only a minor difference seen with the ECAM purified in the presence of 
TCEP (Figure 3-6). Using the ratio of dimer to monomer the Kd was calculated as 1.695 µM 
(using dimer molarity). 
 
 
 
 
 
 
 
Figure 3-6 Increase in dimer with concentration 
Percentage of dimer present in ECAM and ECAM purified with TCEP increases as concentration increases 
with 65% dimer at 13.7 µM and 70% dimer at 16.5 µM respectively. Kd calculated at 1.695 µM 
  
Chapter 3 
66 
 
During the course of this work the crystal structure of an ECAM homologue from 
Salmonella enterica was published181. Although this structure (PDB: 4U48) was submitted 
to the PDB as a monomer it was noted that there is an entwined crystallographic dimer 
with a buried surface area of 9155 Å2 14 (Figure 3-7).  
 
 
 
Figure 3-7 Crystal structure of Salmonella enterica alpha-2-macroglobulin 
 (a) monomer form of SaA2M PDB: 4U48 with (b) entwined dimer described as a crystallographic artefact 14. 
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Using SOMO within Ultrascan, a hydrodynamic bead model of the high resolution 
monomer and dimer models were generated and used to compute their sedimentation 
coefficients 166 (Table 3-1). The �020,� values determined for monomeric and dimeric 
SaA2M are 7.99 S and 12.54 S respectively (Table 3-1). The �020,� values determined for 
species 1 of ECAM purified in the presence and absence of TCEP (7.53 S and 7.49 S, 
respectively), are within 10% of the �020,� value calculated for the high resolution model 
of the monomer SaA2M (7.99 S) (Table 3-1). The �020,� values determined for species 2 
of ECAM purified in the presence and absence of TCEP (10.94 S and 11.20 S respectively), 
are within 15% of the �020,�value, and 12.54 S as calculated for the high resolution model 
of the dimer (Table 3-1). The similarity in the sedimentation coefficient values confirms 
the presence of a monomer and dimer species for ECAM in solution (Table 3-1). However, 
the lower sedimentation coefficients seen for experimental ECAM data indicate that in 
solution both the monomer and dimer are less compact and elongated, with a larger 
surface area resulting in a slower sedimentation compared to the high resolution models. 
The decrease in sedimentation coefficient for the dimer (species 2) as concentration 
increases is due to a crowding effect resulting in faster sedimentation (Figure 3-4, 3-5).  
 
 
Table 3-1 Experimental and computed sedimentation coefficient (S) 
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3.2.3 Sŵall aŶgle X-ƌaǇ sĐatteƌiŶg of ECAM aŶd ĐoŵpaƌisoŶ ǁith high 
ƌesolutioŶ ŵodels  
Previous SAXS analysis described ECAM as a monomer in solution and modelled an 
envelope based on this assumption68,77. With the monomer-dimer equilibrium of ECAM 
noted at even low concentrations, further analysis by SAXS, taking into account the 
dimeric species could provide further understanding of ECAM composition in solution. 
When ECAM was analysed by SAXS there was a distinct difference in intensity at low 
angles when comparing low and high concentration samples that may be due to the 
monomer-dimer exchange seen by SV (Figure 3-8). Normally small angle, low 
concentration data can be merged with wide angle high concentration data, however, as 
SV shows that ECAM is 65% dimer at 6.04 mg ml-1 and 50% at 0.72 mg ml-1 the merging of 
these data is not valid.  
 
 
Figure 3-8 Comparison of raw SAXS data for ECAM at high and low concentrations. 
The differences seen at small angles are distinct when comparing high and low ECAM concentrations. Inset 
graph shows a clear difference at low angles. 
Chapter 3 
69 
 
Guinier analysis of the raw scattering data for ECAM at 6.04 mg ml-1 was used to 
determine the overall size of ECAM calculating the radius of gyration (Rg) as 5.66 ± 0.009 
nm (Figure 3-9 a, b). 
 
 
Figure 3-9 Raw SAXS data for ECAM with Guinier fit. 
(a) Raw scattering curve for ECAM at 6.04 mg ml-1. (b) Guinier fit to the raw scattering data in the Guinier 
region determines an Rg of 5.66 ± 01 nm. The linearity of the residuals indicates the absence of aggregation. 
 
 
The pair-distance distribution function curve, plotting r against p(r), shows distances 
between electrons within the macromolecule in real space (Figure 3-10 a).  From this p(r) 
plot the most frequent distance observed is 6.0 nm and the maximum distance measured 
(Dmax), taken from where p(r) reaches 0 for a second time, is 18.8 nm. The bell-shaped 
curve seen for the p(r) plot is normally indicative of a globular protein, however as this is 
a mixture of two species this is less clear (Figure 3-10 b). The slight hump with a tail 
remaining low at high q values for the Kratky plot can be interpreted as a multi-domain 
protein with a rigid structure (Figure 3-10 b). 
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Figure 3-10 Distance distribution function p(r) analysis and Kratky plot for ECAM indicate a globular 
particle in solution. 
 (a) p(r) distribution of ECAM at 6.04 mg ml-1 has a most frequent distance between electrons of 6.0 nm and 
a Dmax of 18.8 nm. (b) The Kratky plot is a bell-shaped curve confirming a globular protein with a hump 
indicating multiple domains and a tail remaining low suggesting a rigid structure. 
 
 
The SaA2M monomer and dimer high resolution models previously used to generate 
hydrodynamic bead models for modelling sedimentation coefficients were likewise used 
to model SAXS Rg and Dmax values using SOMO within Ultrascan
14,166 (PDB:4U48; 
Figure 3-7, Table 3-2).  
 
 
Table 3-2 Experimentally determined and computed ECAM biophysical properties 
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The zero angle intensity (�0) can be calculated from the Guinier fit of the SAXS curve and 
used to approximate the molecular weight of a sample. The molecular weights calculated 
from �0 as 240 kDa and 271 kDa for ECAM at 0.72 mg ml-1 and 6.04 mg ml-1 respectively 
do not match the molecular weight of either monomer (181 kDa) or dimer (362 kDa) 
(Table 3-2). However, considering that the sample is in equilibrium between monomer 
and dimer, the average of these monomer-dimer molecular weights being 271.5 kDa is a 
closer match to that seen experimentally based on �0   (Table 3-2). The POROD volume can 
also be used to estimate the molecular mass of a protein by dividing by ~1.7176.  The 
calculated POROD volume for ECAM at 6.04 mg ml-1 is 685, when divided by 1.7 gives a 
molecular mass of 403 kDa just over 10% greater than a dimer, 362 kDa. An observed 
increase in Rg and molecular weight calculated from �0    following an increase in 
concentration can be indicative of aggregation or multimerisation182.  As such the 
presence of a monomer-dimer equilibrium that increases in dimer composition with 
concentration follows this trend. The Rg of 5.35 nm and the Dmax of 17.14 nm for the 
SaA2M dimer high resolution model is not a good fit to the experimentally determined Rg 
of 5.66 nm and Dmax of 19.4 nm for ECAM (Table 3-2). The larger Rg and Dmax seen 
experimentally indicate a more elongated molecule than the high resolution model would 
suggest. 
 
CRYSOL was used to calculate SAXS curves for the SaA2M monomer and dimer high-
resolution models (Figure 3-11)180. The CRYSOL fit of the monomer high-resolution model 
to the raw scattering curve for ECAM at 6.04 mg ml-1 shows that there are distinct 
differences in the small angle and mid-range angle with a χ of 11.867 (Figure 3-11)180. The 
dimer high-resolution model CRYSOL fit has a closer match to the raw scattering curve 
than the monomer model, with a distinct match in the small and the wide angle regions 
and a χ of 5.471 (Figure 3-11)180. The dissimilarity between the CRYSOL curves for both 
monomer and dimer high-resolution models and raw scattering curve are expected as the 
protein solution is a mixture of both monomer and dimer (Figure 3-11).  
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Figure 3-11 Comparisons between ECAM experimental scattering and CRYSOL generated unreacted 
SaA2M monomer and dimer high resolution model curves. 
ECAM experimental scattering (black circles, 6.04 mg ml-1) compared with monomer (blue) and dimer (red) 
CRYSOL curves of SaA2M high resolution model PDB: 4U4814,180.  
 
 
Ab initio model generation of particles in solution based on the scattering of X-rays can be 
performed using various programs as part of the ATSAS suite of programs resulting in an 
envelope representing the low resolution model of the protein176. However, generation 
of envelopes was not deemed suitable as the sample is a mixed species of 
monomer-dimer. 
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3.3 DisĐussioŶ 
Previous work has suggested that ECAM forms multimers on activation by proteases but 
is monomeric in its unactivated form67.  In this work, when ECAM was analysed by SEC 
there was clearly two species present when purified in the absence of any reducing agent 
(Figure 3-1). This monomer and dimer population is also seen by SDS-PAGE (Figure 3-1). 
SV analysis confirms the multiple species seen with sedimentation coefficients are similar 
to the simulated sedimentation coefficients from high resolution models (Table 3-1). SV 
analysis also shows that as the concentration of ECAM increases, more dimer is present 
(Figure 3-6). Upon SAXS analysis the increase in Rg and MW calculated from �0  also 
indicate an increase in multimerisation as concentration is increased 
(Figure 3-8, Table 3-2). When sedimentation coefficients are computed for the monomer 
and dimer high resolution models for SaA2M, the higher values than experimental species 
indicate that ECAM is more elongated in solution (Figure 3-12, Table 3-2).  
 
 
 
 
Figure 3-12 ECAM dimer has a larger conformation than SaA2M high resolution model 
The lower sedimentation coefficient and higher Rg and Dmax for experimental ECAM data values indicate 
that ECAM dimer has a larger conformation than seen in the crystallographic dimer for SaA2M. 
 
Chapter 3 
74 
 
 
Further, the higher Rg and Dmax seen experimentally by SAXS when compared to SaA2M 
model computed Rg and Dmax values again indicates a less compact elongated formation 
(Figure 3-12, Table 3-2). The characterisation of ECAM in solution has shown that the 
native protein that has not been reacted with protease is in a monomer-dimer 
equilibrium that increases in dimer ratio with increase in concentration. 
 
 This monomer-dimer mixed species can be observed by SEC, SDS PAGE, AUC and 
ĐoŶfiƌŵed thƌough C‘Y“OL ĐoŵpaƌisoŶ of a ͚ĐƌystallogƌaphiĐ͛ diŵeƌ ǁith “AX“ ƌaǁ 
scattering curve. Further analysis of the high resolution models through simulated 
hydrodynamic parameters confirms the presence of monomer-dimer mixed species seen 
through AUC and SAXS180. The differences seen in CRYSOL curve of SaA2M dimer and 
experimental scattering curve and envelope generated can be explained by the 
monomer-dimer equilibrium shown to be present and the flexibility within a dimer and 
the fluctuation that would be expected between monomer and dimer forms 
(Figure 3-11)180. The dimer form that is seen at high concentrations of protein may form 
under In vivo conditions due to crowding by heterogeneous proteins. ECAM is also a 
membrane anchored protein and when movement is limited to a two dimensional plane 
rather than three dimensions seen in solution it would be expected that dimerization 
could occur at lower protein concentrations than observed in solution (Figure 3-13). 
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Figure 3-13 ECAM model of interaction with inner membrane within periplasm. 
Chapter 4 
76 
 
 
 
 
 
 
 
 
4 CrǇstallisatioŶ aŶd struĐture ŵodel ďuildiŶg of protease 
Đleaǀed ECAM 
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4.1 IŶtƌoduĐtioŶ 
Although, a structure for methylamine activated HA2M has been solved, this is a low 
resolution structure and provides little information on the mechanism of activation of 
αϮMs. IŶ oƌdeƌ to uŶdeƌstaŶd this ŵeĐhaŶisŵ ǁe atteŵpted to eluĐidate the structural 
changes that occur on protease activation of ECAM. As elastase had been used previously 
for characterisation of ECAM and has known cleavage targets within the bait region of 
ECAM this was considered a good candidate for activating ECAM.  
 
4.2 Results 
4.2.1 CƌǇstallisatioŶ of poƌĐiŶe elastase aĐtiǀated ECAM 
Purified ECAM was reacted at a 1:1 molar ratio with porcine elastase and purified by SEC 
with fractions from the two largest peaks being pooled separately for crystallisation trials 
(Figure 4-1). The fractions from the two main peaks are likely to be digestion products of 
ECAM as they elute after full length ECAM. The fractions from these two peaks were 
individually concentrated to 16 mg ml-1 and crystallisation trials were set up using the 
Molecular Dimensions crystallisation screens MORPHEUS®, MIDASTM, JCSG-plus, and 
PACT premier. Crystal growth was only observed for protein from peak 1, in one condition 
fƌoŵ the MIDA“™ sĐƌeeŶ ǁith a ƌeseƌǀoiƌ solutioŶ ĐoŶtaiŶiŶg Ϭ.ϭ M potassiuŵ Đhloƌide, 
0.1 M HEPES, 25% SOKALAN® CP 7, pH 7.0. For optimisation of crystallisation, the 
concentrations of KCl, HEPES, and SOKALAN® were varied as was the pH.  
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Figure 4-1 Size exclusion chromatography of ECAM and ECAM reacted with porcine elastase. 
ECAM purified by size exclusion chromatography shown in blue and ECAM reacted with elastase shown in 
red. Numbered peaks highlight the fractions collected from ECAM reacted with elastase and subsequently 
used for crystallisation trays. ECAM used had previously been purified by Ni2+ affinity chromatography in 
the presence of TCEP. 
 
 
 
The condition resulting in the crystal growth with the largest crystals was similar to the 
initial hit with only a change in pH to 7.5 (Figure 4-2 a). Variation of ratio of protein to 
reservoir solution was also trialled for both SEC protein peaks although crystals were only 
seen in the initial screen for peak 1. A 1:1 ratio of protein solution and reservoir solution 
was found to be the best ratio for crystal growth with crystal appearance within 2 days 
for protein from peak 1. Crystals with similar morphology appeared after 3 weeks for 
protein from peak 2. Upon the appearance of crystals, growth significantly slowed after a 
week, after which time crystals were tested for diffraction on the home beam. 
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Figure 4-2 Crystals from ECAM reacted with porcine elastase and their diffraction. 
(a) Individual rods were separated from the clusters of crystals grown and used for data collection. (b) X-ray 
diffraction image collected at DIAMOND synchrotron light source from crystals of unlabelled porcine 
elastase reacted ECAM; the data set obtained extended to 3.5 Å. 
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As the intention of reacting ECAM with proteases before crystallisation was to obtain 
crystals of ECAM bound to protease, crystals were picked and run on SDS-PAGE and 
bands analysed by trypsin digest and liquid chromatography (LC) followed by mass 
spectrometry (MSMS) of peptides (Figure 4-3). SDS-PAGE showed a faint band at 120 kDa 
and three stronger bands at 90, 75 and 27 kDa. LCMSMS of the peptides obtained by 
trypsin digestion of the bands indicated that there was no porcine elastase present. The 
band at 120 kDa showed peptide hits for the whole protein minus MG domains 1, 2, 3, 
and 7.  The bands at 90 kDa and 75 kDa showed peptide hits for all domains between 
MG8 to the CTMG domain. The band at 27 kDa had peptide hits for domains MG4 and 
MG5 (Figure 4-3). 
 
 
 
 
Figure 4-3 Elastase treated ECAM crystals on SDS-PAGE and LC MSMS peptide coverage from bands. 
Peptide coverage was found from the corresponding domains upon trypsin digestion and LC MSMS. The 
band at 120 kDa (blue) had peptide coverage from the all domains seen in the crystal structure and the 
bands at 90 and 75 kDa (pink) had peptide coverage from the N-terminus seen in the crystal structure.  The 
band seen at 27 kDa (green) had peptide coverage from domains MG4 and 5. 
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The standard reservoir solution that produced crystal growth provided no cryoprotection 
and so it was mixed with various cryoprotectants. Glycerol, ethylene glycol, and PEG 
(various small molecule sizes) were trialled at various ratios, however all of these 
cryoprotectants resulted in the solution obtaining an opaque viscous appearance. As this 
may have a detrimental effect on cryoprotection or stability of crystals, sugars were then 
tested as cryoprotectants. The reservoir solution was mixed with either sucrose or xylitol 
resulting in a saturated sugar reservoir solution. The addition of xylitol was successful at 
providing cryoprotection with a 3:2 ratio of xylitol saturated reservoir solution to 
reservoir solution. Crystals were picked and briefly dipped in the xylitol cryoprotectant 
solution before being tested for diffraction on the home source with the best diffraction 
of ~8 Å found using larger crystals with >500 µm in length and >60 µm in thickness. It was 
found that larger crystals cracked upon being added to the cryoprotectant and this could 
be avoided by soaking crystals in solutions that gradually increases xylitol content until 
the 3:2 ratio that provided cryoprotection. From the diffraction data obtained on the 
home beam it was possible to determine a space group of H3 and cell dimensions of 
176.06, 176.06, 161.13 (a, b, c (Å)), 90, 90, 120 ;α, β, γ (°)). Multiple crystals were stored for 
future data collection at the DIAMOND synchrotron light source (Figure 4-2 b). Data were 
collected for ECAM crystals at the I02, I03 and I24 beamlines at Diamond Light Source 
(Didcot, United Kingdom) at 100 K at the selenium K-edge ;ʄ = Ϭ.ϵϳϵϯϵ ÅͿ usiŶg a Pilatus 
6M detector. 
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4.2.2 PhasiŶg aŶd ŵodel ďuildiŶg of poƌĐiŶe elastase aĐtiǀated ECAM 
Upon successfully collecting a complete data set to 3.5 Å resolution for native porcine 
elastase activated ECAM crystals, molecular replacement phasing of this data was 
attempted using previously published crystal structures of α2M. Although only having 
12% sequence identity between ECAM and α2M, we decided that as the expected 
activated domain orientation should be similar this may work for phasing our data 
through molecular replacement, however this was unsuccessful. The Phyre 2 protein fold 
recognition server was used to generate a model that had the activated domain structure 
of α2M with 100% sequence identity to ECAM, however, this was also unsuccesful183. For 
phasing heavy metal derivatisation was also attempted to allow single-wavelength 
anomalous diffraction (SAD) or multiple-wavelength anomalous diffraction (MAD). 
Crystals were soaked in multiple gold, platinum and palladium salts and although crystals 
changed in colour upon soaking without obvious damage to the crystals, no diffraction 
could be detected. Using selenium labelled protein was the next method attempted to 
provide phase information.  
 
A methionine auxotrophic strain of E. coli (T7 Express Crystal Competent E. coli (New 
England BioLabs)) supplemented with selenomethionine and other essential amino acids 
were used to express ECAM. The previous method of crystallisation after reacting ECAM 
with porcine elastase and purifying by SEC was attempted, however this was 
unsuccessful. After several purifications still resulting in no crystals, unreacted 
selenomethionine labelled ECAM (SeMetECAM) was mixed at a ratio of 100:1 ratio of 
SeMetECAM to porcine elastase using the MORPHEUS®, MIDASTM, JCSG-plus, and PACT 
premier Molecular Dimensions crystallisation screens used previously. Crystals were 
formed with a similar morphology as seen previously under identical crystallisation 
conditions (0.1 M KCl, 0.1 M HEPES, 25% SOKALAN® CP 7, pH 7.0) as for porcine elastase 
reacted unlabelled ECAM protein. This in situ proteolysis was repeated with the 
optimised condition (0.1 M KCl, 0.1 M HEPES, 25% SOKALAN® CP 7, pH 7.5) with 
successful crystal growth. These crystals grew as pointed rods as large as 1 mm long with 
0.1 mm diameter and diffracted to 3.65 Å (Table 4-1).  Several high redundancy SAD data 
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sets were collected from one well diffracting crystal and processed, scaled and merged 
using programs XDS and AIMLESS from the CCP4 suite of programs 167,168,170.  
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Table 4-1 Data collection and refinement statistics (single-wavelength anomalous diffraction) for 
protease cleaved ECAM 
 
    PDB: 4RTD   
Data Collection 
a
 
 
 
Space Group  H3 
 
Cell Dimensions 
 
 
    a, b, c (Å) 176.06, 176.06, 161.13 
 
    α, β, γ (°) 90, 90, 120 
 
Resolution (Å) 46.87-3.65 (4.0-3.65) 
 
Solvent Content (%) 69 
 
No. of unique observations  20753 (4991) 
 
CC1/2 0.998 (0.675)  
Rmerge (%) 39 (378.0)  
Rp.i.m (%) 
b 7.7 (74.4) 
 
Mean I/ơ;I) 13.2 (2.1) 
 
Completeness (%) 99.9 (99.9)  
Redundancy 26.6 (26.7)  
Anomalous completeness (%) 99.9 (99.3) 
 
Anomalous redundancy 12.8 (12.8)  
DelAnom correlation between half-sets 0.335 (0.011)  
Mid-slope Anomalous Normal 
Probability 1.245 
 
   
Refinement statistics 
 
 
Rwork/ Rfree (%) 17.7/23.8  
No. of atoms 8699 
 
RMSD of bond lengths (Å) 0.01 
 
RMSD of bond angles (°) 1.53 
 
Mean/Wilson plot B-value (Å2) 142.1/100.7  
Ramachandran plot (%) c 
 
 
Favoured/Allowed/Outliers 90.7/7.9/1.3 
 
      
Data collected from one crystal 
a Values in parentheses refer to the highest resolution shell. 
b Rp.i.m = Σhkl[1/(N - 1)]1/2Σi|Ii(hkl) - <I(hklͿ>|/ΣhklΣiIi(hkl) 
c Percentages of residues in favoured/allowed regions calculated by the program 
Molprobity
175 
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Upon processing the data and building the model, statistics for data collection, 
experimental phasing and refinement are presented in Table 4-1. The final electron 
density map is of very high quality for a resolution of 3.65 Å, with sidechains clearly 
defined (Figure 4-4). This high quality is due to the phasing obtained from a strong highly 
redundant data set (Table 4-1). 
 
 
 
Figure 4-4 Stereo iŵage struĐture ǁithiŶ ϭ σ eleĐtroŶ deŶsitǇ eŶǀelope. 
(a) Electron density matches the backbone of whole protein structure within electron density envelope 
dƌaǁŶ at ϭ σ leǀel. (b) Thioester region within electron density envelope dƌaǁŶ at ϭ σ leǀel ǁith Đleaƌ 
sidechains apparent at 3.65 Å. 
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Within our protease-activated ECAM structure the distance between the sulphur atom of 
Cϭϭϴϳ aŶd the γ-carbon of Q1190 is 4.6 Å indicating that the thioester bond may not be 
intact (Figure 4-5). However, we cannot rule out the possibility that there is a mixed 
population of molecules some of which possess an intact thioester bond. Due to this 
ambiguity we have represented the thioester without a covalent bond between C1187 
and the γ-carbon of Q1190 and have also omitted the oxygen from the deaminated 
glutamine that would be formed on hydrolysis of the thioester bond (Figure 4-5). 
 
 
 
 
 
 
Figure 4-5 Cleaved thioester of protease-cleaved ECAM. 
The S-Cγ distaŶĐe ďetǁeeŶ Cϭϭϴϳ aŶd QϭϭϵϬ is seeŶ to ďe ϰ.ϲ Å, suggestiǀe of a Đleaǀed thioesteƌ ďoŶd. 
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4.2.3 Oǀeƌall stƌuĐtuƌe of pƌotease-aĐtiǀated ECAM 
Upon completion and validation of the model for protease-activated ECAM, the number 
of Ramachandran outliers (1.3%) remaining was appropriate for a crystal structure with a 
resolution of 3.65 Å. Although Rmerge and Rpim values were high, this can be explained by 
the highly redundant dataset used, but with a CC1/2 of 0.675 in the highest shell these 
data used were judged to be acceptable 184,185. Similar to the domain architecture of 
native SaA2M, un-cleaved ECAM consists of 10 MG domains, with a bait region that is 
predicted to be largely disordered found within MG8, a TED that houses the reactive 
thioester bond and a CUB domain (Figure 4-6 a, b). Elastase-cleaved ECAM, (Figure 4-6 b) 
adopts a conformation similar to that of methylamine-aĐtiǀated huŵaŶ αϮM 
(Figure 4-7 a), but distinct from the unactivated form of SaA2M (Figure 4-7 b). Despite the 
loǁ seƋueŶĐe ideŶtity ďetǁeeŶ huŵaŶ αϮM aŶd ECAM ;ϭϮ%Ϳ, the r.m.s.d ďetǁeeŶ α-
carbons (when using equivalent domains within ECAM structure) for these proteins is 
14.1 Å while for SaA2M and ECAM, which share 82% sequence identity, is 22.1 Å.  Most 
notably, in the structure of the protease cleaved ECAM, interactions between the TED 
and CTMG domain, which protects the thioester bond in unactivated SaA2M, are not 
present.  Instead, the thioester region of TED is solvent exposed and faces the expected 
location of the attacking protease, as it would be positioned when cleaving the bait 
region of ECAM (Figure 4-6 b). Electron density for elastase, in addition to that for MG 
domains 1, 2, 3 and 7, was absent in 2Fo-Fc maps of cleaved ECAM as was electron 
density for 20 amino acid residues (R923 – L942) within the bait region (Figure 4-6). 
Although there is space within the crystal packing to accommodate the presence of 
elastase the lack of any elastase observed upon SDS-PAGE of crystals confirmed the lack 
elastases presence (Figure 4-3). Porcine elastase I has been shown to have specificity of 
cleavage between alanine-alanine and alanine-glycine residues with porcine elastase II 
having specificity between leucine-alanine, leucine-glycine, phenylalanine-alanine,  
phenylalanine-glycine, tyrosine-alanine and tyrosine-glycine residues 186. The absence of 
domains MG1,2,3 and MG7 as well as elastase from the crystal structure could be due to 
elastase not being inhibited by ECAM and proceeding to cleave in various places beyond 
the bait region. The bait region has a RLAALR motif between R941 and R946 within the 
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bait region with a likely cleavage between L942 and A943 as no density is present for 
residues prior to A943. This bait region cleavage site is very close to the cleavage site seen 
in the trypsin cleaved ECAM structure (PDB: 4ZIQ) between residues G948 and G949 187. 
There is a likely cleavage location in the linker of MG3 and MG4 between residues A379 
and G380 with electron density appearing shortly after at S385. With the absence of MG7 
likely cleavage locations for porcine elastase could be between G751 and A752 and L852 
and G853. 
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Figure 4-6 CrǇstal struĐture of porĐiŶe elastase Đleaǀed EsĐheriĐhia Đoli αϮM ;ECAMͿ. 
(a) Schematic representation of the 13 domains of ECAM showing the macroglobulin domains (MG) 
including the C-terminal MG (CTMG) domain, bait region domain (BRD), complement protein 
subcomponent domain (CUB), and the thioester domain (TED) containing the CLEQ motif. White boxes 
represent domains in full length ECAM however not present within crystal structure. (b) The structure of 
elastase cleaved ECAM with the individual domains coloured as in (a) shown in two views from opposing 
directions. Smaller van der Waals surfaces in both views are also presented. In the lower view the alpha-
helical TED is orientated with the CLEQ thioester (drawn as red van der Waals spheres) positioned above 
the pocket, which is thought to accommodate the attacking protease.   
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Figure 4-7 Comparison between trimmed ECAM, SaA2M, and HA2M. 
(a) Structural alignment of methylamine tƌeated huŵaŶ αϮM ;PDB: ϰACQ ŵoŶoŵeƌ tƌiŵŵed to doŵaiŶs 
present in cleaved ECAM) and elastase cleaved ECAM (PDB: 4RTD) in green and red, respectively. (b) 
Structural alignment of native SaA2M (PDB: 4U48 trimmed to domains present in cleaved ECAM) and 
elastase cleaved ECAM (PDB: 4RTD) in blue and red, respectively. Structural alignments were performed 
using the MG domain containing the bait region shown in orange. 
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4.2.4 IŶteƌaĐtioŶ of the BRD ǁith CTMG 
Although it is known that protease cleavage of the largely disordered bait region of both 
huŵaŶ aŶd ďaĐteƌial αϮMs giǀes ƌise to a laƌge ĐoŶfoƌŵatioŶal ƌeaƌƌaŶgeŵeŶt aŶd 
activation of the thioester bond, the mechanism through which this is mediated was 
unclear 20,77. However, the structure of protease cleaved ECAM provides a putative 
mechanism for this process. Thioester bond release may be achieved by the untethering 
of a large region of an unstructured polypeptide chain upon cleavage of the BRD that 
forms new interactions with the CTMG domain, thereby preventing the protective 
interaction with the TED. Specifically, in the elastase-cleaved form of ECAM, additional 
residues (F947 – N963) of the BRD are observed that are disordered in the uncleaved 
SaA2M structure. All of these residues in the protease cleaved ECAM structure are 
ordered, owing to the formation of new binding interface between the BRD and the 
CTMG domain upon protease cleavage (Figure 4-8 a). Critically, the region of the CTMG 
domain that is involved in BRD binding substantially overlaps with the region of the CTMG 
domain that forms the binding interface with the TED in the uncleaved form of the 
protein (Figure 4-8 b). The buried surface area between CTMG and TED in SaA2M is 1972 
Å2 with 3 hydrogen bonds between these domains whereas the buried surface area 
between the elastase cleaved BRD and CTMG in ECAM is 1438 Å2 with 5 hydrogen bonds 
between domains.  
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Figure 4-8 Bait region interactions with the CTMG domain. 
(a) Hydrogen bonding between the cleaved bait region (blue) and CTMG domain (grey), shown as dashed 
yellow lines.  Note the interaction between R956 and M1634, with the CTMG methionine normally involved 
in the hydrophobic pocket found in un-cleaved native SaA2M. MG4 and MG9 are shown in yellow and red 
respectively. (b) Surface representation of the CTMG domain bound to TED in SaA2M (blue) overlaid (by 
superposition of CTMG domains) with the previously disordered bait region bound to the CTMG domain in 
elastase cleaved ECAM (red). The thioester bond within the TED is shown using dark blue van der Waals 
spheres. 
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In the protease cleaved ECAM, hydrogen bond formation between residues of the CTMG 
domain and cleaved bait region involves the highly conserved RDDR and EXMY motifs 
(Figure 4-9). Interestingly, it is residues within these motifs that also form hydrogen 
bonds with the TED in the uncleaved SaA2M protein (Figure 4-9; 14). 
 
 
 
 
 
Figure 4-9 Sequence alignments of conserved motifs involved in thioester pocket and conformational 
activation. 
Highlighted in yellow are tyrosines important for maintaining the hydrophobic pocket protecting the 
thioester bond (CXEQ motif, also shown in yellow). The tyrosine within the C-terminal macroglobulin 
(CTMG) domain which is also involved in protecting thioester is highlighted in blue as well as it is the 
glutamate (in CLEQ) that it coordinates with in the native SaA2M structure (PDB: 4U48). The conserved 
proline found near the thioester is highlighted in green along with the arginine that it coordinates in 
unactivated SaA2M. The residues highlighted in pink orange and red in the CTMG domain coordinate with 
residues N963, G958 and R956 respectively, in the cleaved bait region of elastase cleaved ECAM. 
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4.2.5 BRD Đleaǀage iŶduĐed ĐoŶfoƌŵatioŶal shift  
To characterise the conformational change seen between the unreacted SaA2M structure 
and porcine elastase activated ECAM structure these structures were compared by 
aligning the MG8 domains, which contains the bait region (Figure 4-7 b). Equivalent 
residues were compared between structures in order to determine the movement in Å 
shown in table 4.2 with averages represented in figure 4-10. We propose that the loss of 
the TED interaction with the CTMG domain is sufficient to enable both the large TED 
movement observed in the cleaved ECAM structure, relative to the unactivated SaA2M 
structure, and exposure of the thioester bond (Table 4-2, Figure 4-10 a, b, Movie 1). The 
movement of the TED shows an overall shift of 36 Å, with the MG6 domain moving by 50 
Å (Table 4-2, Figure 4-10 a, b, Movie 1). Both the MG6 and TED arms move in to hug the 
position of where the attacking protease would be located when cleaving the BRD. We 
also looked at the position of the domains not present in porcine elastase ECAM and 
noted that if they remained in the position seen in the SaA2M structure, relative to MG8, 
there would be no clashes with the moving domains (Table 4-2, Figure 4-10 a, b, Movie 1). 
In addition to these global conformational changes, protease cleavage leads to localised 
changes in the environment of the thioester bond that likely lead to its activation.  
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Table 4-2 Movement of domains upon elastase activation 
 
Domain 
ECAM Amino acid 
reference 
Distance 
moved (Å) 
SaA2M Amino acid 
reference 
MG4 R398 1 R390 
  Q420 1.1 Q412 
MG5 M487 14.4 M479 
  H581 36.1 H573 
MG6 E684 46.4 E676 
  A706 57.9 A698 
MG8 N985 2.8 N993 
  D998 2.1 D1006 
MG9 D1048 3.8 D1040 
  L1062 10 L1054 
CUB N1153 19.9 N1145 
  Q1482 37 Q1473 
TED D1259 39.6 D1251 
  Y1311 35.4 Y1303 
  L1391 32.5 L1382 
  Average of TED 35.8   
MG10 N1540 20.1 R1531 
  V1651 14.5 V1642 
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Figure 4-10 Conformational shift of TED relative to MG6 domain of protease-activated ECAM. 
(a) Superposition of protease cleaved ECAM (red) and SaA2M (blue) showing 36 Å shift of the TED. (b) 
Superposition of protease cleaved ECAM (red) and SaA2M (blue) showing 52 Å shift of MG6 domain. 
Structures overlaid by superposition of MG8 containing the BRD. 
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4.2.6 Thioesteƌ ďoŶd aĐtiǀatioŶ of αϮMs 
In the unactivated SaA2M structure, the conserved methionine and tyrosine side chains 
(M1625 and Y1626 in SaA2M) from the CTMG domain form part of the hydrophobic 
pocket, at the interface with the TED, that has been shown to be important in 
maintenance of the thioester bond (Figure 4-9, 4-11)14. The loss of these key side-chain 
interactions and the movement of the additional sidechains which constitute the 
protective hydrophobic pocket (Y1175 and Y1177 in SaA2M, and Y1183, Y1185 in ECAM) 
from the TED expose the thioester bond to the solvent allowing hydrolysis or covalent 
bond formation with the attacking protease (Figure 4-11). As there are no contacts 
present from the CTMG domain providing a hydrophobic pocket to protect the thioester 
from hydrolysis by water, the thioester bond could be cleaved and the deaminated 
glutamine (Q1190) would be converted to glutamic acid.  
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Figure 4-11 MoǀeŵeŶt of residues ǁithiŶ thioester upoŶ protease aĐtiǀatioŶ of ďaĐterial αϮM. 
Overlaid are elastase-cleaved ECAM (red) and native SaA2M (blue) TEDs. Tyrosines thought to protect the 
thioester region from hydrolysis in native SaA2M (Y1175 and Y1177) are orientated away from the 
protease-activated ECAM thioester region (Y1183 and Y1185 in protease-activated ECAM).  
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4.2.7 BiophǇsiĐal ĐhaƌaĐteƌisatioŶ of ECAM ƌeaĐted ǁith ĐhǇŵotƌǇpsiŶ  
When ECAM is reacted with proteases, a conformational change occurs that may lead to 
encapsulation and inhibition of the reacting protease. It has been suggested that ECAM 
functions as an inhibitor of proteases that may include host gut proteases. Within the 
following work the cleavage of ECAM by the human digestive protease chymotrypsin was 
investigated. ECAM was reacted with chymotrypsin and purified by SEC with the intention 
of characterising ECAM in complex with chymotrypsin. Protein from the main peak 
following reaction of ECAM with chymotrypsin was collected and pooled for AUC and 
SAXS analysis (Figure 4-12).  
 
 
Figure 4-12 Purification by SEC of ECAM reacted with chymotrypsin. 
SEC of ECAM that has been reacted with chymotrypsin for 5 minutes on ice and reacted with PMSF 
protease inhibitor before being loaded onto a Superdex S200 SEC column. The main peak indicated was 
pooled for analysis by analytical ultracentrifugation and SAXS. ECAM purification shown in black with ECAM 
reacted with chymotrypsin shown in red. 
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ECAM reacted with chymotrysin and purified by SEC was concentrated for analytical 
ultracentrifugation sedimentation velocity as was previously performed for ECAM. Similar 
to unactivated ECAM, as the concentration of protease-activated ECAM is increased the 
concentration of a second species increases with species 2 becoming distinct between 2-4 
mg ml-1 (Figure 4-13 a)67.  The sedimentation coefficient �020,� determined for ECAM 
reacted with chymotrypsin is 5.85 S for species 1 and 8.88 S for species 2 (Figure 4-13 a, b, 
Table 4-3). When the crystal structure of porcine elastase activated ECAM (PDB:4RTD) is 
analysed hydrodynamically using SOMO within Ultrascan 2.0, an �020,� of 6.68 S is 
calculated which lies between experimental values for species 1 and 2 of ECAM reacted 
with chymotrypsin, 5.84 S and 8.88 S respectively 166(Table 4-3). The two species 
observed are likely monomer and dimer as have been mentioned for ECAM reacted with 
proteases previously67.  The calculated sedimentation coefficient of 6.68 S for crystal 
structure of protease activated ECAM is just under 15% higher than monomer species 1 
(5.84 S) indicating that in solution protease reacted ECAM may have more flexibility and 
elongation than the rigid crystal structure. 
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Figure 4-13 AUC analysis of ECAM reacted with chymotrypsin. 
(a) Continuous c(s) distribution of ECAM reacted with chymotrypsin at various concentrations. (b) 
Integrated sedimentation coefficient values at 20°C in water against concentration of ECAM reacted with 
chymotrypsin.  
 
 
 
Table 4-3 Experimental and computed sedimentation coefficient (s) for ECAM reacted with proteases 
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4.2.8 Sŵall aŶgle X-ƌaǇ sĐatteƌiŶg of ECAM ƌeaĐted ǁith ĐhǇŵotƌǇpsiŶ aŶd 
ĐoŵpaƌisoŶ ǁith ĐƌǇstal stƌuĐtuƌe of ECAM ƌeaĐted ǁith poƌĐiŶe 
elastase 
Dimer formation does not become significant until between 2-4 mg ml-1 and so ECAM 
reacted with chymotrypsin was analysed by SAXS at concentrations between 0.24 mg ml-1 
and 2.3 mg ml-1. The small angle, low concentration data was merged with the wide angle 
high concentration data for better data analysis and a representative envelope of ECAM 
reacted with chymotrypsin in solution. The scattering curve for chymotrypsin activated 
ECAM is representative of a globular protein (Figure 4-14 a). Using the Guinier fit the Rg is 
calculated as 4.01 nm and reveals no particle interference due to the linearity of the 
residuals (Figure 4-14 b). Considering the Kratky plot, the protein in solution is globular 
(Figure 4-14 c).  The p(r) plots also show a bell shaped curve indicating a globular protein 
with a Dmax of 11.92 nm (Figure 4-14 d). 
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Figure 4-14 SAXS data for ECAM reacted with chymotrypsin. 
(a) Raw scattering curve for ECAM (reacted with chymotrypsin) using merged high concentration 
(2.3 mg ml-1), wide angle and low concentration (0.24 mg ml-1), small angle data. (b) Guinier fit to the raw 
scattering data in the Guinier region determines an Rg of 4.01 nm. The linearity of the residuals indicates 
the absence of inter-particle interference. (c) Kratky plot indicates a globular protein. (d) The p(r) 
distribution analysis indicates a globular protein with a much smaller Dmax (11.92 nm) as seen for ECAM 
(18.80 nm). 
 
 
When the scattering curve of ECAM reacted with chymotrypsin is compared with the 
crystal structure of ECAM reacted with porcine elastase using CRYSOL, the curves appear 
very similar at small to wide angles and have a χ value of 0.825 (Figure 4-15)180. This χ 
value is a significantly better match to the curve than that seen for either monomer or 
dimer ECAM (11.867 and 5.471, respectively). The �0 calculated molecular weight for 
chymotrypsin reacted ECAM is 102 kDa and does not match the molecular weight of the 
porcine elastase reacted molecular weight of 127 kDa. The SOMO simulated Rg and Dmax 
values for porcine elastase reacted ECAM of 3.8 nm and 12.42 nm are close to the 
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experimental values seen for chymotrypsin reacted ECAM of 4.01 nm and 11.92 nm 
(Table 4-4)166. However, the larger Dmax seen for the crystal structure indicates that the 
chymotrypsin sample in solution is slightly more compact (Table 4-4).  The close CRYSOL 
fit and similarity in Rg and Dmax values seen between experimental and simulated crystal 
structure confirm that the protein sample in solution is representative of the crystal 
structure. 
 
 
 
Figure 4-15 CRYSOL comparison between elastase activated ECAM crystal structure and chymotrypsin 
activated ECAM SAXS curve. 
(a) Chymotrypsin activated ECAM (Black, merged wide angle data at 2.3 mg ml-1 and small angle data at 
0.24 mg ml-1) comparison with porcine elastase activated ECAM crystal structure (red, PDB: 4RTD) follows 
scattering data. SAXS data comparisons with crystal structures performed using CRYSOL with a χ value of 
0.825180. 
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Table 4-4 Experimentally determined and computed ECAM biophysical properties 
 
 
 
The low resolution envelope generated using DAMMIF for ECAM reacted with 
chymotrypsin has a very similar shape when compared to the crystal structure of ECAM 
reacted with porcine elastase (Figure 4-16)179.
 
Figure 4-16 Crystal structure of elastase treated ECAM overlaid with SAXS envelope of chymotrypsin 
treated ECAM. 
Elastase treated ECAM crystal structure (PDB: 4RTD) aligned within SAXS envelope generated using DAMIF 
with SAXS data collected from Chymotrypsin treated ECAM (merged wide angle data at 2.3 mg ml-1 and 
small angle data at 0.24 mg ml-1). DAMFILT envelope shown in yellow and DAMAVER envelope in blue176. 
Models aligned manually in Pymol. 
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4.3 DisĐussioŶ 
Although it has ďeeŶ suggested that sŵall ŵoleĐule aĐtiǀated huŵaŶ αϮM ƌeseŵďles the 
conformation of the protease cleaved form, there has to date been no detailed structural 
data to confirm this 25. The similarity in overall conformation of protease cleaved ECAM 
ǁith ŵethylaŵiŶe aĐtiǀated huŵaŶ αϮM ĐoŶfiƌŵs that the pƌotease cleaved form and 
ĐheŵiĐally aĐtiǀated foƌŵ of huŵaŶ αϮM are structurally equivalent. In addition, these 
data suggest that the entrapment of cleaving proteases likely occurs in a similar manner 
foƌ BAϮMs as has ďeeŶ pƌoposed foƌ huŵaŶ αϮM 13,188. However, there are clearly key 
differences in the details of the interactions that maintain the inactive conformation of 
BAϮMs aŶd huŵaŶ αϮM, siŶĐe the ƌeĐeŶt stƌuĐtuƌes of uŶaĐtiǀated aŶd ŵethylaŵiŶe 
activated SaA2M show that chemical cleavage of the thioester bond does not in this case 
lead to global conformational changes 13,14. This difference is likely due to the domain 
location of the side-chains that comprise the thioester protecting pocket (Figure 4-17). 
For BA2Ms, this pocket comprises of 2 tyrosine side chains from the TED and a tyrosine 
aŶd a ŵethioŶiŶe side ĐhaiŶ fƌoŵ the CTMG doŵaiŶ ǁheƌeas iŶ eukaƌyotiĐ αϮMs all fouƌ 
residues (3 tyrosine side chains and one methionine side chain) are found in the CTMG 
domain. When SaA2M is reacted with methylamine no conformational change is seen, 
but Y1175 from the TED is displaced 14. The structural counterpart of this side chain 
;YϭϯϬϳ fƌoŵ TEPϭͿ iŶ eukaƌyotiĐ αϮM faŵily ŵeŵďeƌs is, hoǁeǀeƌ, fouŶd ǁithiŶ the 
CTMG domain (Figure 4-17)10.  
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Figure 4-17 CoŵparisoŶ of the thioester proteĐtiŶg poĐket iŶ eukarǇotiĐ aŶd ďaĐterial αϮMs. 
The thioester pocket highlighting conserved residues from the TED (magenta) and CTMG domain (cyan) of 
(a) SaA2M and (b) the eukaƌyotiĐ αϮM faŵily ŵeŵďeƌ TEPϭ ;PDB ϰDϵϰ; Le et al., ϮϬϭϮͿ.  Highlighted side 
ĐhaiŶs aƌe ĐoŶseƌǀed aŵoŶg ďaĐteƌial aŶd eukaƌyotiĐ αϮMs, ƌespeĐtiǀely. 
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It is presumably the rearrangement of this side chain and perhaps other CTMG side chains 
that comprise the thioester protecting pocket, which leads to loss of TED-CTMG domain 
binding and subsequent global conformational changes. The buried surface area seen 
between TED-CTMG in native SaA2M is 27% higher than the surface area buried on 
formation of the BRD-CTMG in protease cleaved ECAM, however, the number of 
hydrogen bonds increases from 3 to 5 (Figure 4-8). Although there is a decrease in the 
buried surface area, the movement in residues involved in the hydrophobic pocket 
protecting the thioester is what triggers conformational change releasing TED allowing 
subsequent interaction with a cleaving protease. 
 
The role of BA2Ms, which are inner membrane anchored periplasmic proteins, has been 
suggested as protease inhibitors that inhibit exogenous proteases that have breached the 
outer membrane. During the course of this work a crystal structure of trypsin activated 
ECAM was published187. This crystal structure showed distinct similarity to porcine 
elastase activated ECAM although all domains were present minus the first N-terminal 
MG domain (Figure 4-18 a). With an r.m.s.d between porcine elastase activated ECAM 
and trypsin activated ECAM of 0.711 using 761 α-carbons, these two forms of 
protease-activated ECAM display very similar structures regardless. The interaction of the 
cleaved bait region with CTMG is also observed in the trypsin activated ECAM structure 
although not analysed within their paper (Figure 4-18 b). Importantly the BRD R956 is also 
seen to hydrogen bond with M1634 confirming the interaction seen within the elastase 
activated crystal structure. In the trypsin activated structure, trypsin was present within 
the crystal lattice, however, not forming a repeating pattern that could diffract. Another 
difference noted was a slightly rotated TED that could be due to this domain being bound 
to a protease molecule in trypsin activated ECAM (Figure 4-18 a).  
 
Investigation of ECAM reacted with chymotrypsin by SAXS resulted in a scattering curve 
that closely matches the CRYSOL simulated curve for ECAM reacted with porcine elastase 
(Figures 4-14, 4-15, 4-16, Table 4-3, 4-4). This indicates that regardless of the identity of 
the cleaving protease the conformational changes in ECAM are similar and closely 
resemble those in HA2M. 
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Figure 4-18 Alignment of protease-activated ECAM structures. 
The alignment of porcine elastase activated ECAM (Red, PDB:4RTD) and trypsin activated ECAM (Cyan, 
PDB:4ZIQ) 187. The full structures shown in (a) have a very similar orientation with an r.m.s.d of 0.711 (using 
761 α-carbons) between structures however, a slight difference in orientation of the TED and extra domains 
for the trypsin activated ECAM are observed. (b)Trypsin activated ECAM displays similar interactions 
between the cleaved bait region and the CTMG as porcine elastase activated ECAM. In trypsin activated 
ECAM a BRD is observed with a slightly shorter length however maintaining the important residue contacts 
seen in porcine elastase activated ECAM. 
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Comparison of the structures of unactivated SaA2M and protease cleaved ECAM 
illustrates how protease induced conformational changes may enable protease 
entrapment (Figure 4-14).  
The movement of the TED arm and MG6 domain arm around the central pocket above 
the ďait ƌegioŶ is siŵilaƌ to the ŵoǀeŵeŶt seeŶ iŶ ŵethylaŵiŶe aĐtiǀated huŵaŶ αϮM. 
When accounting for the domains not present in the protease-activated ECAM structure, 
no clashes are seen between the moving arms and the absent domains 13. The 
entrapment of proteases would limit the proteolysis of smaller substrates as has been 
suggested foƌ huŵaŶ αϮM aŶd ǁould pƌeǀeŶt the Đleaǀage of iŵpoƌtaŶt laƌgeƌ suďstƌates 
such as the peptide component of the peptidoglycan layer or large proteins (Figure 4-19) 
16.  
 
 
 
Figure 4-19 Putative mechanism of protease entrapment and inhibition by ECAM. 
ECAM with membrane anchor within the periplasm of bacteria encounters protease and forms a covalent 
complex upon cleavage, inhibiting the protease from cleaving large substrates. The main body of ECAM 
anchored to the inner membrane is shown in grey and contains the domains showing little movement 
(MG4, 8 & BRD) between native and protease-activated structures or that are not present in the 
protease-activated structure (MG1-3 &7). The blue TED arm (TED, CUB, CTMG & MG9 domains) and green 
MG6 arm (MG5 & 6 domains) entrap the protease with the blue arm containing the thioester that forms a 
covalent bond. 
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Although we cannot be sure why the covalently bound elastase is not present in our 
structure, this may be due to a lack of available and correctly positioned lysine side chains 
on the surface of the protease, since the thioester bond is preferentially cleaved by this 
side chain 13. The lack of MG domains 1, 2, 3 and 7 within the crystal lattice is likely due to 
the MG domains being cleaved by elastase. With both the native SaA2M structure and 
the trypsin activated structure showing a dimer there is likely a physiological importance 
to this. 
 
The structure of protease-activated ECAM suggests a competitive mechanism of 
activation in which cleavage of the BRD allows the normally intrinsically disordered region 
of this domain to outcompete the TED for CTMG domain binding. Loss of the TED-CTMG 
domain interaction leads to a large conformational rearrangement of ECAM and exposure 
of the reactive thioester bond. The structural similarity between methylamine activated 
huŵaŶ αϮM and protease cleaved ECAM suggests that similar mechanisms likely operate 
across the diverse members of the αϮM faŵily. 
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5 The role of PeŶiĐilliŶ-ďiŶdiŶg proteiŶ ϭC iŶ the fuŶĐtioŶ 
of ECAM 
 
 
 
Circular dichroism data was collected and processed by Sharon Kelly. 
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5.1 IŶtƌoduĐtioŶ 
Escherichia coli possess two genes encoding ďaĐteƌial αϮM type proteins. As discussed in 
previous chapters ECAM, one of these two proteins, has been characterised previously6,67 
(Figure 5-1). The gene encoding ECAM (yfhM) exists in an operon with pbpC which 
encodes the nonessential penicillin binding protein Pbp1C (Figure 5-1). It has been 
suggested that these proteins constitute a defence and repair mechanism, with ECAM 
inhibiting invading host proteases and Pbp1C repairing any proteolytic damage to the 
peptidoglycan6,67,123.  
 
 
Figure 5-1 Bacterial α-2-macroglobulin operons and a schematic representation of their expressed 
proteins localized to the bacterial envelope. 
;aͿ BaĐteƌial αϮM opeƌoŶs ECAM aŶd Yfa“ aƌe fouŶd iŶ Escherichia coli and Yfas equivalent operon MagD is 
found in Pseudomonas aeruginosa. (b)Within E. coli, ECAM and Pbp1C are both translocated to the 
periplasm across the inner membrane. MagD in P.aeruginosa, is translocated across the inner membrane to 
the periplasm and is associated with the inner membrane, possibly through interactions with MagB, which 
harbours one transmembrane domain in its C-terminus. The orientation of the MagB in the inner 
membrane was chosen arbitrarily. MagA and MagF, encoded by the same operon, are also partners of the 
membrane associated Mag complex. Figure 5-1 b reproduced from Robert-Genthon et al.201368. 
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Pbp1C has been shown to have transglycosylase (TGase) function however although a 
putative transpeptidase (TPase)domain has been suggested no TPase activity has been 
observed123. Previous characterisation of Pbp1C was performed on protein purified from 
membranes and sepharose columns covalently bound with Pbp1C retained Pbp1B, 
Pbp2,3123. Although Pbp1C is not essential and cannot replace murein production in 
[Pbp1A, Pbp1B] double knockouts, deletion of Pbp1C results in an altered production of 
murein123. Compared to wildtype E. coli, the knockout of pbpC resulted in a decrease in 
peptidoglycan synthesis by 75%123. There was also noted a change in peptidoglycan 
composition with a 371% increase in dimeric subunits that were crosslinked between a 
tetrapeptide disaccharide and a pentapeptide disaccharide123. This was suggested as 
occurring due to Pbp1Cs functioning as a complex with other peptidoglycan synthesis 
proteins such as Mgt and Pbp1B123. 
 
Within the genome of E. coli K12 there is a second operon including a gene encoding a 
ďaĐteƌial αϮM, yfaS. This operon also contains further genes, yfaA, yfaT, yfaQ and yfaP, 
with no characterisation of the encoded proteins performed to date. Pseudomonas 
aeruginosa ĐoŶtaiŶs oŶly oŶe Đopy of ďaĐteƌial αϮM, similar to E. coli yfaS, called MagD 
(Figure 5-1). The MagD operon contains all of the proteins found in the E. coli yfaS operon 
and an additional gene upstream of the homologue magB (Figure 5-1).  
 
The family of penicillin binding proteins includes several enzymes with varied function, 
with class A having both transglycosylase and transpeptidase function, class B having 
transpeptidasease function and class C having carboxypeptidase or endopeptidase 
function. In this chapter in vivo characterisation of ECAM and Pbp1C through western 
blotting and the purification and characterisation of Pbp1C is described. This work was 
undertaken in order to gain insight into the possible function of Pbp1C both individually 
and in concert with its operon partner ECAM. 
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5.2 Results 
5.2.1 IŶ ǀiǀo aŶalǇsis of ECAM 
ECAM is a member of the α2M superfamily and has been suggested to inhibit proteases 
in a similar fashion to α2M14,67,77. To test this hypothesis the behaviour of ECAM in vivo 
was investigated. Western blotting was performed using anti-ECAM antibodies on whole 
cell lysate. When wild type (WT) E. coli K12 cell extracts were blotted using the anti-ECAM 
antibody five distinct bands were observed at 260, 180, 160, 120 and 100 kDa 
(Figure 5-2). The bands at 260 and 180 kDa could be dimer and monomer species 
respectively, as seen for purified ECAM (Figure 5-2, 3-1 c).  
 
 
Figure 5-2 Wild-type phenotype loses ECAM cleavage upon pbpC knockout and returns upon 
complementation. 
Wildtype (WT) E. coli K12 has four significant bands present at 260, 180, 160, 120 and 100 kDa. The ECAM 
kŶoĐkout stƌaiŶ, ΔyfhM, has lost all four major bands with only a faint band present at 100 kDa. E. coli K12 
with pbpC kŶoĐked out ;ΔpbpC) has no band at 160 kDa and has lost the major band at 100 kDa with an 
iŶĐƌease iŶ iŶteŶsity iŶ ďaŶds seeŶ at ϮϲϬ aŶd ϭϴϬ kDa. Δpbp1C has further bands at various molecular 
weights between 160 and 180 kDa.  Bands seen in wildtype at 160 and 100 kDa and that are absent in 
pbp1c knockout are restored on complementation with plasmid based pbpC but remain absent in the 
presence of pBAD18-kan vector control. Cell extracts were analysed by Western blotting using anti-ECAM 
antibodies. 
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Since the most intense band is at 100 kDa this suggests that ECAM is present mostly in a 
cleaved form in growing cells. One possibility is that there is processing of ECAM by 
unidentified bacterial proteins. Since yfhM is generally linked to the gene encoding Pbp1C 
(pbpC), the effect of loss of Pbp1C on processing of ECAM was considered. Interestingly in 
a Δpbpc strain the intense band (at 100 kDa) representing cleaved ECAM is absent and 
bands at 180 and 260 kDa show increased intensity (Figure 5-2).  In addition, a number of 
bands between 180 and 260 kDa are also apparent that are absent in WT E. coli. Thus 
Pbp1C is required for processing of ECAM although from these experiments it is not 
possible to determine if this requires the proteins to directly interact. The laddering effect 
seen between 260 and 180 kDa iŶ the ΔpbpC strain may be due to ECAM covalently 
attaching to proteins in close proximity upon heat denaturation prior to SDS-PAGE 
(Figure 5-2).  
 
In order to confirm that Pbp1C is involved in ECAM processing, the gene encoding Pbp1C 
including the lipid anchor was cloned into the pBAD18-kan vector and used to 
ĐoŵpleŵeŶt the ΔpbpC strain. Two plasmids were generated, one without a stop codon 
in order to subsequently add a Myc-tag (ppbpCo), the second with a stop codon (ppbpCc). 
Both ĐoŵpleŵeŶtatioŶ plasŵids ǁeƌe suĐĐessful iŶ ƌetuƌŶiŶg the ΔpbpC strain to the WT 
phenotype with the most intense ECAM band observed at 100 kDa (Figure 5-2). 
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5.2.2 Role of otheƌ Pďps oŶ ECAM pƌoĐessiŶg 
To determine if ECAM processing is specific to Pbp1C, Western blotting with anti-ECAM 
antibodies of cell lysates from strains lacking other penicillin binding proteins and 
proteins involved in peptidoglycan synthesis was performed. In strains lacking the class A 
penicillin bindiŶg pƌoteiŶs PďpϭA aŶd PďpϭB ;ΔmrcA and ΔmrcB respectively) processing 
of ECAM was similar to WT with an intense ECAM band observed at 100 kDa by western 
blotting with anti ECAM antibodies (Figure 5-3). The knockout for the gene encoding the 
EPase Pďpϳ ;ΔpbpG) as well as knockouts for genes encoding CPases Pbp4, Pbp5 and 
Pďpϲ ;ΔdacA, ΔdacB and ΔdacC respectively) also display a wild type phenotype 
(Figure 5-3). The knockouts for genes encoding a β-lactamase, the monofunctional TGase 
aŶd a peƌiplasŵiĐ pƌotease ;ΔampC, ΔopgH and Δprc respectively) all maintain a wild type 
phenotype with 160 and 100 kDa ECAM cleavage products present (Figure 5-3). 
 
 
Figure 5-3 Strains lacking genes involved in the synthesis of peptidoglycan maintain a wildtype ECAM 
processing phenotype. 
Class A PeŶiĐilliŶ ďiŶdiŶg pƌoteiŶ kŶoĐkouts ΔmrcA aŶd ΔmrcB retain the 160 and 100 kDa bands seen in WT 
E. coli. The WT phenotype is also maintained across various peptidase penicillin binding protein knockouts 
as well as the monofunctional murein synthase (opgH) and prc that encodes a periplasmic protease. Cell 
extracts were analysed by Western blotting using anti-ECAM antibodies. 
 
Chapter 5 
118 
 
Class C penicillin binding proteins include endopeptidases such as Pbp7 and 
carboxypeptidases such as Pbp4. The domain that is inhibited by penicillin in these Pbps is 
very similar in structure to the domain found in class A and class B Pbps. WheŶ β-lactams 
such as ampicillin react with Pbps they covalently link to the active site residue of the 
peptidase domain and inactivate catalytic function be it transpeptidase, carboxypeptidase 
or endopeptidase. Our hypothesis was that by adding ampicillin at a concentration just 
above the minimum inhibitory concentration Pbp1C would be chemically `knocked out͛ 
resulting in a similar phenotype as seen in the ΔpbpC strain, with respect to ECAM 
processing (Figure 5-3). On addition of ampicillin there is an increase in intensity of bands 
at 180 and 260 kDa however the cleavage product bands do not disappear indicating 
partial inhibition of Pbp1C function (Figure 5-3). 
 
 
 
Figure 5-4 Chemical inhibition of Pbp1C in WT shows similar phenotypic characteristics seen in ΔpbpC  
Bands at 260 and 180 kDa appear when WT is grown in the presence of a minimum inhibitory concentration 
of ampicillin (4 ug ml-1) indicating less cleavage of ECAM and a build-up of monomer and dimer as seen in 
ΔpbpC. Cell extracts were analysed by Western blotting using anti-ECAM antibodies. 
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5.2.3 PďpϭC eǆpƌessioŶ, ƌefoldiŶg aŶd puƌifiĐatioŶ 
In order to determine if Pbp1C directly interacts with ECAM and is involved in ECAM 
processing I attempted to purify Pbp1C. The gene encoding Pbp1C, pbpC, was cloned 
including an N-terminal 6-histidine tag. The gene amplified by PCR was cloned into 
pET21a using NdeI and XhoI. This plasmid was transformed into BL21(DE3) E. coli cells for 
inducible expression. Cells were grown at 37°C in LB, to an OD600 of 0.6 and 0.1 mM IPTG 
was added to induce Pbp1C expression. Cells were grown for a further four hours and 
lysed. Although Pbp1C was being expressed at high levels these were not soluble and 
even with modification in levels of IPTG and growth temperature, the protein remained 
insoluble as a white inclusion body. Several gradual N-terminal domain truncations were 
cloned in order to attempt to obtain a soluble Pbp1C however these all resulted in similar 
inclusion bodies.  
 
At this time I showed that ampicillin inactivates Pbp1C, therefore I decided to use 
kanamycin as a selection marker (Figure 5-4). The pbpC gene was cloned into pET28a 
which uses kanamycin for selection. However, the protein remained insoluble, forming 
inclusion bodies under various expression conditions.  
 
It was therefore decided to attempt to solubilise, refold and purify Pbp1C from inclusion 
bodies expressed from the plasmid pCF4, consisting of full-length pbpC within the pET28a 
kanamycin vector. The inclusion body was washed using low concentrations of detergent 
and solubilised in 5% sodium lauroyl sarcosinate (sarkosyl), 50 mM Tris-HCl, 200mM NaCl, 
pH 7.5. This solubilised protein was then dialysed into 0.5% Triton X100 50 mM Tris-HCl, 
200mM NaCl, pH 7.5 at 4°C overnight. This protocol resulted in soluble PbpC with a good 
level of purity. However, due to the various problems associated with Triton X100 such as 
significant absorbance at the wavelength used to measure protein concentration (280 
nm), several other detergents were tested. The refolding protocol was performed with 
TWEEN ϮϬ, βOG ;Ŷ-OĐtyl β-D-Glucopyranoside), CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate), DDM (n-DodeĐyl β-D-
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maltoside), deoxycholic acid and LDAO (Lauryldimethylamine oxide) used at the 
respective critical micelle concentrations for dialysis in order to find an alternative 
detergent to triton X100. Detergent solubilised Pbp1C samples were run on an analytical 
S200 size exclusion column to compare how these detergents performed in refolding 
Pbp1C. Equal weights of inclusion body were used with each detergent in order to 
compare refolding yield. The detergents CHAPS, deoxycholic acid and TWEEN 20 all 
resulted in multiple peaks and so were not considered further for refolding. DDM had a 
very low yield and so was also not considered further. The two best candidates for 
refolding Pbp1C were LDAO and BOG. LDAO resulted in a sharp peak and was used for 
future experiments (Figure 5-5).  
 
 
 
Figure 5-5 SEC of LDAO refolded Pbp1C. 
A small analytical S200 column was used to purify Pbp1C refolded using various detergents. Shown is the 
chromatogram of Pbp1C refolded using LDAO (Lauryldimethylamine oxide). Pbp1C runs by SDS-PAGE at a 
molecular weight of approximately 75 kDa. 
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In order to further confirm that Pbp1C had been successfully refolded, circular dichroism 
spectroscopy was performed to estimate secondary structure present using the 
Provencher & Glockner method (Figure 5-6 a)162. YASPIN and Jpred online secondary 
structure prediction servers were used to predict the secondary structure for Pbp1C 
(Figure 5-6 b)189,190. The calculated secondary structure based on CD is 26.6% α-helix and 
25.3% β-sheet. This is in good agreement with the predicted secondary structure of PbpC 
from YASPIN and Jpred. 
 
 
Figure 5-6 Circular dichroism spectroscopy indicates that Pbp1C has native secondary structure. 
 (a) Far-UV spectrum of Pbp1C (6 µM) in 0.05 M sodium phosphate, 0.1% LDAO, pH 7.5 shows that greater 
than 50% of the protein has secondary structure elements. Estimates are based on the average of all 
matching solutions and calculated using the Provencher & Glockner method162. (b) Table showing the 
results from CD calculated secondary structure elements compared to the primary sequence predicted 
secondary structure using the YASPIN and Jpred online servers189,190. 
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Further structural characterisation of Pbp1C that had been refolded with LDAO was 
attempted by SAXS however due to the presence of detergent micelles the data was not 
suitable for analysis. Any attempt to dialyse the LDAO out resulted in aggregation of the 
protein. Crystal screens were also set up at 10 and 20 mg ml-1 Pbp1C using the Molecular 
Dimensions crystallisation screens MORPHEUS®, MIDASTM, JCSG-plus, and PACT premier 
however the few crystals that appeared were salt. 
As Pbp1C was successfully refolded it was decided to see if Pbp1C is directly responsible 
for the cleavage of ECAM observed in vivo by Western blotting. To test this, 2.5 µM of 
Pbp1C was reacted with 2.5 µM of ECAM in 50 mM Tris, 200 mM NaCl, pH 7.5 with 0.1% 
LDAO at room temperature for 15 minutes. This reaction resulted in no apparent cleavage 
of ECAM indicating that there is no cleavage of ECAM by Pbp1C under these conditions 
(Figure 5-7). This lack of cleavage may be due to the fact Pbp1C may not have been 
refolded into an enzymatically active state. The experiment was repeated including a final 
concentration of 1 mM of magnesium, calcium or potassium within the buffer, however 
no cleavage was observed. 
 
Figure 5-7 Refolded Pbp1C shows no processing of ECAM in vitro 
 The combined sample of ECAM with Pbp1C shows the same composition as the proteins individually with 
no cleavage products.  
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5.3 DisĐussioŶ 
The work discussed in this chapter sought to determine if Pbp1C is involved in the 
function of ECAM. Interestingly, deletion of pbpC results in a significant change in ECAM 
processing, such that cleaved ECAM species that are present in WT E. coli are absent in a 
ΔpbpC strain. Instead the bands representing full length and dimeric ECAM, show 
increased intensity. The western blots are performed on denatured samples and so any 
dimers would be expected to denature and appear as a single band, however due to the 
presence of a thioester able to form a covalent linkage, denatured ECAM could be 
covalently binding to a second molecule of ECAM (Figure 5-2). Alternatively, it may be 
that during denaturation of the dimer form seen in solution, this becomes entangled 
resulting in the observed dimer by SDS-PAGE. The covalent binding of ECAM to other 
proteins upon denaturation could also explain the laddering seen between 260 kDa and 
180 kDa (Figure 5-2). The various bands seen between the 180 kDa monomer and 260 
kDa dimer upon deletion of pbpC could be proteins that form a complex with ECAM and 
Pbp1C under normal conditions (Figure 5-2). These proteins, in close proximity to native 
ECAM become covalently bound upon denaturation of ECAM.  
 
The bands seen at 160 kDa and 100 kDa within wildtype cells are cleavage products due 
to the processing of ECAM in vivo and the bait region is where ECAM is cleaved by 
proteases in vitro (Figure 5-2)14. Upon denaturation prior to SDS-PAGE this cleavage 
would result in two fragments of ECAM, the N-terminus to bait region domain and BRD to 
C-terminus (100 kDa and 80 kDa respectively). The bands seen by Western blot using anti-
ECAM antibodies of wild type cells resulted in major bands at 260 kDa, 180 kDa, 160 kDa 
and 100 kDa. As mentioned previously the 260 kDa band could be a dimer of ECAM 
covalently bound via the thioester during denaturation and the 180 kDa band a monomer 
of ECAM. There remains a question of what the 160 kDa and 100 kDa bands consist of? 
From our data showing the knockout of the gene encoding Pbp1C results in the loss of 
cleavage products of ECAM it could be the case that Pbp1C is directly responsible for the 
processing of ECAM. As such, the 160 kDa band could represent Pbp1C (calculated 85 kDa 
by sequence, 75 kDa by SDS-PAGE) covalently bound to the 80 kDa BRD to C-terminus 
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fragment of ECAM (Figure 5.8). The 100 kDa band could represent the N-terminus to BRD 
fragment upon cleavage at the bait region or may be a protease (approximately 20 kDa in 
size) that cleaves ECAM and has been covalently bound to the BRD to C-terminus 
fragment (Figure 5.8).  
 
 
Figure 5-8 Possible composition of bands seen by Western blot. 
The band seen at 260 kDa may be a dimer of two ECAM molecules that have covalently bound by thioester 
bond upon denaturation as they are in close proximity natively. The band seen at 180 kDa is full length 
ECAM. Pbp1C may cleave ECAM at the bait region the 80 kDa C-terminus that contains the thioester 
covalently binds Pbp1C resulting in a 160 kDa complex. As the protein sample has been denatured the 100 
kDa N-terminus of ECAM separates or may be a complex between an unknown protease (~20 kDa in size) 
covalently bound to the C terminal fragment of ECAM. 
 
The possible interaction of ECAM and Pbp1C may constitute a regulation mechanism, 
which through steric hindrance limits aĐĐess to the PďpϭC ͚tƌaŶspeptidase͛ aĐtiǀe site. 
Instead of Pbp1C being a transpeptidase, crosslinking sidechains within the peptidoglycan 
network, the peptidase domain may cleave peptide sidechains similar to a LD- or DD-
CPase. This enzyme could have specificity for the bait region of ECAM allowing 
conformational activation encapsulating Pbp1C, limiting the cleavage of side chains to the 
subunits Pbp1C has incorporated via its transglycosylase domain (Figure 5-9). The 
peptides found at the terminus of the pentapeptide subunit are D-amino acids whereas 
the peptides within ECAM are L-amino acids suggesting that if Pbp1C is cleaving ECAM it 
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would not have enzyme activity for peptidoglycan pentapeptides, however further work 
is required to investigate this. 
 
 
Figure 5-9 Model of how Pbp1C and ECAM function in live cells. 
Pbp1C functioning as a LD- or DD-carboxypeptidase cleaves ECAM resulting in a complex that limits the 
function of Pbp1C to cleave peptides from subunits transported by its transglycosylase (TGase) domain. 
 
 
The refolding of Pbp1C appears to have been successful as CD data show secondary 
structure comparable with that predicted by secondary structure (Figure 5-6). The lack of 
any cleavage of ECAM by refolded Pbp1C however, if cleavage is directly mediated by 
Pbp1C, could indicate that the active site is not functional (Figure 5-7). The requirement 
of detergent in order to keep Pbp1C stable is most likely due to the transglycosylase 
domain normally interacting with the membrane. The lack of any cleavage of ECAM by 
refolded Pbp1C adds evidence against its direct involvement in ECAM processing, and 
further work is required to confirm or disprove the hypothesis that Pbp1C directly cleaves 
ECAM. As the peptidase domain may be involved with the cleavage of peptides from 
peptidoglycan, it may be possible to purify this isolated domain as a soluble protein to 
directly test this hypothesis. 
 
Chapter 6 
126 
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OŶe ďƌaŶĐh of the αϮM supeƌfaŵily aƌe pƌotease iŶhiďitoƌs that act by covalently linking 
to the attacking protease and sterically hindering its ability to bind substrate. ECAM is a 
ŵeŵďeƌ of this ďƌaŶĐh of αϮM fouŶd iŶ E. coli that has been predicted to form a defence 
and repair mechanism alongside Pbp1C, a protein involved in peptidoglycan synthesis6,67.  
 
Using analytical ultracentrifugation sedimentation velocity we have shown that unreacted 
ECAM exists in a monomer-dimer equilibrium (Figure 3-2 b, 3-3, 3-4, 3-5). Both the ECAM 
monomer and dimer are more elongated in solution when compared to the native crystal 
model of SaA2M, a Salmonella enterica homologue of ECAM (Table 3-2). Further 
investigation of the monomer and dimer of ECAM by SAXS confirms the presence of a 
monomer and dimer species in solution that is more elongated than the crystal dimer of 
SaA2M (Table 3-2).   
 
There remains a question of why ECAM exists in a monomer-dimer equilibrium within the 
periplasm. The bait region within the dimer high resolution model of SaA2M is buried, 
forming an interface with the MG domains (MG1 and MG2) involved in binding to the 
membrane (Figure 6-1 a). Since in the SaA2M dimer structure these MG domains block 
access to the bait region the dimer form is most likely an inactive form, perhaps acting as 
a reservoir available to replace cleaved monomeric ECAM (Figure 6-1 b). 
 
Chapter 6 
128 
 
 
Figure 6-1 Availability of bait region for cleaving proteases. 
Surface representation of SaA2M as dimer with main MG body coloured grey, MG6 arm coloured green, 
TED arm coloured blue and bait region coloured red. (a) SaA2M dimer showing the limited availability of the 
bait region in the dimer. (b) SaA2M monomer with a bait region clear of obstruction. (PDB: 4U4814) 
 
 
Although attempts to crystallise a native unreacted form of ECAM were unsuccessful, 
crystals of elastase cleaved ECAM were obtained (Figure 4-2 a). This protease-activated 
form not only matches the domain orientation of the small molecule activated form of 
HA2M but also has an almost identical domain arrangement to trypsin activated ECAM 
with only a small amount of movement apparent by the TED (Figure 4-7 a, 4-18 a). 
Although no evidence could be found that crystals of porcine elastase activated ECAM 
contained elastase within the lattice, trypsin activated ECAM contains trypsin within its 
crystal lattice although the protease is not ordered enough to give strong diffraction187.  
The difference in orientation of the TED between trypsin and elastase activated structures 
may be due to trypsin being bound to this domain. SAXS analysis of ECAM cleaved by 
chymotrypsin resulted in a low resolution envelope that appears very similar to the high 
resolution model of ECAM reacted with porcine elastase (Figure 4-15, Table 4-4). Further, 
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the CRYSOL curve generated for porcine elastase reacted ECAM closely resembles the 
experimental scattering curve for ECAM reacted with chymotrypsin (Figure 4-14)180. This 
shows that upon protease cleavage a similar conformational change occurs regardless of 
the protease that cleaves ECAM.   
 
In porcine elastase cleaved ECAM, the cleaved bait region interacts with the CTMG. 
Importantly this interaction includes a residue that normally interacts with the TED to 
form a hydrophobic pocket that protects the thioester from solvent (Figure 4-17). The 
interaction of the cleaved bait region with the CTMG is also seen in trypsin activated 
ECAM187. The presence of this interaction between CTMG and cleaved bait region in both 
high resolution models of cleaved ECAM (trypsin and porcine elastase cleaved ECAM) 
adds further evidence that the disruption of the TED-CTMG interaction is the trigger for 
ĐoŶfoƌŵatioŶal aĐtiǀatioŶ iŶ ŵeŵďeƌs of the αϮM family (Figure 4-18 b).  
 
Previous work has suggested that ECAM functions alongside Pbp1C as a protease inhibitor 
that defends against host proteases breaching the outer-membrane with Pbp1C repairing 
any damage to the peptidoglycan6,67. In this work it was shown that Pbp1C is involved in 
ECAM processing, although a direct effect could not be demonstrated in vitro. We show 
that in wild type cells cleavage of ECAM occurs in the absence of exogenous proteases 
(Figure 5-2). The cleavage products seen in wildtype ECAM are not observed in a strain 
lacking pbpC but return upon complementation of the ΔpbpC with plasmid based pbpC 
(Figure 5-2). The loss of these breakdown products in this deletion mutant could indicate 
that Pbp1C is involved in the regulation of ECAM. The lack of any interaction seen upon 
addition of ECAM to refolded Pbp1C suggests that the relationship is indirect; however, 
the lack of interaction may be due to incorrect/incomplete refolding of Pbp1C. It could 
also be suggested that Pbp1C cleaves ECAM in vivo at the bait region forming a complex 
between the two (Figure 5-8). The band seen at 160 kDa could be the complex between 
Pbp1C and the C-terminal ECAM fragment (that contains a thioester covalently linking 
both) and the band at 100 kDa could be the remaining N-terminal fragment (Figure 5-8). 
Similaƌ to αϮM, ECAM has ďeeŶ shoǁŶ to iŶhiďit pƌoteases thƌough ĐoǀaleŶtly ďiŶdiŶg to 
the cleaving protease and restricting the proteases access to larger substrates, however 
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allowing access to small substrates67. If the hypothesis that ECAM forms a complex with 
Pbp1C is correct then ECAM may act as a regulator of Pbp1C function, limiting access of 
certain substrates to the active site (Figure 6-2). Although the suggestion of Pbp1Cs 
cleavage ECAM could explain the observed processing of ECAM further work is required 
to confirm if this is the case (Figure 6-2). To confirm that Pbp1C is able to cleave ECAM, 
mutagenesis on the active sites of the transpeptidase and transglycosylase domains could 
be performed. 
 
 
 
Figure 6-2 Model of ECAM reacting with Pbp1C and proteases. 
Native monomer ECAM available for cleavage could react with Pbp1C limiting its function to small subunits 
or inhibition of invading protease. 
 
References 
131 
 
 
 
  
 
 
 
7 RefereŶĐes 
 
 
 
 
 
 
 
  
References 
132 
 
1. Barrett, A. J. & Starkey, P. M. The Interaction of a-2-Macroglobulin with 
Proteinases. J. Biochem. 133, 709–724 (1973). 
2. With, C., Westergaardg, J. G. & Sottrup-jensensli, L. Characterization of Human 
Pregnancy Zone Protein. J. Biol. Chem. 260, 15723–15735 (1985). 
3. Lin, M. Cell surface antigen CD109 is a novel member of the alpha 2 
macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99, 1683–
1691 (2002). 
4. Li, Z.-F., Wu, X. & Engvall, E. Identification and characterization of CPAMD8, a novel 
member of the complement 3/alpha2-macroglobulin family with a C-terminal Kazal 
domain. Genomics 83, 1083–93 (2004). 
5. Galliano, M.-F. et al. A novel protease inhibitor of the alpha2-macroglobulin family 
expressed in the human epidermis. J. Biol. Chem. 281, 5780–9 (2006). 
6. Budd, A. et al.  BaĐteƌial αϮ-macroglobulins: colonization factors acquired by 
horizontal gene transfer from the metazoan genome? Genome Biol. 5, R38 (2004). 
7. de Bruijn, M. H. & Fey, G. H. Human complement component C3: cDNA coding 
sequence and derived primary structure. Proc. Natl. Acad. Sci. U. S. A. 82, 708–712 
(1985). 
8. Blanchong, C. a. et al. Genetic, structural and functional diversities of human 
complement components C4A and C4B and their mouse homologues, Slp and C4. 
Int. Immunopharmacol. 1, 365–392 (2001). 
9. Tack, B. F. et al.  Fifth component of human complement: purification from plasma 
and polypeptide chain structure. Biochemistry 18, 1490–1497 (1979). 
10. Baxter, R. H. G. et al. Structural basis for conserved complement factor-like 
function in the antimalarial protein TEP1. Proc. Natl. Acad. Sci. U. S. A. 104, 11615–
11620 (2007). 
11. Sottrup-Jensen, L. et al. Common evolutionary origin of a2-macroglobulin and 
complement components C3 and C4. Proc Natl Acad Sci USA 82, 9–13 (1985). 
12. Dodds, A. W. & Law, S. K. A. The phylogeny and evolution of the thioester bond-
containing proteins. Immunol. Rev. 166, 15–26 (1998). 
13. Marrero, A. et al. The Đƌystal stƌuĐtuƌe of huŵaŶ αϮ-macroglobulin reveals a 
unique molecular cage. Angew. Chemie - Int. Ed. 51, 3340–3344 (2012). 
14. Wong, S. G. & DesseŶ, A. “tƌuĐtuƌe of a ďaĐteƌial αϮ-macroglobulin reveals mimicry 
of eukaryotic innate immunity. Nat. Commun. 5, 4917 (2014). 
15. Le, B. V., Williams, M. et al.  Molecular Basis for Genetic Resistance of Anopheles 
gambiae to Plasmodium: Structural Analysis of TEP1 Susceptible and Resistant 
Alleles. PLoS Pathog. 8, (2012). 
16. Sottrup-Jensen, L. a-Macroglobulins: Structure, Shape, and Mechanism of 
Proteinase Complex Formation. J. Biol. Chem. 264, 11539–11542 (1989). 
17. G. S. Salvesen & J. Travis. Human plasma proteinase inhibitors. Biochem. Annu. Rev. 
110, 256–261 (1983). 
References 
133 
 
18. Cohn, E. J. & Strong, L. E. Preparation and properties of serum and plasma proteins; 
a system for the separation into fractions of the protein and lipoprotein 
components of biological tissues and fluids. J. Am. Chem. Soc. 68, 459–475 (1946). 
19. Cassiman, J. & Berghe, H. Van Den. Human Pregnancy Zone Protein and alpha-2-
Macroglobulin. J. Biol. Chem. 261, 16622–16625 (1986). 
20. Barrett, B. A. J. et al.  The EleĐtƌophoƌetiĐally ͛ “loǁ ͛ aŶd ͛ Fast ͛ Foƌŵs of the aoϮ-
Macroglobulin Molecule. Biochem. J. 181, 401–418 (1979). 
21. Enghild, J. J. et al.  PƌoteiŶase ďiŶdiŶg aŶd iŶhiďitioŶ ďy the ŵoŶoŵeƌiĐ α-
ŵaĐƌogloďuliŶ ƌat αϭ-inhibitor-3. J. Biol. Chem. 264, 11428–11435 (1989). 
22. Sottrup-Jensen, L. et al.  The a-Macroglobulin Bait Region. J. Biol. Chem. 264, 
15781–15789 (1989). 
23. Sottrup-Jensen, L. et al.  A THIOL-ESTER IN a2-MACROGLOBULIN CLEAVED DURING 
PROTEINASE COMPLEX FORMATION. FEBS Lett. 121, 275–279 (1980). 
24. Armstrong, P. B. & Quigley, J. P. a 2 -ŵaĐƌogloďuliŶ : aŶ eǀolutioŶaƌily ĐoŶseƌǀed 
arm of the innate immune system. Dev. Comp. Immunol. 23, 375–390 (1999). 
25. Tapon-bretaudiere, J. et al.  Electron microscopy of the conformational changes of 
alpha 2-macroglobulin from human plasma. EMBO J. 4, 85–89 (1985). 
26. Huang, W. et al.  P. G. Localization of basic residues required for receptor binding 
to the single alpha-helix of the receptor binding domain of human alpha2-
macroglobulin. Protein Sci. 7, 2602–2612 (1998). 
27. Raymond, W. W. et al. alpha(2)-Macroglobulin Capture Allows Detection of Mast 
Cell Chymase in Serum and Creates a Reservoir of Angiotensin II-Generating 
Activity. J. Immunol. 182, 5770–5777 (2009). 
28. WICHER, V. & DOLOVICH, J. et al. INTERACTIONS OF BACILLUS-SUBTILIS ALKALINE 
PROTEINASES WITH A2-MACROGLOBULIN AND A1-ANTITRYPSIN. Int. Arch. Allergy 
Appl. Immunol. 40, 779–780 (1971). 
29. Peslova, G. et al. Hepcidin, the hormone of iron metabolism, is bound specifically 
to alpha-2-macroglobulin in blood. Blood 113, 6225–6236 (2009). 
30. Sarma, J. V. & Ward, P. a. The Compliment System. NIH Public Access author 
Manuscr. 343, 227–235 (2012). 
31. Hee, C. K. et al.  Regenerative Tendon and Ligament Healing: Opportunities with 
Recombinant Human Platelet-Derived Growth Factor BB-Homodimer. TISSUE Eng. 
PART B-REVIEWS 18, 225–234 (2012). 
32. Bramanti, V. et al. Astroglial-conditioned media and growth factors modulate 
proliferation and differentiation of astrocytes in primary culture. Neurochem. Res. 
32, 49–56 (2007). 
33. Nancey, S. et al. Serum interleukin-6, soluble interleukin-ϲ ƌeĐeptoƌ aŶd CƌohŶ͛s 
disease activity. Dig. Dis. Sci. 53, 242–247 (2008). 
34. Wiesmann, C. et al. Structure of C3b in complex with CRIg gives insights into 
regulation of complement activation. Nature 444, 217–220 (2006). 
References 
134 
 
35. Bork, P. & Beckmann, G. The CUB Domain A widespread module in 
developmentally regulated proteins. J. Mol. Biol. 231, 539–545 (1993). 
36. Doan, N. & Gettins, P. G. W. Human alpha2-macroglobulin is composed of multiple 
domains, as predicted by homology with complement component C3. Biochem. J. 
407, 23–30 (2007). 
37. Law, S. K. & Dodds,  a W. The internal thioester and the covalent binding properties 
of the complement proteins C3 and C4. Protein Sci. 6, 263–274 (1997). 
38. Ikai, A. et al.  A ƌeĐoŵďiŶaŶt ďait ƌegioŶ ŵutaŶt of huŵaŶ α Ϯ-macroglobulin 
exhibiting an altered proteinase-inhibiting spectrum. Cytotechnology 31, 53–60 
(1999). 
39. Van Rompaey, L. et al.  Design of a new protease inhibitor by the manipulation of 
the bait region of a-2-macroglobulin: inhibition of the tobacco etch virus protease 
by mutant a-2-macroglobulin. Biochem. J. 195, 191–195 (1995). 
40. Hoffmann, J. A. et al.  R. A. B. Phylogenetic perspectives in innate immunity. 
Science (80-. ). 284, 1313–1318 (1999). 
41. Medzhitov, R. & Janeway, C. Innate immune recognition: mechanisms and 
pathways. Immunol. Rev. 173, 89–97 (2000). 
42. Walport, M. J. Advances in immunology: Complement (First of two parts). N. Engl. 
J. Med. 344, 1058–1066 (2001). 
43. Walport, M. J. Advances in immunology: Complement (Second of two parts). N. 
Engl. J. Med. 344, 1140–1144 (2001). 
44. Janssen, B. J. C. et al. Structures of complement component C3 provide insights 
into the function and evolution of immunity. Nature 437, 505–511 (2005). 
45. Kidmose, R. T. et al. Structural basis for activation of the complement system by 
component C4 cleavage. Proc. Natl. Acad. Sci. U. S. A. 109, 15425–15430 (2012). 
46. Ricklin, D. & Lambris, J. D. Complement-targeted therapeutics. Nat. Biotechnol. 25, 
1265–1275 (2007). 
47. Mizuno, Y. et al.  ISOLATION AND CHARACTERIZATION OF A MANNAN-BINDING 
PROTEIN FROM RAT-LIVER. J. Biol. Chem. 256, 4247–4252 (1981). 
48. Drickamer, K. et al.  L. MANNOSE-BINDING PROTEINS ISOLATED FROM RAT-LIVER 
CONTAIN CARBOHYDRATE-RECOGNITION DOMAINS LINKED TO COLLAGENOUS 
TAILS - COMPLETE PRIMARY STRUCTURES AND HOMOLOGY WITH PULMONARY 
SURFACTANT APOPROTEIN. J. Biol. Chem. 261, 6878–6887 (1986). 
49. Ezekowitz, R. A. B. et al.  A HUMAN MANNOSE-BINDING PROTEIN IS AN ACUTE-
PHASE REACTANT THAT SHARES SEQUENCE HOMOLOGY WITH OTHER VERTEBRATE 
LECTINS. J. Exp. Med. 167, 1034–1046 (1988). 
50. Turner, M. W. Mannose-binding lectin: The pluripotent molecule of the innate 
immune system. Immunol. Today 17, 532–540 (1996). 
51. Matsushita, M. & Fujita, T. Ficolins and the lectin complement pathway. Immunol. 
Rev. 180, 78–85 (2001). 
References 
135 
 
52. Fujimori, Y. et al. Molecular cloning and characterization of mouse ficolin-A. 
Biochem. Biophys. Res. Commun. 244, 796–800 (1998). 
53. Gorski, J. P. et al.  Characterization of human C4a anaphylatoxin. J. Biol. Chem. 256, 
2707–2711 (1981). 
54. Dahl, M. R. et al. MASP-3 and its association with distinct complexes of the 
mannan-binding lectin complement activation pathway. Immunity 15, 127–135 
(2001). 
55. Kishore, U. & Reid, K. B. M. C1q: structure, function, and receptors. 
Immunopharmacology 49, 159–170 (2000). 
56. Strainic, M. G. et al. Locally produced complement fragments C5a and C3a provide 
both costimulatory and survival signals to naive CD4(+) T cells. Immunity 28, 425–
435 (2008). 
57. Gorski, J. P. et al.  C4a: the third anaphylatoxin of the human complement system. 
Proc. Natl. Acad. Sci. U. S. A. 76, 5299–5302 (1979). 
58. Klos, A. et al. The role of the anaphylatoxins in health and disease. Mol. Immunol. 
46, 2753–2766 (2009). 
59. Guo, R. F. et al.  Role of C5a-C5aR interaction in sepsis. Shock 21, 1–7 (2004). 
60. Huber-Lang, M. et al. Generation of C5a by phagocytic cells. Am. J. Pathol. 161, 
1849–1859 (2002). 
61. Okinaga, S. et al. C5L2, a nonsignaling C5A binding protein. Biochemistry 42, 9406–
9415 (2003). 
62. Flierl, M. A. et al. Functions of the complement components C3 and C5 during 
sepsis. Faseb J. 22, 3483–3490 (2008). 
63. Sarma, V. J. et al.  Complement in lung disease. Autoimmunity 39, 387–394 (2006). 
64. Janssen, B. J. C. et al.  Structure of C3b reveals conformational changes that 
underlie complement activity. Nature 444, 213–216 (2006). 
65. Starkey, P. M. & Barrett,  a J. Evolution of alpha 2-macroglobulin. The 
demonstration in a variety of vertebrate species of a protein resembling human 
alpha 2-macroglobulin. Biochem. J. 205, 91–95 (1982). 
66. Budd, A. et al.  Bacterial alpha2-macroglobulins: colonization factors acquired by 
horizontal gene transfer from the metazoan genome? Genome Biol. 5, R38 (2004). 
67. Doan, N. & Gettins, P. G. W. alpha-Macroglobulins are present in some gram-
negative bacteria: characterization of the alpha2-macroglobulin from Escherichia 
coli. J. Biol. Chem. 283, 28747–56 (2008). 
68. Robert-Genthon, M. et al. Unique features of a Pseudomonas aerugiŶosa αϮ-
macroglobulin homolog. MBio 4, (2013). 
69. Roux, A. et al.  Combined Inactivation and Expression Strategy To Study Gene 
FuŶĐtioŶ uŶdeƌ PhysiologiĐal CoŶditioŶs : AppliĐatioŶ to IdeŶtifiĐatioŶ of Neǁ 
Escherichia coli Adhesins. J. Bacteriol. 187, 1001–1013 (2005). 
70. Blaschkowski, H. P. et al.  Routes of Flavodoxin and Ferredoxin Reduction in 
References 
136 
 
Escherichia coli. Eur. J. Biochem. 123, 563–569 (1982). 
71. Blattner, F. R. The Complete Genome Sequence of Escherichia coli K-12. Science 
(80-. ). 277, 1453–1462 (1997). 
72. Winsor, G. L. et al. Pseudomonas Genome Database: improved comparative 
analysis and population genomics capability for Pseudomonas genomes. Nucleic 
Acids Res. 39, D596–D600 (2011). 
73. Goodman, A. L. et al. A signaling network reciprocally regulates genes associated 
with acute infection and chronic persistence in Pseudomonas aeruginosa. Dev. Cell 
7, 745–754 (2004). 
74. Ventre, I. et al. Multiple sensors control reciprocal expression of Pseudomonas 
aeruginosa regulatory RNA and virulence genes. Proc. Natl. Acad. Sci. U. S. A. 103, 
171–176 (2006). 
75. Basler, M. & Mekalanos, J. J. Type 6 Secretion Dynamics Within and Between 
Bacterial Cells. Science (80-. ). 337, 815 (2012). 
76. Schwarz, S. et al.  What is type VI secretion doing in all those bugs? TRENDS 
Microbiol. 18, 531–537 (2010). 
77. Neves, D. et al. CoŶfoƌŵatioŶal states of a ďaĐteƌial αϮ-macroglobulin resemble 
those of human complement C3. PLoS One 7, e35384 (2012). 
78. Pointon, J. a. et al. A highly unusual thioester bond in a pilus adhesin is required for 
efficient host cell interaction. J. Biol. Chem. 285, 33858–33866 (2010). 
79. Mandlik, A. et al.  Pili in Gram-positive bacteria: assembly, involvement in 
colonization and biofilm development. Trends Microbiol. 16, 33–40 (2008). 
80. Telford, J. L. et al.  Pili in Gram-positive pathogens. Nat Rev Micro 4, 509–519 
(2006). 
81. Waksman, G. & Hultgren, S. J. Structural biology of the chaperone– usher pathway 
of pilus biogenesis. Nat. rev. Microbiol. 7, 765–774 (2009). 
82. Linke-Winnebeck, C. et al. Structural model for covalent adhesion of the 
Streptococcus pyogenes pilus through a thioester bond. J.Biol.Chem. 289, 177–189 
(2014). 
83. Dodds, A. W. et al.  The reaction mechanism of the internal thioester in the human 
complement component C4. Nature 379, 177–179 (1996). 
84. Sauvage, E. et al.  The penicillin-binding proteins: Structure and role in 
peptidoglycan biosynthesis. FEMS Microbiol. Rev. 32, 234–258 (2008). 
85. Guinane, C. M. et al.  Contribution of penicillin-binding protein homologs to 
antibiotic resistance, cell morphology, and virulence of Listeria monocytogenes 
EGDe. Antimicrob. Agents Chemother. 50, 2824–2828 (2006). 
86. Massova, I. & Mobashery, S. MINIREVIEW Kinship and Diversification of Bacterial 
Penicillin-Binding Proteins and ␤ -Lactamases. Antimicrob. Agents Chemother. 42, 
1–17 (1998). 
87. Macheboeuf, P. et al.  Penicillin binding proteins: key players in bacterial cell cycle 
References 
137 
 
and drug resistance processes. FEMS Microbiol. Rev. 30, 673–691 (2006). 
88. Vollmer, W. et al.  Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol. 
Rev. 32, 259–286 (2008). 
89. Yousif, S. Y. et al.  G. Lysis of EsĐheƌiĐhia Đoli ďy β-lactam antibiotics: deletion 
analysis of the role of penicillin-binding proteins 1A and 1B. J. Gen. Microbiol. 131, 
2839–2845 (1985). 
90. Von Rechenberg, M. et al. Ampicillin/penicillin-binding protein interactions as a 
model drug-target system to optimize affinity pull-down and mass spectrometric 
strategies for target and pathway identification. Proteomics 5, 1764–73 (2005). 
91. Vollmer, W. et al. Demonstration of molecular interactions between the murein 
polymerase PBP1B, the lytic transglycosylase MltA, and the scaffolding protein 
MipA of Escherichia coli. J. Biol. Chem. 274, 6726–6734 (1999). 
92. Barbosa, M. et al.  Development of a whole-cell assay for peptidoglycan 
biosynthesis inhibitors. Antimicrob. Agents Chemother. 46, 943–946 (2002). 
93. Bearne, S. L. & Blouin, C. Inhibition of Escherichia coli glucosamine-6 phosphate 
synthase by reactive intermediate analogues - The role of the 2-amino function in 
catalysis. J. Biol. Chem. 275, 135–140 (2000). 
94. Badet-Denisot, M. A. et al.  Characterization of L-glutamine:D-fructose-6-
phosphate amidotransferase from an extreme thermophile Thermus thermophilus 
HB8. Arch. Biochem. Biophys. 337, 129–136 (1997). 
95. Bearne, S. L. Active site-directed inactivation of Escherichia coli glucosamine-6-
phosphate synthase - Determination of the fructose 6-phosphate binding constant 
using a carbohydrate-based inactivator. J. Biol. Chem. 271, 3052–3057 (1996). 
96. Badet-denisot, M. A. et al.  MECHANISTIC INVESTIGATIONS ON GLUCOSAMINE-6-
PHOSPHATE SYNTHASE. Bull. Soc. Chim. Fr. 130, 249–255 (1993). 
97. Branstrom, A. A. et al.  In situ assay for identifying inhibitors of bacterial 
transglycosylase. Fems Microbiol. Lett. 191, 187–190 (2000). 
98. Atrih, A. et al.  Structural analysis of Bacillus subtilis 168 endospore peptidoglycan 
and its role during differentiation. J. Bacteriol. 178, 6173–6183 (1996). 
99. Benson, T. E. et al.  The structure of the substrate-free form of MurB, an essential 
enzyme for the synthesis of bacterial cell walls. Structure 4, 47–54 (1996). 
100. Mengin-Lecreulx, D. et al.  Identification of the mpl gene encoding UDP-N-
acetylmuramate: L-alanyl-gamma-D-glutamyl-meso-diaminopimelate ligase in 
Escherichia coli and its role in recycling of cell wall peptidoglycan. J. Bacteriol. 178, 
5347–5352 (1996). 
101. Azzolina, B. A. et al.  The cell wall and cell division gene cluster in the Mra operon 
of Pseudomonas aeruginosa: Cloning, production, and purification of active 
enzymes. Protein Expr. Purif. 21, 393–400 (2001). 
102. Anderson, M. S. et al.  Kinetic mechanism of the Escherichia coli UDPMurNAc-
tripeptide D-alanyl-D-alanine-adding enzyme: Use of a glutathione S-transferase 
fusion. Biochemistry 35, 16264–16269 (1996). 
References 
138 
 
103. VanHeijenoort, Y. et al.  MEMBRANE INTERMEDIATES IN THE PEPTIDOGLYCAN 
METABOLISM OF ESCHERICHIA-COLI - POSSIBLE ROLES OF PBP-1B AND PBP-3. J. 
Bacteriol. 174, 3549–3557 (1992). 
104. Ha, S. H. A. et al.  The 1 . 9 Å crystal structure of Escherichia coli MurG , a 
membrane-associated glycosyltransferase involved in peptidoglycan biosynthesis. 
Protein Sci. 9, 1045–1052 (2000). 
105. Mohammadi, T. The essential peptidoglycan glycosyltransferase MurG forms a 
complex with proteins involved in lateral envelope growth as well as with proteins 
involved in cell division in Escherichia coli. Mol. Microbiol. 65, 1106–1121 (2007). 
106. Lok-To, S. et al. MurJ is the flippase of lipid-linked precursors for peptidoglycan 
biogenesis. Science (80-. ). 719, 220–222 (2014). 
107. Typas, A. et al.  From the regulation of peptidoglycan synthesis to bacterial growth 
and morphology. Nat. Rev. Microbiol. 10, 123–36 (2012). 
108. Vollmer, W. & Bertsche, U. Murein (peptidoglycan) structure, architecture and 
biosynthesis in Escherichia coli. Biochim. Biophys. Acta 1778, 1714–1734 (2008). 
109. Izaki, K., Matsuhas.M & Stroming.Jl. BIOSYNTHESIS OF PEPTIDOGLYCAN OF 
BACTERIAL CELL WALLS .13. PEPTIDOGLYCAN TRANSPEPTIDASE AND D-ALANINE 
CARBOXYPEPTIDASE - PENICILLIN-SENSITIVE ENZYMATIC REACTION IN STRAINS OF 
ESCHERICHIA COLI. J. Biol. Chem. 243, 3180–& (1968). 
110. Typas, A. et al. Regulation of peptidoglycan synthesis by outer-membrane proteins. 
Cell 143, 1097–109 (2010). 
111. Hoeltje, J. V. et al.  U. Novel type of murein transglycosylase in Escherichia coli. J. 
Bacteriol. 124, 1067–1076 (1975). 
112. Contreras-Martel, C. et al. Crystal structure of penicillin-binding protein 1a (PBP1a) 
reveals a mutational hotspot implicated in beta-lactam resistance in Streptococcus 
pneumoniae. J. Mol. Biol. 355, 684–96 (2006). 
113. Bertsche, U. et al. Interaction between two murein (peptidoglycan) synthases, 
PBP3 and PBP1B, in Escherichia coli. Mol. Microbiol. 61, 675–690 (2006). 
114. Derouaux, A. et al. The monofunctional glycosyltransferase of Escherichia coli 
localizes to the cell division site and interacts with penicillin-binding protein 3, 
FtsW, and FtsN. J. Bacteriol. 190, 1831–4 (2008). 
115. Hoskins, J. et al. Gene disruption studies of penicillin-binding proteins 1a, 1b, and 
2a in Streptococcus pneumoniae. J. Bacteriol. 181, 6552–6555 (1999). 
116. Vats, P. et al.  Assembly of the MreB-associated cytoskeletal ring of Escherichia coli. 
Mol. Microbiol. 72, 170–182 (2009). 
117. Wientjes, F. B. & Nanninga, N. ON THE ROLE OF THE HIGH-MOLECULAR-WEIGHT 
PENICILLIN-BINDING PROTEINS IN THE CELL-CYCLE OF ESCHERICHIA-COLI. Res. 
Microbiol. 142, 333–344 (1991). 
118. Holtje, J. V. Molecular interplay of murein synthases and murein hydrolases in 
Escherichia coli. Microb. Drug Resist. 2, 99–103 (1996). 
119. Lefevre, F. et al.  Topographical and functional investigation of Escherichia coli 
References 
139 
 
penicillin-binding protein 1b by alanine stretch scanning mutagenesis. J. Bacteriol. 
179, 4761–4767 (1997). 
120. Lovering, A. L. et al.  “tƌuĐtuƌal aŶalysis of aŶ ͚opeŶ͛ foƌŵ of PBPϭB fƌoŵ 
Streptococcus pneumoniae. Protein Sci. 15, 1701–1709 (2006). 
121. Meisel, U. et al.  Overproduction of inactive variants of the murein synthase PBP1B 
causes lysis in Escherichia coli. J. Bacteriol. 185, 5342–5348 (2003). 
122. Paik, J. et al.  Mutational analysis of the Streptococcus pneumoniae bimodular class 
a penicillin-binding proteins. J. Bacteriol. 181, 3852–3856 (1999). 
123. Ho, J. et al.  Cloning and Characterization of PBP 1C , a Third Member of the 
Multimodular Class A Penicillin-binding Proteins of Escherichia coli *. J. Biol. Chem. 
274, 32031–32039 (1999). 
124. Goffin, C. & Ghuysen, J. M. Multimodular penicillin binding proteins: An enigmatic 
family of orthologs and paralogs. Microbiol. Mol. Biol. Rev. 62, 1079–+ (1998). 
125. Morlot, C. et al. Crystal structure of a peptidoglycan synthesis regulatory factor 
(PBP3) from Streptococcus pneumoniae. J. Biol. Chem. 280, 15984–15991 (2005). 
126. Wissel, M. C. & Weiss, D. S. Genetic analysis of the cell division protein FtsI (PBP3): 
amino acid substitutions that impair septal localization of FtsI and recruitment of 
FtsN. J. Bacteriol. 186, 490–502 (2004). 
127. Denome, S. A. et al.  Escherichia coli mutants lacking all possible combinations of 
eight penicillin binding proteins: Viability, characteristics, and implications for 
peptidoglycan synthesis. J. Bacteriol. 181, 3981–3993 (1999). 
128. Van Asselt, E. J. et al.  High resolution crystal structures of the Escherichia coli lytic 
transglycosylase Slt70 and its complex with a peptidoglycan fragment. J. Mol. Biol. 
291, 877–898 (1999). 
129. Thunnissen, A. et al. DOUGHNUT-SHAPED STRUCTURE OF A BACTERIAL 
MURAMIDASE REVEALED BY X-RAY CRYSTALLOGRAPHY. Nature 367, 750–754 
(1994). 
130. Uehara, T. & Park, J. T. Identification of MpaA, and amidase in Escherichia coli that 
hydrolyzes the gamma-D-glutamyl-meso-diaminopimelate bond in murein 
peptides. J. Bacteriol. 185, 679–682 (2003). 
131. Potluri, L. Septal and lateral wall localization of PBP5, the major D,D-
carboxypeptidase of Escherichia coli, requires substrate recognition and membrane 
attachment. Mol. Microbiol. 77, 300–323 (2010). 
132. Fukushima, T. et al.  Characterization of new L,D-endopeptidase gene product CwlK 
(previous YcdD) that hydrolyzes peptidoglycan in Bacillus subtilis. Mol. Genet. 
Genomics 278, 371–383 (2007). 
133. Thunnissen, A. et al.  THE CATALYTIC DOMAIN OF A BACTERIAL LYTIC 
TRANSGLYCOSYLASE DEFINES A NOVEL CLASS OF LYSOZYMES. Proteins-Structure 
Funct. Genet. 22, 245–258 (1995). 
134. Reid, C. W. et al.  Inhibition of membrane-bound lytic transglycosylase B by NAG-
thiazoline. Febs Lett. 574, 73–79 (2004). 
References 
140 
 
135. Van Straaten, K. E. et al.  Crystal structure of MltA from Escherichia coli reveals a 
unique lytic transglycosylase fold. J. Mol. Biol. 352, 1068–1080 (2005). 
136. Van Asselt, E. J. et al.  Crystallographic studies of the interactions of Escherichia coli 
lytic transglycosylase Slt35 with peptidoglycan. Biochemistry 39, 1924–1934 (2000). 
137. Bateman, A. & Bycroft, M. The structure of a LysM domain from E-coli membrane-
bound lytic murein transglycosylase D (MltD). J. Mol. Biol. 299, 1113–1119 (2000). 
138. Von Rechenberg, M. et al. Affinity chromatography as a means to study 
multienzyme complexes involved in murein synthesis. Microb. Drug Resist. 2, 155–
157 (1996). 
139. Izaki, K., Matsuhas.M & Stroming.Jl. GLYCOPEPTIDE TRANSPEPTIDASE AND D-
ALANINE CARBOXYPEPTIDASE - PENICILLIN-SENSITIVE ENZYMATIC REACTIONS. 
Proc. Natl. Acad. Sci. U. S. A. 55, 656–& (1966). 
140. Keck, W. & Schwarz, U. ESCHERICHIA-COLI MUREIN-DD-ENDOPEPTIDASE 
INSENSITIVE TO BETA-LACTAM ANTIBIOTICS. J. Bacteriol. 139, 770–774 (1979). 
141. Keck, W. et al.  CLONING AND CHARACTERIZATION OF MEPA, THE STRUCTURAL 
GENE OF THE PENICILLIN-INSENSITIVE MUREIN ENDOPEPTIDASE FROM 
ESCHERICHIA-COLI. Mol. Microbiol. 4, 209–219 (1990). 
142. Kishida, H. et al. Crystal structure of penicillin binding protein 4 (dacB) from 
Escherichia coli, both in the native form and covalently linked to various antibiotics. 
Biochemistry 45, 783–792 (2006). 
143. Romeis, T. & Holtje, J. V. SPECIFIC INTERACTION OF PENICILLIN-BINDING PROTEIN-
3 AND PROTEIN-7/8 WITH SOLUBLE LYTIC TRANSGLYCOSYLASE IN ESCHERICHIA-
COLI. J. Biol. Chem. 269, 21603–21607 (1994). 
144. Romeis, T. & Holtje, J. V. PENICILLIN-BINDING PROTEIN-7/8 OF ESCHERICHIA-COLI 
IS A DD-ENDOPEPTIDASE. Eur. J. Biochem. 224, 597–604 (1994). 
145. Harris, F. et al.  Investigations into the mechanisms used by the C-terminal anchors 
of Escherichia coli penicillin-binding proteins 4, 5, 6 and 6b for membrane 
interaction. Eur. J. Biochem. 269, 5821–5829 (2002). 
146. Heidrich, C. Involvement of N-acetylmuramyl-L-alanine amidases in cell separation 
and antibiotic-induced autolysis of Escherichia coli. Mol. Microbiol. 41, 167–178 
(2001). 
147. Uehara, T. & Park, J. T. An anhydro-N-acetylmuramyl-L-alanine amidase with broad 
specificity tethered to the outer membrane of Escherichia coli. J. Bacteriol. 189, 
5634–5641 (2007). 
148. Weidel, W. & Pelzer, H. Bagshaped macromolecules - a new outlook on bacterial 
cell walls. Adv. Enzymol. 26, 193–232 (1964). 
149. SCHLEIFE.KH & KANDLER, O. PEPTIDOGLYCAN TYPES OF BACTERIAL CELL-WALLS 
AND THEIR TAXONOMIC IMPLICATIONS. Bacteriol. Rev. 36, 407–477 (1972). 
150. Markiewicz, Z. et al.  Murein structure and lack of DD- and LD-carboxypeptidase 
activities in Caulobacter crescentus. J. Bacteriol. 156, 649–655 (1983). 
151. Glauner, B. et al.  The composition of the murein of Escherichia coli. J. Biol. Chem. 
References 
141 
 
263, 10088–10095 (1988). 
152. Meroueh, S. O. et al. Three-dimensional structure of the bacterial cell wall 
peptidoglycan. Proc. Natl. Acad. Sci. U. S. A. 103, 4404–4409 (2006). 
153. Gan, L. et al.  Molecular organization of Gram-negative peptidoglycan. Proc. Natl 
Acad. Sci. USA 105, 18953–18957 (2008). 
154. Applied, G. et al. Interaction network containing conserved and essential protein 
complexes in Escherichia coli. Nature 433, 531–537 (2005). 
155. Atrih, A. et al.  Analysis of peptidoglycan structure from vegetative cells of Bacillus 
subtilis 168 and role of PBP 5 in peptidoglycan maturation. J. Bacteriol. 181, 3956–
3966 (1999). 
156. Turner, R. D. et al.  Cell wall elongation mode in Gram-negative bacteria is 
determined by peptidoglycan architecture. Nat. Commun. 4, 1496 (2013). 
157. Eurofins. Eurofins MWG Operon. (2015). at <http://www.operon.com/> 
158. Source. Source BioScience. (2015). at <http://www.sourcebioscience.com/> 
159. ExPASy. ProtParam. (2015). at <http://web.expasy.org/protparam/> 
160. Gasteiger, E. et al. Protein Identification and Analysis Tools on the ExPASy Server. 
Proteomics Protoc. Handb. 571–607 (2005). doi:10.1385/1-59259-890-0:571 
161. Fingerprints facility, U. of D. Proteomic analysis. (2015). at 
<http://proteomics.lifesci.dundee.ac.uk/> 
162. Provencher, S. W. & Glöckner, J. Estimation of globular protein secondary structure 
from circular dichroism. Biochemistry 20, 33–37 (1981). 
163. Whitmore, L. & Wallace, B. a. Protein secondary structure analyses from circular 
dichroism spectroscopy: Methods and reference databases. Biopolymers 89, 392–
400 (2008). 
164. Tucker, H., Allan, W., Greg, D. & Bill, B. SEDNTERP. (2011). at 
<http://sednterp.unh.edu/> 
165. Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity 
ultracentrifugation and lamm equation modeling. Biophys. J. 78, 1606–1619 
(2000). 
166. Brookes, E. et al.  The implementation of SOMO (SOlution MOdeller) in the 
UltraScan analytical ultracentrifugation data analysis suite: Enhanced capabilities 
allow the reliable hydrodynamic modeling of virtually any kind of 
biomacromolecule. Eur. Biophys. J. 39, 423–435 (2010). 
167. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. Sect. D Biol. 
Crystallogr. 62, 72–82 (2006). 
168. Kabsch, W. Xds. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 125–132 (2010). 
169. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–
674 (2007). 
170. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta 
Crystallogr. Sect. D Biol. Crystallogr. 67, 235–242 (2011). 
References 
142 
 
171. Sheldrick, G. M. Experimental phasing with SHELXC/D/E: Combining chain tracing 
with density modification. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 479–485 
(2010). 
172. Terwilliger, T. C. et al. Decision-making in structure solution using Bayesian 
estimates of map quality: The PHENIX AutoSol wizard. Acta Crystallogr. Sect. D Biol. 
Crystallogr. 65, 582–601 (2009). 
173. Emsley, P. et al.  Features and development of Coot. Acta Crystallogr. Sect. D Biol. 
Crystallogr. 66, 486–501 (2010). 
174. Vagin, A. a. et al. REFMAC5 dictionary: Organization of prior chemical knowledge 
and guidelines for its use. Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 2184–2195 
(2004). 
175. Chen, V. B. et al. MolProbity: All-atom structure validation for macromolecular 
crystallography. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 12–21 (2010). 
176. Petoukhov, M. V. et al. New developments in the ATSAS program package for 
small-angle scattering data analysis. J. Appl. Crystallogr. 45, 342–350 (2012). 
177. Volkov, V. V & Svergun, D. I. small-angle scattering. 860–864 (2003). 
178. Svergun, D. I. et al.  Determination of domain structure of proteins from X-ray 
solution scattering. Biophys. J. 80, 2946–2953 (2001). 
179. Franke, D. & Svergun, D. I. DAMMIF , a program for rapid ab-initio shape 
determination in small-angle scattering. J. Appl. Crystallogr. 42, 342–346 (2009). 
180. Svergun, D. et al.  CRYSOL a Program to Evaluate X-ray Solution Scattering of 
Biological Macromolecules from Atomic Coordinates. J. Appl. Crystallogr. 28, 768–
773 (1995). 
181. Wong, S. G. & DesseŶ, A. “uppleŵeŶtaƌy Mateƌials “tƌuĐtuƌe of a ďaĐteƌial α Ϯ - 
-macroglobulin reveals mimicry of eukaryotic innate immunity. Nat. Commun. 1–10 
(2014). 
182. Putnam, C. D. et al.  X-ray solution scattering (SAXS) combined with crystallography 
and computation: defining accurate macromolecular structures, conformations and 
assemblies in solution. Q. Rev. Biophys. 40, 191–285 (2007). 
183. Kelley, L. A. et al.  The Phyre2 web portal for protein modeling , prediction and 
analysis. Nat. Protoc. 10, 845–858 (2015). 
184. Karplus, P. A. & Diederichs, K. Linking crystallographic model and data quality. 
Science (80-. ). 29, 997–1003 (2012). 
185. Diederichs, K. & Karplus, P. a. Better models by discarding data? Acta Crystallogr. 
Sect. D Biol. Crystallogr. 69, 1215–1222 (2013). 
186. Vered, M. et al.  Digestion of elastin. Int. J. Pept. Protein Res. 76–84 (1985). 
187. Garcia-Ferrer, I. et al. Structural and functional insights into Escherichia coli α 2 -
macroglobulin endopeptidase snap-trap inhibition. Proc. Natl. Acad. Sci. 
201506538 (2015). doi:10.1073/pnas.1506538112 
188. Meyer, C. et al.  HuŵaŶ αϮ-macroglobulin--another variation on the venus flytrap. 
References 
143 
 
Angew. Chem. Int. Ed. Engl. 51, 5045–7 (2012). 
189. Lin, K. et al.  A simple and fast secondary structure prediction method using hidden 
neural networks. Bioinformatics 21, 152–159 (2005). 
190. Drozdetskiy,  A. et al.  JPred4: a protein secondary structure prediction server. 
Nucleic Acids Res. 1–6 (2015). doi:10.1093/nar/gkv332 
 
 
 
Publications 
144 
 
 
 
 
 
 
 
 
PuďliĐatioŶs 
 
 
 
 
 
 
 
 
research papers
1478 http://dx.doi.org/10.1107/S1399004715008548 Acta Cryst. (2015). D71, 1478–1486
Received 24 February 2015
Accepted 30 April 2015
Edited by R. McKenna, University of
Florida, USA
Keywords: -2-macroglobulin; protease
inhibitor; conformational change; intrinsic
disorder.
PDB reference: Escherichia coli
-2-macroglobulin activated by porcine
elastase, 4rtd
Supporting information: this article has
supporting information at journals.iucr.org/d
Structure of protease-cleaved Escherichia coli
a-2-macroglobulin reveals a putative mechanism of
conformational activation for protease entrapment
Cameron D. Fyfe,a Rhys Grinter,a Inokentijs Josts,a Khedidja Mosbahi,a
Aleksander W. Roszak,b,c Richard J. Cogdell,c Daniel M. Wall,a Richard J. S.
Burchmore,a Olwyn Byrond and Daniel Walkera*
aInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of
Glasgow, Glasgow G12 8QQ, Scotland, bWestCHEM, School of Chemistry, College of Science and Engineering,
University of Glasgow, Glasgow G12 8QQ, Scotland, cInstitute of Molecular Cell and Systems Biology, College of
Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, and dSchool of Life
Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland.
*Correspondence e-mail: daniel.walker@glasgow.ac.uk
Bacterial -2-macroglobulins have been suggested to function in defence as
broad-spectrum inhibitors of host proteases that breach the outer membrane.
Here, the X-ray structure of protease-cleaved Escherichia coli -2-macro-
globulin is described, which reveals a putative mechanism of activation and
conformational change essential for protease inhibition. In this competitive
mechanism, protease cleavage of the bait-region domain results in the
untethering of an intrinsically disordered region of this domain which disrupts
native interdomain interactions that maintain E. coli -2-macroglobulin in
the inactivated form. The resulting global conformational change results in
entrapment of the protease and activation of the thioester bond that covalently
links to the attacking protease. Owing to the similarity in structure and domain
architecture of Escherichia coli -2-macroglobulin and human -2-macro-
globulin, this protease-activation mechanism is likely to operate across the
diverse members of this group.
1. Introduction
-2-Macroglobulins (2Ms) are found in eukaryotic blood,
invertebrate haemolymph, the eggs of birds and reptiles, and
the bacterial periplasm, where they are thought to play a role
in the restriction of proteolytic cleavage (Sottrup-Jensen,
1989; Lin et al., 2002; Budd et al., 2004; Li et al., 2004; Doan &
Gettins, 2008). Eukaryotic 2Ms have been shown to play
important roles in regulating the proteolytic cleavage of a
wide range of proteases and are involved in processes such as
fibrinolysis and coagulation (De Boer et al., 1993). Bacterial
2Ms (BA2Ms) are produced by a wide range of Gram-
negative bacteria ranging from human pathogenic and
commensal strains to plant pathogens and marine bacteria
(Budd et al., 2004). Escherichia coli 2M (ECAM) contains
the conserved thioester bond that is characteristic of the 2Ms
and which is essential for covalent binding to cleaving
proteases (Budd et al., 2004; Doan & Gettins, 2008; Neves et
al., 2012).
The gene encoding ECAM, yfhM, is frequently found in an
operon with pbp1C, which encodes penicillin-binding protein
1C (Pbp1C; Budd et al., 2004; Doan & Gettins, 2008). Pbp1C is
predicted to be a bifunctional transpeptidase and transglyco-
sylase owing to its homology to Pbp1A and Pbp1B, which are
both essential for the synthesis of the peptidoglycan layer
ISSN 1399-0047
(Schiffer & Ho¨ltje, 1999; Budd et al., 2004). Both ECAM and
Pbp1C are periplasmic proteins that are anchored to the inner
membrane and have been proposed to function together in
defence and repair against proteases that damage the bacterial
cell wall (Budd et al., 2004). Specifically, it has been postulated
that the host proteases produced in defence against bacterial
infection, which gain access to the periplasmic space, are
inhibited by ECAM, with Pbp1C acting to repair damage
(Budd et al., 2004).
The overall structure of 2Ms comprises a series of -sheet
sandwich macroglobulin (MG) domains forming a ‘keyring’
shape, a bait-region domain (BRD) spanning the body of the
ring, a mostly helical thioester domain (TED) connected to
the ‘keyring’ by a complement protein subcomponent (CUB)
domain, and a C-terminal MG (CTMG) domain (Janssen et al.,
2005; Marrero et al., 2012; Wong & Dessen, 2014). Within
eukaryotic 2Ms there are eight MG domains including
CTMG, which is also known as the receptor-binding domain
(MG1–MG7, CTMG), while BA2Ms contain ten MG domains
including two N-terminal MG domains anchoring the protein
to the inner membrane within the periplasm (MG1–MG9,
CTMG) (Huang et al., 1998; Doan & Gettins, 2007; Marrero
et al., 2012; Wong & Dessen, 2014). The TED contains a
conserved CXEQ motif where a thioester bond is formed,
which on activation can covalently link the 2M to lysine
residues on the surface of the attacking protease (Sottrup-
Jensen et al., 1980, 1989; Osterberg & Malmensten, 1984;
Jacobsen & Sottrup-Jensen, 1993; Janssen et al., 2005; Abdul
Ajees et al., 2006; Marrero et al., 2012; Wong & Dessen, 2014).
2Ms are activated through the protease cleavage of a largely
disordered bait region, which results in a conformational
change that both traps the protease in a cage-like structure
and exposes the highly reactive thioester bond (Travis &
Salvesen, 1983; Sottrup-Jensen, 1989; Sottrup-Jensen et al.,
1989; Doan & Gettins, 2008).
In human 2M, chemical cleavage of the thioester bond by
methylamine results in a large conformational change that has
been interpreted by electron microscopy as similar to that
observed on protease cleavage (Sottrup-Jensen et al., 1980;
Tapon-Bretaudie´re et al., 1985; Dodds et al., 1996; Dodds &
Law, 1998; Marrero et al., 2012). In contrast, the recently
elucidated structures of the BA2M from Salmonella enterica
serovar Typhimurium (SaA2M) in its unactivated and
methylamine-activated forms show that although the overall
domain structure of BA2Ms is highly similar to that of human
2M, there is no major conformational change of the bacterial
form on chemical cleavage of the thioester bond (Doan &
Gettins, 2008; Neves et al., 2012; Wong & Dessen, 2014). In the
structures of both bacterial and eukaryotic 2Ms the thioester
bond lies close to the surface of the TED, but is protected from
hydrolysis by a hydrophobic pocket at the interface between
the TED and the CTMG domain (Janssen et al., 2005; Le et al.,
2012; Wong & Dessen, 2014).
Owing to a lack of detailed structural information on
protease-cleaved forms of 2M, the mechanism through which
cleavage of the BRD activates 2M is not known. However, it
has been suggested that upon cleavage within human 2M the
cleaved BRD interacts with MG2 (MG4 in BA2M), resulting
in conformational activation (Marrero et al., 2012). Alter-
natively, within human 2M it has been suggested that the bait
region interacts with the TED, the MG6 (MG8 in BA2M) and
the CUB domains (Marrero et al., 2012). However, in the
absence of a crystal structure of a protease-cleaved form of
2M the mechanism of protease-induced activation remains
speculative.
To elucidate the mechanism of protease-induced 2M
activation, we crystallized and solved the X-ray structure of a
porcine elastase-cleaved form of ECAM, a close homologue of
SaA2M (81% amino-acid sequence identity) for which the
structure of the unactivated form was recently solved (Wong
& Dessen, 2014). Interestingly, the structure of protease-
activated ECAM is highly similar to that of chemically acti-
vated human 2M (12% amino-acid sequence identity) and
reveals a clear mechanism of how conformational rearrange-
ment is triggered on protease cleavage. Key to activation is
the untethering of the intrinsically disordered bait region on
cleavage, allowing this disordered region of polypeptide to
outcompete the domain–domain interactions that normally
maintain the thioester bond in its unactivated form. This
suggests a general mechanism through which members of the
large and important 2M superfamily are activated.
2. Materials and methods
All chemicals were purchased from Sigma unless mentioned
otherwise.
2.1. Cloning and protein purification of ECAM
The gene for ECAM, yfhM from E. coli K-12, was amplified
by PCR and cloned into pET-21a vector using NdeI and XhoI
restriction sites. The first 22 residues from the N-terminus of
the gene, containing a signal sequence identified using
SignalP, were excluded from the construct. The stop codon
was also excluded, resulting in a protein consisting of residues
23–1631 and a C-terminal 6His tag (LEHHHHHH). ECAM
was initially overexpressed in E. coli BL21(DE3) cells and
subsequently in T7 Express Crystal Competent E. coli cells
(methionine-auxotrophic strain, New England Biosciences)
using an inducible T7 promoter with 1 mM isopropyl -d-1-
thiogalactopyranoside (IPTG) as the inducer. Bacteria
expressing ECAM were grown in lysogeny broth; seleno-
methionine-labelled ECAM was obtained using M9 minimal
medium supplemented with 50 mg l1 selenomethionine and
20 mg l1 of each of nine essential amino acids (excluding
methionine). Cells were grown at 37C to an OD600 of 0.6,
protein production was induced by the addition of 1 mM
IPTG and the cells were grown for a further 6 h. The cell pellet
was collected by centrifugation at 4400g for 15 min and the
cells were resuspended in binding buffer [20 mM Tris, 10 mM
imidazole, 500 mM sodium chloride, 5 mM tris(2-carboxy-
ethyl)phosphine (TCEP) pH 7.5] and lysed by sonication with
1 mg ml1 lysozyme in the presence of protease inhibitors
(Complete Mini, Roche). Cell debris was removed by centri-
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fugation at 46 000g for 30 min at 4C. The cell supernatant was
then loaded onto a HisTrap HP column (GE Healthcare) and
the bound protein was eluted with elution buffer (20 mM Tris,
500 mM imidazole, 500 mM sodium chloride, 5 mM TCEP pH
7.5) using a linear gradient increasing from 10 to 500 mM.
Fractions containing ECAM were pooled and dialysed over-
night at 4C into 50 mM Tris, 200 mM sodium chloride pH 7.5
and run on a Superdex S200 gel-filtration column (GE
Healthcare). Central fractions from the peak were combined
and concentrated using a 100 kDa molecular-weight cutoff
centrifugal concentrator.
2.2. Crystallization and structure building
Purified ECAM was reacted in a 1:1 molar ratio with
porcine elastase (MP Biomedicals) in 50 mM Tris, 200 mM
NaCl pH 7.5 on ice for 5 min before being loaded onto a
Superdex S200 gel-filtration column (GE Healthcare). The
two major peaks from gel filtration were concentrated to
16 mg ml1 separately using 100 kDa molecular-weight cutoff
centrifugal concentrators and used in crystallization trials.
Several hundred crystallization conditions were tested,
including the JCSG-plus, MIDAS and Morpheus screens
(Molecular Dimensions), for both concentrated peaks. A
Cartesian Honeybee 8+1 (Harvard Bioscience) robot was used
with 96-well plates, dispensing 0.5 ml reservoir solution and
0.5 ml protein sample. Subsequent scaled-up crystal growth
was performed using 2.5 ml reservoir solution and 2.5 ml
protein sample. The initial crystal was grown in conditions
consisting of 0.1M potassium chloride, 0.1M HEPES, 25%
Sokalan CP 7 pH 7.0, and upon optimization the pH was
adjusted to 7.5 for larger crystal growth. Crystals were grown
using equal volumes of protease-cleaved ECAM and reservoir
solution using sitting-drop vapour diffusion, with crystals
appearing after 2 d at 16C for the second fraction and after
two weeks for the first fraction. Cryoprotection was optimized
with a 3:2 ratio of xylitol-saturated reservoir solution to
reservoir solution. Crystals were briefly soaked and flash-
cooled in liquid nitrogen for data collection. The best
diffraction resolution obtained was 3.8 A˚, and molecular
replacement with methylamine-activated 2M (PDB entry
4acq) was unsuccessful, most likely as the sequence identity
with the human homologue was low (12%) and owing to the
difference in domain orientation between the structural
models (Marrero et al., 2012). Further expression was
performed using a methionine-auxotrophic strain of E. coli
BL21 (T7 Express Crystal Competent E. coli, New England
Bioscience) and the purification and crystallization screens
were repeated using selenomethionine-labelled protein. As
repeating the previous protocol with selenomethionine-
labelled protein was unsuccessful, in situ proteolytic cleavage
screening was performed using porcine elastase. Successful
crystallization was achieved using a 1:100 ratio of porcine
elastase to selenomethionine-labelled ECAM. Crystallization
was successful in the same condition as used previously, with
the crystal having a similar appearance and the same space
group as previous unlabelled crystals. These crystals diffracted
to 3.65 A˚ resolution and phases were obtained using single-
wavelength anomalous diffraction (SAD).
Data were collected for ECAM crystals on the I02, I03 and
I24 beamlines at Diamond Light Source, Didcot, England at
100 K at the Se K edge ( = 0.97939 A˚) using a PILATUS 6M
detector. A high-redundancy SAD data set was processed and
scaled using XDS and AIMLESS from the CCP4 suite of
programs (Evans, 2006; Kabsch, 2010; Winn et al., 2011).
Selenium sites were located using SHELXC/D, with the best
substructure solution consisting of 23 sites (Sheldrick, 2010).
These selenium sites were input along with the SAD data set
to AutoSol within the PHENIX package to perform phasing
and density modification (Terwilliger et al., 2009). Density
modification in AutoSol was sufficient to break the phase
ambiguity owing to the high solvent content of the crystal
(69%). This yielded interpretable, low-resolution maps in
which density corresponding to secondary-structure elements
and larger amino-acid side chains was visible. Initially, the
-helical TED domain was built in Coot using idealized
-helical sections (Emsley et al., 2010). The loops between
these sections were connected where density was available.
The six selenomethionine sites in this domain provided the
starting sites for the building of amino-acid side chains in the
TED domain, although owing to the resolution initially only
larger side chains and those where continuous sequence could
be determined were built. In addition to the building of the
TED domain, a number of 2M-derived polyalanine MG
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Table 1
Data-collection and refinement statistics (single-wavelength anomalous
diffraction) for protease-cleaved ECAM.
Data were collected from one crystal. Values in parentheses are for the highest
resolution shell.
Data collection
Space group H3
Unit-cell parameters (A˚, ) a = b = 176.06, c = 161.13,
 =  = 90,  = 120
Resolution (A˚) 46.87–3.65 (4.00–3.65)
Solvent content (%) 69
No. of reflections 20753 (4991)
CC1/2 0.998 (0.675)
Rmerge (%) 39.0 (378.0)
Rp.i.m.† (%) 7.7 (74.4)
hI/(I )i 13.2 (2.1)
Completeness (%) 99.9 (99.9)
Multiplicity 26.6 (26.7)
Anomalous completeness (%) 99.9 (99.3)
Anomalous multiplicity 12.8 (12.8)
DelAnom correlation between half sets 0.335 (0.011)
Mid-slope of anomalous normal probability 1.245
Refinement
Rwork/Rfree (%) 17.7/23.8
No. of atoms 8699
Average B factor (A˚2) 144
R.m.s. deviations
Bond lengths (A˚) 0.01
Bond angles () 1.53
Ramachandran plot‡ (%)
Favoured 90.7
Allowed 7.9
Outliers 1.3
PDB code 4rtd
† Rp.i.m. =
P
hklf1=½NðhklÞ  1g
1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ.
‡ Percentages of residues in favoured/allowed regions calculated by MolProbity (Chen
et al., 2010).
domains were rigid-body fitted into their corresponding
density and manually real-space refined in Coot (Emsley et al.,
2010). As with the TED domain, where possible side chains
were fitted using the positions of selenomethionine Se atoms
as starting sites. This initial building yielded a partial model,
which was then used in conjunction with the selenomethionine
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Figure 1
Crystal structure of porcine elastase-cleaved E. coli 2M (ECAM). (a) Schematic representation of the 13 domains of ECAM showing the macroglobulin
domains (MG) including the C-terminal MG (CTMG) domain, the bait-region domain (BRD), the complement protein subcomponent (CUB) domain
and the thioester domain (TED) containing the CLEQmotif. (b) The structure of elastase-cleaved ECAMwith the individual domains coloured as in (a).
Smaller van der Waals surfaces in both views are also presented. In the left view the -helical TED is orientated with the CLEQ thioester (drawn as red
van der Waals spheres) positioned above the pocket which is thought to accommodate the attacking protease. (c) Structural alignment of methylamine-
treated human 2M (PDB entry 4acq monomer trimmed to the domains present in cleaved ECAM) and elastase-cleaved ECAM (PDB entry 4rtd) in
green and red, respectively. (d) Structural alignment of native SaA2M (PDB entry 4u48 trimmed to the domains present in cleaved ECAM) and elastase-
cleaved ECAM (PDB entry 4rtd) in blue and red, respectively. Structural alignments were performed using the MG domain containing the bait region
(shown in orange).
substructure to rephase the experimental data using MR-SAD
phasing in Phaser (McCoy et al., 2007). This process led to
phase improvement and the appearance of new features in the
map, which were modelled, and the process was repeated
iteratively. Partway through the building process the atomic
coordinates for SaA2M were published (PDB entry 4u48;
Wong & Dessen, 2014), and the domains from this model
provided validation of the MG-domain placement and side-
chain modelling in our experimentally phased map. The
SaA2M structure also provided a template for building the
more difficult sections of the model. At this point restrained
TLS refinement using REFMAC5 was found to stably improve
both Rwork and Rfree, and refinement was performed and
the model was improved and finished manually in Coot
(Murshudov et al., 2011; Emsley et al., 2010). Electron density
for the thioester bond indicated that the deaminated gluta-
mine forms no covalent bond to the cysteine. Before submis-
sion of the final model, the quality of the structure was
assessed using the MolProbity webserver (Chen et al., 2010).
The atomic coordinates and structure factors were deposited
in the Protein Data Bank (PDB entry 4rtd). Statistics for data
collection, experimental phasing and refinement are presented
in Table 1. For mass-spectrometric analysis of protease-
cleaved ECAM, crystals were washed in reservoir solution
before being dissolved in deionized water and heated to 96C
in bromophenol blue sample buffer for 5 min. The sample was
then run on a NuPAGE Novex 4–12% bis-tris gel (Invitrogen)
and visible bands were cut for proteomic analysis. Samples
were digested by trypsin and analysed by LC-MS/MS (Orbi-
trap XL) performed at the Fingerprints Proteomics Facility at
the University of Dundee.
3. Results
3.1. Overall structure of protease-activated ECAM
To determine the structural changes that occur on protease
cleavage of ECAM, we performed protease digestion with
porcine elastase and used the major products from gel filtra-
tion of cleaved ECAM to perform crystallization trials. This
yielded diffracting crystals in 0.1M potassium chloride, 0.1M
HEPES, 25% Sokalan CP 7 pH 7.0 with cleaved ECAM. In
order to obtain phase information, we attempted to repeat this
process with selenomethionine-labelled ECAM, but this failed
to yield crystals. However, an alternative strategy of in situ
proteolysis and crystallization with selenomethionine-labelled
ECAM was successful. This method yielded crystals that
diffracted to 3.65 A˚ resolution. Upon completion and valida-
tion of the model of protease-activated ECAM, the number of
Ramachandran outliers remaining was appropriate for a
crystal structure with a resolution of 3.65 A˚. Although the
Rmerge and Rp.i.m. values were high, this can be explained by the
highly redundant data set used; with a CC1/2 of 0.675 in the
highest shell, these data used were judged to be acceptable
(Karplus & Diederichs, 2012; Diederichs & Karplus, 2013).
Similar to the domain architecture of native SaA2M,
uncleaved ECAM consists of ten MG domains, with a largely
disordered bait-region domain found within MG8, a TED
that houses the reactive thioester bond and a CUB domain
(Fig. 1a). Elastase-cleaved ECAM (Fig. 1b) adopts a confor-
mation similar to that of methylamine-activated human 2M
(Fig. 1c) but distinct from the unactivated form of SaA2M
(Fig. 1d). Despite the low sequence identity between human
2M and ECAM (12%), the r.m.s.d. between C atoms for
these proteins is 14.1 A˚, while that for SaA2M and ECAM,
which share 82% sequence identity, is 22.1 A˚. Most notably, in
the structure of the protease-cleaved ECAM, interactions
between the TED and the CTMG domain, which protects the
thioester bond in unactivated SaA2M, are not present.
Instead, the thioester region of TED is solvent-exposed and
faces the expected location of the attacking protease, as it
would be positioned when cleaving the bait region of ECAM
(Fig. 1b). Electron density for elastase, in addition to that for
MG domains 1, 2, 3 and 7, was absent in 2Fo  Fc maps of
cleaved ECAM, as was electron density for 20 amino-acid
residues (Arg923–Leu942) within the bait region. Analysis of
elastase-cleaved ECAM by SDS–PAGE and mass spectro-
metry confirms that MG domains 1, 2, 3 and 7 are absent from
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Figure 2
Bait-region interaction with the CTMG domain. (a) Here we show
hydrogen bonding between the cleaved bait region (blue) and the CTMG
domain (grey) as dashed yellow lines. Note the interaction between
Arg956 and Met1634, with the CTMG methionine normally involved in
the hydrophobic pocket found in uncleaved native SaA2M. MG4 and
MG9 are shown in yellow and red, respectively. (b) Surface representa-
tion of the CTMG domain bound to the TED in SaA2M (blue) overlaid
(by superposition of CTMG domains) with the previously disordered bait
region bound to the CTMG domain in elastase-cleaved ECAM (red). The
thioester bond within the TED is shown as dark blue van der Waals
spheres.
the crystallized protein (Supplementary Fig. S1). Two bands at
90 and 75 kDa on SDS–PAGE have similar peptide coverage,
encompassing the same domains (Supplementary Fig. S1).
However, the reason for the difference in apparent molecular
weights between these two species is not known.
3.2. Interaction of the BRD with the CTMG domain
Although it is known that protease cleavage of the largely
disordered bait region of both human and bacterial 2Ms
gives rise to a large conformational rearrangement and acti-
vation of the thioester bond, the mechanism through which
this is mediated was unclear (Barrett et al., 1979; Neves et al.,
2012). However, the structure of protease-cleaved ECAM
provides a clear mechanism for this process. Thioester bond
release is achieved by the untethering of a large region of an
unstructured polypeptide chain upon cleavage of the BRD
that forms new interactions with the CTMG domain, thereby
preventing the protective interaction with the TED. Specifi-
cally, in the elastase-cleaved form of ECAM additional resi-
dues (Phe947–Asn963) of the BRD are observed that are
disordered in the uncleaved SaA2M structure. All of these
residues in the protease-cleaved ECAM structure are ordered
owing to the formation of a new binding interface between
the BRD and the CTMG domain upon protease cleavage
(Fig. 2a). Critically, the region of the CTMG domain that is
involved in BRD binding substantially overlaps with the
region of the CTMG domain that forms the binding interface
with the TED in the uncleaved form of the protein (Fig. 2b).
The buried surface area between the CTMG domain and TED
in SaA2M is 1972 A˚2, with three hydrogen bonds between
these domains, whereas the buried surface area between the
elastase-cleaved BRD and the CTMG domain in ECAM is
1438 A˚2, with five hydrogen bonds between the domains. In
the protease-cleaved ECAM, hydrogen-bond formation
between residues of the CTMG domain and the cleaved bait
region involves the highly conserved RDDR and EXMY
motifs (Fig. 3). Interestingly, it is residues within these motifs
that also form hydrogen bonds to the TED in the uncleaved
SaA2M protein (Fig. 3; Wong & Dessen, 2014).
3.3. Cleavage-induced conformational changes and thioester-
bond activation of a2Ms
We propose that the loss of the interaction of the TED with
the CTMG domain is sufficient to enable both the large TED
movement observed in the cleaved ECAM structure relative
to the unactivated SaA2M structure and the exposure of the
thioester bond (Fig. 4a, Supplementary Movie S1). The
movement of the TED domain shows an overall shift of 36 A˚,
with the MG6 domain moving by 50 A˚ and with both the MG6
and TED arms hugging the position at which the attacking
protease would be located to cleave the BRD (Fig. 4a,
Supplementary Movie S1). In addition to these global
conformational changes, protease cleavage leads to localized
changes in the environment of the thioester bond that are
likely to lead to its activation. In the unactivated SaA2M
structure the conserved methionine and tyrosine side chains
(Met1625 and Tyr1626 in SaA2M) from the CTMG domain
form part of the hydrophobic pocket at the interface with the
TED that has been shown to be important in maintenance of
the thioester bond (Wong & Dessen, 2014). The loss of these
key side-chain interactions and the movement of the addi-
tional side chains which constitute the protective hydrophobic
pocket (Tyr1175 and Tyr1177 in SaA2M and Tyr1183 and
Tyr1185 in ECAM) from the TED exposes the thioester bond
to the solvent, allowing hydrolysis or covalent-bond formation
with the attacking protease (Fig. 4b). As there are no contacts
present from the CTMG domain providing a hydrophobic
pocket to protect the thioester from hydrolysis by water, the
thioester bond could be cleaved and the deaminated gluta-
mine (Gln1190) would be converted to a glutamic acid. Within
our protease-activated ECAM structure the distance between
the S atom of Cys1187 and the C atom of Gln1190 is 4.6 A˚,
indicating that the thioester bond may not be intact (Supple-
mentary Fig. S2). However, we cannot rule out the possibility
that there is a mixed population of molecules, some of which
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Figure 3
Sequence alignments of conserved motifs involved in the thioester pocket and conformational activation. Highlighted in yellow are tyrosines important
for maintaining the hydrophobic pocket protecting the thioester bond (CLEQ motif, also shown in yellow). The tyrosine within the C-terminal
macroglobulin (CTMG) domain, involved in protecting the thioester, which coordinates to the glutamate within the CLEQ motif in the native SaA2M
structure is highlighted in blue (PDB entry 4u48). The conserved proline found near the thioester is highlighted in green along with the arginine that it
coordinates in unactivated SaA2M. The residues highlighted in pink, orange and red in the CTMG domain coordinate to residues Asn963, Gly958 and
Arg956, respectively, in the cleaved bait region of elastase-cleaved ECAM.
possess an intact thioester bond. Owing to this ambiguity, we
have represented the thioester without a covalent bond
between Cys1187 and the C atom of Gln1190 and have also
omitted the O atom from the deaminated glutamine that
would be formed on hydrolysis of the thioester bond.
4. Discussion
Although it has been suggested that small-molecule-activated
human 2M resembles the conformation of the protease-
cleaved form, there have to date been no detailed structural
data to confirm this (Tapon-Bretaudie´re et al., 1985). The
similarity in the overall conformation of protease-cleaved
ECAM to that of methylamine-activated human 2M confirms
that the protease-activated and chemically activated forms of
human 2M are structurally equivalent. In addition, these data
suggest that the entrapment of cleaving proteases is likely to
occur in a similar manner for BA2Ms as has been proposed
for human 2M (Marrero et al., 2012; Meyer et al., 2012).
However, there are clearly key differences in the details of the
interactions that maintain the inactive conformations of
BA2Ms and human 2M, since the recent structures of
unactivated and methylamine-activated SaA2M show that
chemical cleavage of the thioester bond does not lead to
global conformational changes in this case (Marrero et al.,
2012; Wong & Dessen, 2014). This difference is likely to be
owing to the domain location of the side chains that comprise
the thioester-protecting pocket (Supplementary Fig. S3). In
BA2Ms this pocket comprises two tyrosine side chains from
the TED and a tyrosine and a methionine side chain from the
CTMG domain, whereas in eukaryotic 2Ms all four residues
(three tyrosine side chains and one methionine side chain) are
found in the CTMG domain. When SaA2M is reacted with
methylamine no conformational change is seen, but Tyr1175
from the TED is displaced (Wong & Dessen, 2014). The
structural counterpart of this side chain (Tyr1307 from TEP1)
in eukaryotic 2M family members is, however, found within
the CTMG domain (Supplementary Fig. S3; Baxter et al.,
2007). It is presumably the rearrangement of this side chain
and perhaps other CTMG side chains that comprise the
thioester-protecting pocket which leads to the loss of TED–
CTMG domain binding and subsequent global conformational
changes. The buried surface area seen between the TED and
the CTMG domain in native SaA2M decreases by 27%
compared with that of the BRD and the CTMG domain in
protease-cleaved ECAM; however, the number of hydrogen
bonds increases. Although there is a decrease in the buried
surface area, it is the interaction between important residues
for protecting the thioester that would be expected to trigger
conformational change releasing TED and allow subsequent
interaction with a cleaving protease.
The role of BA2Ms, which are inner membrane-anchored
periplasmic proteins, has been suggested as protease inhibitors
that inhibit exogenous proteases that have breached the outer
membrane. Comparison of the structures of unactivated
SaA2M and protease-cleaved ECAM illustrates how protease-
induced conformational changes enable protease entrapment
(Fig. 5). The movement of the TED-domain arm and MG6-
domain arm around the central pocket above the bait region
is similar to the movement seen in methylamine-activated
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Figure 4
Conformational shift of the TED and thioester of protease-activated ECAM. (a) Superposition of protease-cleaved ECAM (red) and SaA2M (blue)
showing a 36 A˚ shift of the TED. Structures were overlaid by superposition of MG8 containing the BRD. (b) Overlaid elastase-cleaved ECAM (red) and
native SaA2M (blue) TEDs. Tyrosines thought to protect the thioester region from hydrolysis in native SaA2M (Tyr1175 and Tyr1177) are orientated
away from the protease-activated ECAM thioester region (Tyr1183 and Tyr1185 in protease-activated ECAM).
human 2M; when accounting for the domains that are not
present in the protease-activated ECAM structure no clashes
are seen between the moving arms and the absent domains
(Marrero et al., 2012). The entrapment of proteases would
limit the proteolysis to smaller substrates, as has been
suggested for human 2M, and would prevent the cleavage of
important larger substrates such as the peptide component of
the peptidoglycan layer or large proteins (Fig. 5; Sottrup-
Jensen, 1989). Although we cannot be sure why the covalently
bound elastase is not present in our structure, this may be
owing to a lack of available and correctly positioned lysine
side chains on the surface of the protease, since the thioester
bond is preferentially cleaved by this side chain (Marrero et
al., 2012). The lack of MG domains 1, 2, 3 and 7 within the
crystal lattice is likely to be owing to the MG domains being
cleaved by the elastase.
In summary, the structure of protease-activated ECAM
shows a competitive mechanism of activation in which clea-
vage of the BRD allows the normally intrinsically disordered
region of this domain to outcompete the TED for CTMG-
domain binding. Loss of the TED–CTMG domain interaction
leads to a large conformational rearrangement of ECAM and
exposure of the reactive thioester bond. The structural simi-
larity between methylamine-activated human 2M and
protease-cleaved ECAM suggests that similar mechanisms are
likely to operate across the diverse members of the 2M
family.
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